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CHAPTER 1 
Introduction 
Scope of the thesis 
Part of this chapter was published in: 
Hematopoietic (stem) cell development— 
how divergent are the roads taken? 
Mari-Liis Kauts, Chris S. Vink and Elaine Dzierzak 
FEBS Letters August 2016; DOI: 10.1002/1873-3468.12372. 

Introduction 
Hematopoiesis is initiated by a transient wave of primitive blood cell emergence 
Blood cells are one of the first differentiated cell/tissue lineages generated in the 
vertebrate embryo. Surprisingly, they are produced even before the circulation is 
established (Palis et al., 2001). Transient waves of hematopoietic cell production are first 
initiated extra-embryonically in the yolk sac (YS) blood islands (Palis et al., 1999) which 
are derived from mesodermal cells that migrate to the YS at neural plate stage. At 
embryonic day 7 (E7) the mesodermal aggregates generate the first blood cells (Figure 
1) (Haar and Ackerman, 1971; Palis et al., 1999). The emergence of blood cells in the
YS is in close relationship to the appearance of endothelial cells that form the first
vascular structures. This spatiotemporal association between the emergence of
hematopoietic and endothelial cells has led to the hypothesis that they arise from a
common bipotential ancestor, which is termed the hemangioblast (Palis et al., 2001).
Figure 1.  Sites and times of blood cell generation in the mouse embryo.  
Blood generation in the mouse embryo starts in the blood islands of extra embryonic yolk sac (YS) 
at embryonic day 7 (E7) with a transient wave of ‘primitive’ erythrocyte, megakaryocyte and 
macrophage production. The erythrocytes and megakaryocytes of that stage are short-lived and 
disappear by E9. Primitive macrophages are hypothesized to be the source of tissue resident 
macrophages in the adult brain. The second wave of blood generation gives rise to bipotential 
erythroid-myeloid progenitors (EMPs) that emerge in the YS from E8.25. Shortly thereafter, 
lymphoid potential in detected. The paired dorsal aortae contain lymphoid potential as do the 
allantois/chorion. In the third hematopoietic wave, long-lived transplantable hematopoietic stem 
cells (HSCs) are generated beginning at E10.5 in the aorta-gonads mesonephros (AGM) region. 
HSCs are also detected in the vitelline (VA) and umbilical (UA) arteries, YS, placenta and in 
embryonic head. HSCs and EMPs migrate to the fetal liver (FL) where they expand and reside 
before migrating to the bone marrow niches. 
The first genetic evidence supporting a common precursor for hematopoietic and 
endothelial lineages came from deletion of the Flk1 receptor tyrosine kinase gene in the 
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mouse. Flk1 expression is detected as early as at E7 in the YS mesoderm (Yamaguchi 
et al., 1993). Embryos lacking Flk1 are not viable and interestingly, show a complete 
absence of mesodermal cell aggregates in the YS. It was concluded that Flk1 is required 
for mesodermal cell migration to form YS blood islands and for making hematopoietic 
and endothelial cells (Shalaby et al., 1995) and suggested that a bipotential 
hemangioblast generates hematopoietic and endothelial cells. Intriguingly, lineage 
marking/tracing experiments have shown that there is little/no overlap in the mesodermal 
precursors that are forming the endothelial and hematopoietic cells in individual blood 
islands, suggesting a separation in fate early before migration to the YS (Ueno and 
Weissman, 2006). 
Mouse embryonic stem cell (ESC) hematopoietic differentiation studies facilitated the 
search for putative hemangioblast-like cells. ESCs are self-renewing pluripotent cells 
derived from the inner cell mass of the blastocyst (Evans and Kaufman, 1981). They 
are characterised by their ability to contributed to all cells types of the developing 
embryo, including the germ line when re-introduced into the host blastocyst (Bradley et 
al., 1984). In vitro, they provide a platform for deriving cell types of different lineages 
(Keller, 1995; Smith, 2001).  
ESCs differentiated in in the presence of vascular endothelial growth factor (VEGF) and 
stem cell factor (SCF) for 2.5 days generated blast-colony forming progenitor cells (BL-
CFC) that were able to give rise to both, hematopoietic and endothelial cells (Choi et 
al., 1998). The BL-CFC (putative hemangioblast) represents a transient population that 
persists for a very short time in the differentiation culture. It expresses genes common 
to both hematopoietic and endothelial lineage, including Flk1 (Kennedy et al., 1997). 
Later it was shown that the BL-CFC have an additional differentiation potential to 
cardiomyocyte lineage (Kouskoff et al., 2005) and thus, the physical isolation of the 
hemangioblast remains difficult. Nonetheless, to better understand embryonic 
hematopoiesis, in vitro ESC hematopoietic differentiation models have been widely 
used as they recapitulate the early stages of hematopoietic cell development and 
differentiate to almost all hematopoietic lineages, thus facilitating biochemical analyses 
of transcription factors and other regulatory molecules involved in development.  
The earliest blood cells detected in the embryo are primitive erythrocytes, 
macrophages and megakaryocytes 
Blood cells that emerge in the first wave of hematopoietic cell generation are ‘primitive’ 
erythrocytes, macrophages and rare megakaryocyte progenitors (Palis et al., 1999; 
Tober et al., 2007). This developmental wave is categorized as ‘primitive’ due to the 
distinctive characteristics of the erythrocytes and erythrocyte colony forming unit cells 
(EryP-CFU-Cs). ‘Primitive’ red blood cells are nucleated and are 3 times larger than fetal 
and 6 times larger than adult erythrocytes (Kingsley et al., 2006; Kingsley et al., 2004). 
Moreover, they produce a developmentally distinct embryonic (βH1) globin, which is not 
detected in adult erythrocytes. ‘Primitive’ erythrocytes peak in numbers at E8.25 and 
disappear rapidly by E9 (Palis et al., 1999; Tober et al., 2007).  The short developmental 
time of these cells resembles the transient nature of hemangioblast-like cells, thus 
supporting the hypothesis that they originate from a short-lived precursor.  
Concurrently, rare macrophage progenitors are detected in the YS (Bertrand et al., 2005; 
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Palis et al., 1999). ‘Primitive’ macrophages from this first YS hematopoietic wave (E7-
7.5) are directly derived from the blood islands and do not go through a monocyte 
intermediate (Naito et al., 1990; Naito et al., 1996; Takahashi et al., 1989) that 
characterizes the macrophages generated from hematopoietic stem cells (HSC) in the 
adult bone marrow. Once the bloodstream is established at E8.25-8.5 (McGrath et al., 
2003) the YS derived macrophages migrate to the developing tissues where they become 
‘tissue resident’ macrophages expressing high levels of F4/80 macrophage surface 
marker. These include macrophages in the skin, microglia in the brain, Kupffer cells in 
the liver and Langerhans cells in the epidermis. Recent lineage tracing studies suggest 
that ‘tissue resident’ macrophages in the skin, liver and lung are replaced before birth by 
‘monocyte derived’ macrophages generated in later waves of hematopoietic 
development (Gomez Perdiguero et al., 2015). In contrast, the labeled brain microglia 
cells are retained throughout adult life. Unique to these macrophages, as compared to 
those in the adult, are high F4/80 expression, c-Myb transcription factor independence 
and PU.1 transcription factor dependence (Gomez Perdiguero et al., 2015; Hoeffel et al., 
2015; Kierdorf et al., 2013; Schulz et al., 2012). By E9.5, the quantitative abundance of 
phenotypic ‘primitive’ macrophages and megakaryocytes in the embryo further suggests 
that these cells are directly generated in the first hematopoietic wave and not from the 
later waves of hematopoietic progenitor and stem cell generation (Bertrand et al., 2005; 
McGrath et al., 2015).  
The need for all the early blood cells in the embryo before the circulation is not yet fully 
established. However, ‘primitive’ erythrocytes may be necessary for providing the rapidly 
growing embryo with oxygen, macrophages for phagocytosis of cells during tissue 
remodeling and for lymphatic development. The role of megakaryocytes is uncertain, 
although they are closely associated with red blood cells. Whether some of these 
primitive cells are directly involved in the emergence of later definitive hematopoietic cell 
types, remains a to be addressed. 
Multipotent progenitors are generated in the YS during a second wave of blood 
cell generation 
After the generation of ‘primitive’ erythrocytes, macrophages and megakaryocytes, 
another wave of hematopoietic cell production begins at E8.25 in the YS (Figure 1). It 
overlaps temporally with the first wave (Palis et al., 1999), but produces functionally more 
complex bipotential erythroid-myeloid progenitors (EMP). EMP cells express high levels 
of tyrosine receptor kinase cKit (CD117) and CD41, and by E9.5 are positive for 
granulocyte-monocyte marker CD16/32 expression (McGrath et al., 2015). EMP-derived 
erythrocytes are distinguished from their earlier, ‘primitive’ counterpart by the expression 
of adult (βmajor) globin (Palis et al., 1999) and by undergoing enucleation. Thus, based 
in this complexity and the generation of adult-like cells this wave is termed ‘definitive’ 
(Frame et al., 2013). However, cKithiCD41+CD16/32+ EMPs lack lymphoid cell potential, 
and are able to provide only short-term in vivo reconstitution, giving rise to mainly 
circulating red blood cells (McGrath et al., 2015). Hence, EMPs are distinct from HSCs.  
Study of Ncx1 null mice which lack circulation, show that EMPs are generated in the YS 
and not in the embryo proper through E9.5 (Lux et al., 2008; McGrath et al., 2015). They 
appear to emerge from cKit+ cell clusters found in the venous and arterial vessels of the 
YS (Frame et al., 2016). These cells then colonize the newly forming liver around late E9 
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(Frame et al., 2013) and give rise to the large numbers of erythrocytes, macrophages, 
granulocytes and monocytes found before the establishment of a permanent 
hematopoietic system (Gomez Perdiguero et al., 2015).  
 
Other hematopoietic cells generated in the second wave are rare cells with lymphoid 
potential, B-1 B cell progenitors. They are detected at E8.5/9.5 in the YS and aorta (Godin 
et al., 1995; Yokota et al., 2006; Yoshimoto et al., 2012). Mast cells are also found in the 
YS from E9.5 onwards (Sonoda et al., 1983). Taken together, this ‘definitive’ wave of 
hematopoietic cell generation yields more adult-like functionally competent blood cell 
types. Also, there is growing evidence that these cells may play an interactive role in 
promoting the third wave of hemogenesis and HSC generation (Espin-Palazon et al., 
2014; Li et al., 2014; Travnickova et al., 2015). 
The first HSCs emerge intraembryonically in a third wave of blood cell generation 
Adult type HSCs are defined by their robust ability to long-term repopulate all blood 
lineages upon transplantation into irradiated adult recipients. Figure 2 shows 
hematopoietic hierarchy with HSCs at the top. HSCs are able to reproduce themselves 
(self-renew) and give rise to all mature blood lineage cells via progenitor intermediates. 
HSCs are quiescent cells, whereas proliferation capacity is increased in the progenitor 
cell state.  
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Figure 2. Hematopoietic cell hierarchy. Hematopoietic stem cells (HSC) are at the top of the 
hematopoietic cell hierarchy. They self-renew and give rise to committed progenitor cells, which 
differentiate to generate mature cells of all the blood lineages. The progression of rather quiescent 
HSCs to progenitor cells is associated with the increase in the proliferation rate. Adapted from 
(Bryder et al., 2006). Generating HSCs in vitro from embryonic stem cells (ESC) and induced 
pluripotent stem cells (iPSC) has been a long term goal of blood research. To date, it has been 
feasible to derive unipotent cells and (multipotent) progenitors, however, the attempts to robustly 
convert ESCs/iPSCs into self-renewing multipotent engrafting HSCs, has largely failed. MPP, 
multipotent progenitor; CMP, common myeloid progenitor; MEP, megakaryocyte/erythroid 
progenitor; GMP, granulocyte/monocyte progenitor; CLP, common lymphoid progenitor; NK 
natural killer cell.  
In the mouse embryo, the first adult HSCs appear and are autonomously generated in 
the aorta-gonads-mesonephros (AGM) region at E10.5 (Figure 1) (Medvinsky and 
Dzierzak, 1996; Muller et al., 1994). They are also found in the vitelline and umbilical 
arteries (VA, UA) and in the head (de Bruijn et al., 2000; Li et al., 2012). Shortly thereafter, 
HSCs are detected in the YS, placenta, circulation and fetal liver (FL) (Gekas et al., 2005; 
Medvinsky and Dzierzak, 1996; Muller et al., 1994; Ottersbach and Dzierzak, 2005). 
Whereas the YS and placenta may be capable of autonomously generating HSCs, the 
FL serves only as a niche for the expansion of HSCs (and EMPs) made in the other 
tissues (Ema and Nakauchi, 2000; Gekas et al., 2005; Kumaravelu et al., 2002). Just 
before birth HSCs migrate to the bone marrow where they reside throughout mammalian 
adult life in specialized niches (Mendelson and Frenette, 2014). 
HSCs are generated from a subset of embryonic endothelial cells that possess 
hemogenic potential - the hemogenic endothelial cells (HEC) (Figure 3A) (Dzierzak and 
Speck, 2008; Jaffredo et al., 2005). They are detected at the time when clusters of 
hematopoietic cells appear on the ventral wall of the dorsal aorta. These intra-aortic 
hematopoietic cluster cells (IAHC) are cKit+ and at E10.5, approximately 600 IAHCs (1-
19 cKit+ cells per cluster) were found along the length of the embryo by whole mount 
embryo imaging (Yokomizo and Dzierzak, 2010). Figure 3B shows the Gata2Venus 
mouse model where Gata2 expression is found in almost all IAHCs. The hematopoietic 
cell clusters are also found in the YS vasculature (Figure 3C). Vital imaging of the mouse 
embryonic aorta at the time of HSC generation revealed the transition of morphologically 
flat endothelial cells to cells that bulge out of the vascular wall and form round 
hematopoietic cells in the lumen of the aorta. This process was visualized in Ly6a (Sca1) 
GFP fluorescent reporter transgenic embryos. GFP is expressed in all embryonic and 
adult HSCs in the mouse (Chen et al., 2011; de Bruijn et al., 2000; Li et al., 2012; Ma et 
al., 2002; Ottersbach and Dzierzak, 2005) and hence, is an excellent reporter for 
observing the emergence of HSCs. To visualize EHT in the aorta by confocal time-lapse 
imaging, thick sections of Ly6aGFP E10.5 embryos were stained with a combination of 
antibodies against hematopoietic and endothelial cell surface markers (Boisset et al., 
2010). HECs that give rise to HSCs could be distinguished from other aortic endothelial 
cells by the expression of GFP. Rare GFP+cKit+CD41+ cells were observed bulging into 
the lumen of the aorta directly from GFP+CD31+ ventral aortic endothelial cells, thus 
facilitating tracking single cells as they transition from an endothelial cell to a HSC/HPC. 
This process is generally known as the endothelial-to-hematopoietic transition (EHT).  
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Figure 3. Emergence of HSCs through EHT in the AGM and in the YS. 
A) A subset of aortic endothelium – the hemogenic endothelial cells (HEC), transdifferentiate to
form intra aortic hematopoietic cluster cells (IAHC) and hematopoietic stem cells (HSC). Drawing
of a transverse section through mouse aorta indicating HECs, IAHCs and emerging HSCs. B)
Gata2 is one of the pivotal transcription factors marking HECs, IAHCs and emerging HSCs. Thus,
Gata2Venus reporter expression can be exploited to visualize the emergence of HSCs. Upper
panel displays an immunostained fluorescent image of a transverse section of embryonic day (E)
10.5 aorta-gonads-mesonephros (AGM) region. Lower panel shows magnified IAHCs in the
dotted square region of the upper panel. Gata2 (green) is found in most of the CD34+ (red) IAHCs
(arrowhead) and in some endothelial cells. Gata2 is also detected in a few round CD34- cells
(asterisk) that are closely associated with IAHCs suggesting that they arose from clusters. C)
CD34+Gata2+ clusters are also found in the YS vasculature. Size bars 20 μm.
EHT has also been imaged in zebrafish embryos, however the process is slightly different 
than that observed in the mouse embryos. The HECs in zebrafish bulge ablumenally, 
and emerge as hematopoietic cells in the interstitial region between the aorta and axial 
vein. Moreover, multi-cell clusters do not form. Emerging zebrafish HSCs/HPCs are 
marked by c-Myb expression (Jing and Zon, 2011). Vital time-lapse imaging of compound 
transgenic c-Myb-GFP:Kdr1(Flk1 endothelial marker)-mCherry zebrafish embryos 
demonstrates that hematopoietic cells acquiring CD41 expression emerge directly from 
endothelium in the ventral side of the dorsal aorta (Bertrand et al., 2010; Bertrand et al., 
2008; Kissa and Herbomel, 2010). They move quickly to extravasate into the lumen of 
the axial vein where they enter the circulation. They are next found to enter specific 
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niches in caudal hematopoietic tissue, the equivalent of the mouse fetal liver (Tamplin et 
al., 2015).  
EHT has also been recapitulated in vitro and detected by time-lapse imaging of ESC 
hematopoietic differentiation cultures. ESC-derived cells expressing the endothelial 
marker Tie2 and cKit, when exposed to hematopoietic culture conditions, give rise to 
CD41+ hematopoietic cells that down-regulate Tie2 (Eilken et al., 2009; Lancrin et al., 
2009). Together these data provide in vitro and in vivo morphological and phenotypical 
evidence of HSC/HPC emergence via EHT – a process that is conserved in human ESCs 
(Rafii et al., 2013) and all vertebrate embryos (Jaffredo et al., 2005) thus far examined.  
The Gata2 transcription factor - a pivotal regulator of HSC/HPC development 
The Gata2 (GATA binding protein 2) transcription factor is one of the key players in the 
development of HSCs and HPCs. It belongs to the evolutionarily conserved Gata 
transcription factor family, together with 5 other members (Gata1-6). They get their name 
from the DNA motif A/TGATAA/G what they bind to, and they have two conserved zinc 
finger domains (Bresnick et al., 2010; Ko and Engel, 1993). Three Gata family factors are 
associated with hematopoiesis - Gata2 with HSCs/HPCs, Gata1 with mainly erythroid 
development and Gata3 with T lymphopoiesis (Ho et al., 1991; Kitajima et al., 2006). 
Gata2 and Gata3 expression is also detected in the developing central nervous system 
(Nardelli et al., 1999) and Gata3 has been associated with the developmental regulation 
of several tissues such as the ear, kidney and mammary gland (Asselin-Labat et al., 
2007, Labastie et al., 1995, Karis et al., 2001). Gata4-6 are involved in cardiac 
development (Charron and Nemer, 1999; Molkentin et al., 2000). Gata2 is dysregulated 
in several hematological malignancies, including MonoMac disease, Emberger’s 
syndrome and familial AML and myelodysplastic syndrome reviewed in (Bresnick et al., 
2012; Spinner et al., 2014). 
The importance of the Gata2 in the process of HSC/HPC generation was first highlighted 
by the creation of a germline knockout mouse model. Strikingly, Gata2 homozygous 
deletions resulted in embryonic lethality at E10.5 (e.g. the time of the first HSC 
emergence) that was accompanied by severe fetal liver anemia (Okuda et al., 1996; Tsai 
et al., 1994). Functional studies revealed that Gata2-/-  embryos are defective for 
‘definitive’ hematopoiesis, as demonstrated by greatly reduced progenitor numbers (Ling 
et al., 2004; Tsai et al., 1994). In vitro hematopoietic differentiation experiments with 
Gata2-/- ESCs show that they retain the ability to undergo ‘primitive’ erythroid 
differentiation, however, at reduced levels. ‘Definitive’ hematopoietic progenitor 
generation is profoundly impaired. Analysis of ESC-generated Gata2-/- chimeric mice 
revealed a lack of knockout cell contribution to any of the hematopoietic organs (Okuda 
et al., 1996; Tsai et al., 1994).  
The temporal and spatial expression patterns of Gata2 in the embryo (as determined by 
in situ hybridization and immunostaining) support their important cell-intrinsic role in HSC 
and HPC generation. Gata2 is expressed at E8.0 in the YS, which at that time is the main 
site of hematopoietic cell generation (Minegishi et al., 2003; North et al., 1999; Robert-
Moreno et al., 2005). Gata2 is expressed in IAHCs in the embryonic arteries and all such 
hematopoietic clusters are absent in the aortae and other major arteries of the Gata2-/- 
embryos (Chen et al., 2009; de Pater et al., 2013; Nardelli et al., 1999; North et al., 1999; 
Pimanda et al., 2007). 
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The continuum of expression during the transition from endothelial cells to hematopoietic 
cluster cells in static images of the aorta implicates a role for Gata2 in the process of 
EHT. Indeed, conditional deletion of Gata2 in hemogenic endothelium marked by 
vascular endothelial-cadherin (Vec) demonstrates that it is essential in the HECs for the 
formation of hematopoietic clusters and importantly, for the generation of functional HPCs 
and HSCs (Chen et al., 2011; de Pater et al., 2013; Zovein et al., 2008). Gata2 continues 
to be essential in the HSCs after they are made, as demonstrated by Gata2 deletion in 
Vav-Cre (expressed in HSCs) conditional knockout embryos (de Pater et al., 2013). Thus, 
Gata2 plays pivotal role in hematopoietic development, affecting mainly the ‘definitive’ 
stage in which multipotent HPCs and HSCs are generated, and continues to be required 
for the maintenance of the emerged HSCs. 
Strictly controlled Gata2 expression levels determine the progression of EHT 
It is of importance to note that HSC and HPC development is highly dependent on the 
Gata2 expression levels. Gata2+/- embryos have profoundly reduced numbers of AGM 
HSCs, HPCs, and IAHCs. The bone marrow of Gata2+/- adult mice contains normal 
quantities of HSCs, but these are qualitatively impaired, as observed in competitive 
transplantation assays (de Pater et al., 2013; Ling et al., 2004; Rodrigues et al., 2005). 
Overexpression of Gata2 also results in abnormal hematopoiesis: it reduces bone 
marrow colony forming unit-cell (CFU-C) and colony forming unit-spleen (CFU-S) activity 
and results in a failure of multilineage reconstitution (Gao et al., 2013). Hematopoietic 
differentiation of ESCs overexpressing Gata2 suggests that abnormally high Gata2 
expression blocks T and B cell generation, resulting in myeloid-biased cell production 
(Ikonomi et al., 2000; Nandakumar et al., 2015). Thus, Gata2 expression levels are likely 
to be involved in controlling cell fate decisions. Recent transcriptome analysis of placental 
cells suggests that Gata2 is continuously expressed in hemogenic and hematopoietic 
progenitors, but downregulated during commitment to blood lineages (Pereira et al., 
2016). Also, Gata2 expression is downregulated during ESC-derived hemangioblast 
differentiation into blast cells (Lugus et al., 2007), thus indicating that levels of Gata2 may 
play a role in HSC and HPC expansion and potency. 
Gata2 functions synergistically with Runx1 to regulate its downstream targets 
Although deletion of a single allele of Gata2 or Runx1 (another pivotal hematopoietic 
transcription factor) disrupts HSC and HPC development, it does not result in embryonic 
lethality (Cai et al., 2000; North et al., 1999; Tsai et al., 1994). Strikingly, the analysis of 
Gata2+/-: Runx1+/- compound embryos showed a trend towards fewer hematopoietic 
progenitors and the absence of double haploinsufficient offspring due to embryonic 
lethality (Wilson et al., 2010). These data suggest that Gata2 functions together with 
Runx1 in the same cells to control the expression of hematopoietic genes involved in 
HSC and progenitor cell generation.  
Further evidence for combinatorial function of Gata2 and Runx1 comes from an extensive 
Chromatin Immunoprecipitation Seq (ChIP-seq) and bioinformatics analysis revealing 
interaction complexes between a heptad of hematopoietic cell specific transcription 
factors that includes Runx1 and Gata2. The vast majority of heptad bound promoter and 
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enhancer regions of hematopoietic genes contain a GATA consensus binding sequence. 
Only approximately 40% of them contain a Runx consensus binding motif, suggesting 
that the formation of a complex and/or Gata2 binding may be required for the recruitment 
of Runx1 to the regulatory elements within the complex (Wilson et al., 2010). Similar 
higher order protein complexes, such as the Ldb1 complexes, are found in erythroid cell 
development where adaptor molecule Ldb1 mediates the interactions between a variety 
of binding partners (Meier et al., 2006; Mylona et al., 2013). Combinatorial interactions 
within the heptad complex result in hematopoietic cell type-specific chromatin binding 
and downstream gene expression. How exactly the complex functions in cell fate 
specification is yet unknown. Whether the factors act sequentially or all at the same time, 
whether they regulate each other, and how individual factor levels affect complex 
formation is a matter of debate.  
Runx1 
Similar to Gata2, Runx1 plays a crucial role in HSC/HPC development as was first 
revealed by the homozygous deletion of Runx1 that resulted in embryonic lethality (at 
E12.5) accompanied by severe hematopoietic defects (Okuda et al., 1996; Tsai et al., 
1994). Functional studies revealed that although Runx1-/- mice make ‘primitive’ 
hematopoietic cells, they completely lack ‘definitive’ hematopoietic progenitors in the YS 
and fetal liver, and importantly, no HSCs are generated in the AGM (Cai et al., 2000; 
Okuda et al., 1996). Mutant ESC differentiation studies show that Runx1-/- ESCs generate 
fewer ‘primitive’ erythroid cells, and the generation of ‘definitive’ hematopoietic 
progenitors is profoundly compromised. Like the deletion of Gata2, Runx1-/- ESCs were 
unable to contribute to any of the hematopoietic organs (Okuda et al., 1996; Tsai et al., 
1994).  
Runx1 is expressed at E8.0 in the YS. Slightly thereafter, from E8.5 to E11.5, Runx1 
expression marks the endothelial cells on the ventral side of the aorta, umbilical and 
vitelline arteries, placenta and IAHCs. As a result of Runx1 deletion, all hematopoietic 
clusters are absent in the aortae and other major arteries (Chen et al., 2009; North et al., 
1999; Li et al., 2012; Rhodes et al., 2008). Conditional deletion of Runx1 in Vec/Tie2-Cre 
expressing HECs, demonstrates its requirement for the formation of hematopoietic 
clusters and for the generation of functional HPCs/HSCs (Chen et al., 2011; de Pater et 
al., 2013; Zovein et al., 2008). It has been shown by tamoxifen-induced deletion of Runx1 
in Vec-Cre expressing cells that Runx1 is specifically required for HSC generation 
between E10.5 and E11.5 (Tober et al., 2013). The vital imaging of Runx1 morphant 
zebrafish embryos provided an interesting insight into its role. In the absence of Runx1, 
aortic endothelial cells undergo sudden death as they attempt transition to hematopoietic 
cells, thus suggesting that Runx1 is required during EHT for the survival of emerging 
hematopoietic cells (Kissa and Herbomel, 2010). However, Runx1 is not required for the 
maintenance of HSCs after they have been generated (Chen et al., 2009, Liakhovitskaia 
et al., 2014), thus suggesting for a more strict role than Gata2.  
Runx1 also functions in a dose dependent manner. Runx1+/- embryos generate fewer 
HPCs and HSCs (Cai et al., 2000; Mukouyama et al., 2000; Robin et al., 2006; Wang et 
al., 1996). Fascinatingly, Runx1+/- embryos experience a temporal shift in the emergence 
of HSCs. HSCs are detected earlier than normal: at E10 in the AGM and YS, and HSC 
generation is prematurely terminated in the E11 AGM (Cai et al., 2000). The E10.5/11.5 
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aorta in Runx1+/- embryos have fewer IAHCs, suggesting that Runx1 haploinsufficiency 
reduces HSC generation, maintenance and/or proliferation.  
 
Taken together, the expression and function of Gata2 greatly overlaps with the one of 
Runx1, although the requirement for Runx1 is temporally more restricted. The fact that 
Gata2 and Runx1 double haploinsufficiency is lethal, while single factor 
haploinsufficiency is not, demonstrates these transcription factors act in concert to 
regulate HSC/HPC development. Importantly, the dose dependent requirement of both 
factors illustrates the highly-tuned control over hematopoietic development and suggests 
that depending on the expression level, they may define different cellular identities.  
Gpr56, a downstream target of Gata2, is a novel positive regulator of 
hematopoiesis 
As described in the previous section, downstream hematopoietic gene targets of the 
heptad transcription factors have been identified through genome-wide analysis in a 
hematopoietic progenitor cell line, HPC-7 (Wilson et al., 2010). The expression of these 
heptad factors was recently examined by RNA sequencing of cells undergoing EHT in 
vivo (endothelial cells, hemogenic endothelial cells, HPCs and HSCs) in the AGM at the 
time of HSC generation (Solaimani Kartalaei et al., 2015). Comparative transcriptome 
datasets show that heptad transcription factor expression is increasing during EHT, and 
is accompanied by transcriptional activation of several downstream target genes. One 
such target gene is the G-protein coupled receptor 56 (Gpr56) that is significantly 
upregulated (38-fold) in HSCs as compared with hemogenic endothelial cells (Solaimani 
Kartalaei et al., 2015). Notably, Gpr56 expression is downregulated as a result of Gata2 
(regulatory element) deletion, which is accompanied with severe disruption of 
hematopoiesis and embryonic lethality (Gao et al., 2013). Moreover, chromatin 
immunoprecipitation (ChIP) experiments reveal direct binding of Gata2 to the Gpr56 +37 
enhancer (Solaimani Kartalaei et al., 2015; Chacon et al., 2014) thus indicating that 
Gpr56 is a direct target of Gata2. The precise function of Gpr56 in hematopoiesis is as 
yet unknown. Studies in the 32D cell line show that Gpr56 expression keeps cells in a 
blast cell stage blocking their terminal differentiation (Solaimani Kartalaei et al., 2015). 
Hence it is likely that Gpr56 is involved in vivo for the acquisition of the self-renewal 
properties during the embryonic generation of hematopoietic progenitors and/or stem 
cells. This is supported by the finding of highly upregulated expression of Gpr56 in difficult 
to treat AMLs where it regulates anti-apoptotic functions (Saito et al., 2013). In zebrafish, 
it has been shown that Gpr56 knockdown abrogates HSC/HPC emergence in the dorsal 
aorta (Solaimani Kartalaei et al., 2015) thereby supporting its functional involvement in 
EHT, but its function in the process of HSC generation in vertebrate development is as 
yet unknown. 
The concept of preHSCs - do HSCs establish their fate prior to EHT?  
Vital imaging of vertebrate embryos demonstrates that HSCs and HPCs are generated 
by morphological transdifferentiation of specialized endothelial cells (Boisset et al., 
2010), and genetic tracing studies show that functional HSCs/HPCs descend from cells 
expressing endothelial markers (Zovein et al., 2008). But when is hematopoietic fate, and 
more precisely, when is HSC fate established? Current research interests are addressing 
the issue of whether HSC fate and function is determined in the endothelium during EHT, 
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or primed earlier or later in development. 
A Runx1+23 enhancer GFP (+23GFP) reporter mouse was used to explore this issue 
(Nottingham et al., 2007; Swiers et al., 2013). Runx1 expression in vast majority of mouse 
hematopoietic stem and progenitor cells and aortic endothelial cells is controlled by a 
Runx1 +23 enhancer, thus the +23GFP mouse model allows specific isolation of 
hemogenic endothelial cells (Nottingham et al., 2007; Swiers et al., 2013). Transcription 
analysis (Fluidigm) with a panel of endothelial and hematopoietic genes demonstrated 
that at E8.5 the +23GFP expressing aortic hemogenic endothelium is distinguished from 
+23GFP negative endothelium by higher expression of hematopoietic regulators such as
Meis1, Gata2, Gata3 and TAL1. Single cell transcriptome analysis showed in
approximately 50% of +23GFP hemogenic endothelial cells that higher Meis1 expression
is accompanied by downregulation of the endothelial marker Etv2, thus arguing for
hematopoietic fate establishment earlier than previously recognized (Swiers et al., 2013).
At a later developmental time (at E10.5) in the Ly6a GFP model, the transcriptome of the
aortic hemogenic endothelial fraction (CD31+ckit-GFP+) showed differences to the
endothelial fraction (CD31+ckit-GFP-), with heptad transcription factor and Notch gene
expression increased (Solaimani Kartalaei et al., 2015). Few indications of hematopoietic
gene expression were found in the hemogenic endothelial fraction as compared to the
HPC/HSC fraction (CD31+ckit+GFP+). However, these experiments were performed with
populations of sorted cells and await single cell transcriptomic analysis. Importantly, the
expression of the heptad factors is the first and pivotal step directing a hematopoietic
program, and as such Runx1+23GFP is an excellent indicator showing that the
hemogenic and hematopoietic programs are established already in a subset of
endothelial cells at the beginning stage of ‘definitive’ hematopoietic cell development.
If hematopoietic and HSC commitment occurs earlier than functional HSCs emerge, the 
aortic endothelium may harbor immature cells that in the proper microenvironment are 
able to mature into functional HSCs. To test this, an OP9 stromal cell co-aggregation 
culture was established that facilitates the ex vivo maturation of 
hematopoietic/endothelial cells obtained by multi-surface marker phenotypic sorting 
(Rybtsov et al., 2011). Using this approach, it was shown that E9.5 dorsal aorta contains 
a VEC+CD41+CD45-CD43- cell population (termed pro-HSC) that lacks repopulating 
activity in direct in vivo transplantation assays. However, when co-aggregated with OP9 
and ex vivo cultured for 7 days in the presence of SCF, IL-3 and Fms-related tyrosine 
kinase 3 ligand (Flt3L), this population is able to reconstitute the hematopoietic system 
of the recipient (Rybtsov et al., 2014). These pro-HSCs are almost devoid of endothelial 
cells and it is thought that they may represent a stage directly downstream of the 
Runx1+23GFP+ hemogenic endothelium present in the E8.5 AGM (Swiers et al., 2013).  
Also, the E10.5 and E11.5 AGM is thought to contain immature HSCs. This 
VEC+CD41lowCD45-CD43+ population (termed pre-HSC) up-regulates CD45 expression 
when co-aggregated with OP9 and mature into functional, repopulating HSCs (Rybtsov 
et al., 2011). Interestingly, it has been proposed that the pre-HSCs may be generated 
independently of Runx1, as a developmental block is not observed before the transition 
of CD41+ cells to CD45+ in Runx1 deficient mice (Liakhovitskaia et al., 2014). Cells with 
a pre-HSC phenotype are present also in the E11.5 YS and FL, but they are not able to 
mature into engrafting HSCs. Thus, functional pre-HSCs are thought to be present mainly 
in the AGM region and in the extraembryonic arteries (Boisset et al., 2015; Gordon-
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Keylock et al., 2013; Rybtsov et al., 2014; Rybtsov et al., 2011).  
 
These data propose that definitive HSCs may be primed for a hematopoietic gene 
expression program very early in development, making the precise temporal onset of the 
HSC program debatable. However, it should be taken into account that ex vivo 
manipulations, such as stromal cell and explant (co-)cultures, consequently introduce 
new variables into the model, that might not be present in in vivo. Advances in in vivo 
lineage and vital imaging tracing tools and single cell transcriptomics will assist in further 
investigations of such cells under more physiologic conditions representative of the in 
vivo embryonic milieu.  
The divergence in the HSC emergence path 
Recent studies have suggested that mouse embryonic head produces adult HSCs and 
HPCs independently from other hematopoietic organs and circulation. Lineage tracing 
experiments show that embryonic head-derived HSC progeny contribute to the adult HSC 
population (Li et al., 2012). However, to date, it has not been demonstrated that the head 
HSCs are emerging via an EHT in a similar manner to those in AGM. Moreover, the head 
vasculature lacks IAHCs (Iizuka et al., 2016; Li et al., 2016). Also, head HSCs do not 
seem to go through the putative pre-HSC state since no/few pre-HCSs have been 
reported in the head as demonstrated by OP9 co-aggregation culture of E11.5 head 
region (Rybtsov et al., 2016). These studies suggest that there may be an alternative way 
by which functional HSCs are generated, and could include generation in different spatial 
and temporal frameworks, and different regulatory programs and networks. Defining such 
mechanisms could contribute to answering questions currently arising in the field of 
hematopoiesis: for instance, such information may clarify the source of heterogeneity 
among HSCs – BMP-activated and BMP-non-activated, myeloid or lymphoid biased 
(Crisan et al., 2015; Yamamoto et al., 2013). Also, it may provide insight into why there 
are many more HPCs in the IAHCs than HSCs (Boisset et al., 2015), and explain the 
source of the large cohort of FL HSCs that appears within 24 hours following the 
generation of the first HSCs in the AGM, and the rapid decrease in the pre-HSC numbers 
in the AGM (Rybtsov et al., 2016). 
Approaches to generate bone fide HSCs 
The importance of precisely characterizing all the discrete steps and distinct factors 
required for in vivo HSC/HPC development lies in the ability to apply this knowledge to 
ex vivo cell culture strategies with the potential to drive HSC generation. As there is 
shortage of HSCs for clinical cell replacement therapies to treat blood-related genetic 
diseases and leukemia, there is a need for their bone fide generation, as well as for 
protocols facilitating their ex vivo expansion. Early studies by Doetchman et al., gave 
initial evidence that mature blood cells can be generated from ESCs (Doetschman et al., 
1985). This lead to the thinking that it might be possible to derive HSCs from pluripotent 
stem cells (Figure 2 lower panel). Indeed, the principle basis of generating long-term 
engrafting HSCs from pluripotent stem cells has been shown by studies transplanting 
undifferentiated mouse and human induced pluripotent stem cells (iPSCs) into 
immunocompromised mice. The teratomas that developed from the injected iPSCs 
contained donor-cell derived HSCs, and when the putative HSCs were isolated and 
transplanted, they repopulated the hematopoietic system (Amabile et al., 2013; Suzuki 
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et al., 2013). Followed the initial study by Doetchman, a few groups reported the 
successful generation of multilineage repopulating HSCs from mouse ESCs by the use 
of serum/cytokines (Burt et al., 2004; Palacios et al., 1995). Unfortunately, these results 
did not lead to the development of a robust HSC generation method. Another approach 
to obtain engrafting HSCs takes advantage of the genetic manipulation of pluripotent 
stem cells (PSC) by the overexpression of (transcription) factors (Kitajima et al., 2011; 
Kyba et al., 2002; Matsumoto et al., 2009; Wang et al., 2005). However, these results 
have not been translated into a human PSC platform, and the use of genetic manipulation 
(and possibly oncogenes) hampers the use of these cells in clinical applications. A more 
recent approach relies on the dogma, introduced by Yamanaka and colleagues 
(Takahashi and Yamanaka, 2006), that somatic cell fate can be changed by specific 
transcription factors, known as reprogramming. In these studies, a carefully selected 
cocktail of hematopoietic transcription factors is expressed in mature cells to convert 
them phenotypically and functionally into (induced) HSCs (Riddell et al., 2014; Sandler 
et al., 2014; Vereide et al., 2014). In addition, these studies demonstrate that when 
knowing the correct factors, a pluripotent state can be bypassed, thus avoiding many of 
the risks and limitations involved in the PSC differentiation approaches. These studies 
potentially represent a major advance towards achieving clinically-relevant HSCs, 
however, so far, no defined cocktail of factors, their essential dosage or temporal 
expression requirement has been reported that enables robust HSCs derivation. Thus, 
there is still a long way to go in order to specifically define and describe the path for in 
vitro HSC development. Moreover, most of these studies used integrating vectors, which 
may lead to insertional mutagenesis, introduces another hurdle that has to be overcome 
in order to translate this methodology into clinic.  
The main goals of this study are to understand the involvement of Gata2 in the stepwise 
establishment of the adult blood system. We aim to explore how Gata2 functions in the 
process of the HPC/HSC development in vivo, and whether the readout can be applied 
in vitro to better understand the PSC hematopoietic differentiation cultures. We 
hypothesize that Gata2 has a vital role in the establishment of the in vivo HPC/HSC fate 
and in the generation of blood (progenitor) cells in vitro, and thus, Gata2 reporter 
facilitates the tracing and isolation of hematopoietic (progenitor/stem) cells emerging in 
the ESC differentiation cultures.  
The specific aims of this thesis are: 
1. To explore, compare and contrast Gata2 transcription factor expression during
embryonic hematopoietic development in a Gata2Venus mouse model and
embryonic stem cells.
2. To investigate the functional potential of Gata2 expressing cells during in vivo and
in vitro hematopoietic development and differentiation.
3. To examine the role of Gpr56, a Gata2 downstream target signaling molecule in
Gata2Venus ESCs.
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Scope of the thesis 
The adult hematopoietic system consists of a hierarchy of cells that progress from a stem 
cell state to the terminally differentiated cells of over ten functionally distinct blood cell 
lineages. While hematopoietic stem cells (HSC) are rare, long-lived and self-renewing, 
there are many intermediate progenitor cell types that lose their multi-lineage and self-
renewing potency in a stepwise manner before becoming mature functioning blood cells. 
The maintenance and homeostasis of the adult hematopoietic system relies on the 
balanced self-renewal and differentiation of the HSCs. HSC transplantation has been 
used since the 1950s, and has yielded significant therapeutic success in curing blood 
cancer and patients with blood-related genetic disease. Nonetheless, several restrictions 
in using these adult stem cells in transplantation apply, including insufficient availability 
of compatible donors, shortage of stem cells in samples and inability to expand them ex 
vivo. One way to overcome these limitations is to attempt to generate HSCs in vitro by 
utilizing the recent advance of induced pluripotent stem cell technology and their 
hematopoietic differentiation. Today, this approach is still challenged by the limited 
understanding of the signals and factors that drive the stepwise emergence of blood 
(stem/progenitor) cells in vivo, thus subsequently hampering the in vitro production of 
clinically-relevant HSCs for blood cancer therapies. 
One of these pivotal components in embryonic generation of HSC is the Gata2 
transcription factor, whose role in the differentiation and specification of blood cells is the 
focus of this thesis.  
Chapter 1 is dedicated to introducing the current knowledge about events and factors 
involved in the stepwise embryonic development of the hematopoietic system and HSCs, 
and the establishment of the adult hematopoietic cell hierarchy. Chapter 2 utilizes two 
embryonic stem cell (ESC) reporter lines (Gata2Venus and Ly6AGFP) to temporally trace 
the development and emergence of hematopoietic (progenitor) cells that possess 
increasingly complex mulitlineage hematopoietic potential. These reporters are well 
described in the mouse embryogenesis, thus facilitating a comparison between in vivo 
waves of hematopoiesis and in vitro ESC differentiation to enrich and isolate functional 
hematopoietic cells with defined potency. The Gata2 downstream target Gpr56 is 
potentially a novel positive regulator of HSC/HPC emergence. Chapter 3 utilizes 
Gata2Venus reporter ESCs to investigate the involvement of Gpr56 hematopoiesis, 
revealing its redundant requirement for the generation of multipotent hematopoietic 
progenitors. Besides hematopoietic stem and progenitor cells, Gata2 expression is also 
specific for mast cells. Chapter 4 takes advantage of the Gata2Venus ESC reporter line 
to introduce a novel approach in rapidly generating mast cells for inflammation and 
allergy research. In Chapter 5, the Gata2Venus mouse model (generated from the 
Gata2Venus ESCs) is described. Venus fluorochrome expression in vivo recapitulates 
the expression of Gata2 and allows for the isolation of live Gata2-expressing cells, 
revealing that Gata2 marks all functional HSCs, but not all HPCs, thus identifying a 
Gata2-indepenent progenitor population. Finally, in Chapter 6, the main findings of this 
thesis, their relevance and importance to our understanding of HSC and hematopoietic 
progenitor generation and differentiation are discussed, together with providing 
applications and future directions of this work. 
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Abstract 
In vivo hematopoietic generation occurs in distinct waves of primitive and definitive 
progenitor, and hematopoietic stem cell (HSC) emergence. The differentiation of 
pluripotent stem cells (PSC) potentially offers a source for hematopoietic cell therapies, 
but, despite many approaches, it is still not possible to robustly generate hematopoietic 
cells in vitro. This is partly due to the inability to trace/enrich hematopoietic emergence 
by precise temporal programs. We use novel Gata2Venus (G2V) and Ly6aGFP (LG) 
PSC reporters derived from mice, where they mark emerging hematopoietic 
progenitor/stem cells. We show that in vitro hematopoietic differentiation occurs in distinct 
waves of primitive and definitive potential traced by the G2V reporter. These stages are 
followed by LG expression discriminating a third wave of hematopoietic emergence. 
These results, facilitated by tracing/enrichment of cells with progressive hematopoietic 
properties, demonstrate that in vitro PSC differentiation is analogous to the waves of 
hematopoietic cell generation found in the mouse embryo. 
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Introduction 
Since the first report of blood cell production from embryonic stem cells (ESC) more than 
30 years ago (Doetschman et al., 1985), it has been a long term goal to use such cultures 
of pluripotent stem cells (PSC) to produce mature hematopoietic cells, definitive 
hematopoietic progenitor cells (HPC), and hematopoietic stem cells (HSC). With the 
advent of patient-specific induced pluripotent stem cells (iPSC), this approach could 
potentially be used in cell replacement therapies for treating blood disorders without the 
adverse effects of rejection. Whereas some progress towards differentiation into distinct 
blood lineages has been made through addition of growth factors to ESC/iPSC 
differentiation cultures (Doulatov et al., 2013; Kennedy et al., 2012; Pearson et al., 2015; 
Vodyanik et al., 2005), and some limited in vivo repopulation has been achieved by 
overexpression of transcription factors (Kyba et al., 2002), the ex vivo approaches have 
provided little insight into whether these cultures recapitulate the in vivo hematopoietic 
development.  
The natural development of the hematopoietic system begins in the conceptus just after 
the emergence of mesodermal cells from the primitive streak. It occurs in 
spatiotemporally distinct waves (reviewed in (Dzierzak and Speck, 2008; Kauts et al., 
2016)). The first wave of hematopoietic cell generation occurs in the yolk sac (YS) blood 
islands at mouse embryonic day 7 (E7), producing a transient cell population consisting 
mainly of primitive erythrocytes (Palis et al., 1999). Definitive erythrocytes and myeloid 
cells appear in the YS starting at E8.25 and originate from erythroid-myeloid progenitors 
(EMP) (Bertrand et al., 2007; Frame et al., 2013). Shortly thereafter, progenitors with 
erythroid-myeloid-lymphoid potential arise (Godin et al., 1995). The production of HSCs 
is initiated in the final wave starting at E10.5 in the aorta-gonads-mesonephros region 
(AGM) (Medvinsky and Dzierzak, 1996; Muller et al., 1994) and is tightly controlled by a 
combination of extrinsic and intrinsic factors.  
The Gata2 transcription factor plays a pivotal intrinsic role in EMP, HPC and HSC 
generation in the embryo (de Pater et al., 2013; Gao et al., 2013). Gata2-/- mouse and 
human ESCs show defective hematopoietic differentiation (Huang et al., 2015; Tsai et 
al., 1994). In our Gata2Venus (G2V) reporter mice, in which levels of Gata2 expression 
are normal, it was found that Gata2 expression marks all HSCs and the majority of HPCs 
(Kaimakis et al., 2016). Gata2 expression is found in endothelial cells of the E8.5 YS and 
dorsal aorta. It continues to be expressed in the E10.5 YS hematopoietic cells and in the 
aorta where it is detected in cKit+CD31+ hematopoietic cluster cells (Kaimakis et al., 
2016). A recent study reports that the majority of human ESC-derived HPCs are also 
marked by GATA2 expression (Huang et al., 2016). Thus, fluorescent reporter expression 
driven from pivotal hematopoietic regulators have facilitated the examination of 
HPC/HSC as they emerge in the mouse embryo. Another fluorescent reporter that marks 
hemogenic endothelial cells and some hematopoietic cluster cells in the embryo is 
Ly6a(Sca1)GFP (LG). The expression of this transgene marks all HSCs and the 
HSC/HPC-generating hemogenic endothelium (Chen et al., 2011; de Bruijn et al., 2002; 
Solaimani Kartalaei et al., 2015) and allowed the observation of endothelial-to-
hematopoietic-transition of these cells in the E10.5 mouse aorta (Boisset et al., 2010). 
However, unlike G2V, LG expression is initiated in the AGM only beginning of late E9 
(Mascarenhas et al., 2009), and thus, it distinguishes the induction of the intraembryonic 
definitive HPC/HSC program. 
34
Taking into account the highly complicated spatiotemporal organization of in vivo blood 
development, it is likely that the ability to generate definitive HPC/HSC in vitro in a robust 
manner will depend on a better understanding of the precise temporal molecular and 
cellular programs occurring in the ESC differentiation cultures, and rely on enrichment 
methodologies with pivotal reporters to identify and isolate the cell populations of interest. 
Such reporters can provide a powerful tool to study the dynamics of functional HPC/HSC 
generation in in vitro PSC differentiation cultures and their relationship to normal 
developmental HPC/HSC generation.  
Here we examine the temporal expression of the novel G2V and LG reporters in a 
stepwise system of induction, enrichment, and differentiation of ESCs to examine the 
emergence and progress of functional hematopoietic activity. We show that the temporal 
wave-like expression of the G2V reporter during ESC differentiation corresponds to 
waves of primitive and definitive hematopoietic emergence. Gata2 is co-expressed in 
these cells with all hematopoietic heptad transcription factors and marks all functional 
HPCs emerging in the sequential primitive and EMP-definitive waves. LG expression is 
specific to HPCs that emerge/persist in later differentiation stages, exclusively marking 
multipotent definitive progenitors. Thus, our models demonstrate that ESC hematopoietic 
differentiation occurs in a spatiotemporal wave-like manner that is highly analogous to 
the three in vivo waves of hematopoietic cell generation in the mouse embryo.  
Experimental procedures 
ESC differentiation. ESC differentiation was performed as described in Keller et al., 
(2002). ESCs were harvested by trypsinization and MEF depleted by incubating in IMDM 
+ 15% FSC (HyClone) + 1 % P/S (Gibco) for 30 minutes. EB formation was induced by
culturing 25 000 cells/ml on a shaker at 40 rpm. On day 3, the EB medium containing
IMDM +15% FBS (HyClone), +1% P/S, 2mM GlutaMAX (Gibco), 50 µg/ml ascorbic acid
(Sigma), 4x10-4 M monothgioglycerol (Sigma), 300 µg/ml transferrin (Roche) was
supplemented with 5% proteome free hybridoma medium (Gibco). From day 6 onwards,
100 ng/ml SCF, 1 ng/ml IL-3 and 5 ng/ml IL-11 were added. For hemangioblast analysis,
5 ng/ml BMP4 was added on day 0-3 (all PeproTech).
FACS analysis/sorting. EBs were washed 1x with PBS and incubated in TrypLE Express 
(Gibco) at 37°C for 3-5 minutes. Enzyme was deactivated by adding PBS + 10% FBS + 
1% P/S and a homogenous single-cell suspension was obtained by re-suspending with 
a P1000 pipette. G2V expression could be detected readily in the cells. Antibody staining 
was performed on ice for 30 minutes at a concentration of 106 cells/100 μl. Antibodies 
are listed in Supplementary Table 1. Dead cells were excluded with Hoechts33342 
(Invitrogen). Cells were analyzed on FACS Scan, Fortessa (5LSR, 6LSR) or sorted on 
FACS Aria III SORP or Fusion (BD). Data analysis was performed with FlowJo software 
(Tree star). 
Hematopoietic progenitor assay. For the generation of blast colonies (BL-CFC assay), 
day 3 EB derived cells were plated in methylcellulose (Stem Cell Technologies) 
supplemented with 10% FCS, vascular endothelial growth factor (VEGF, 5 ng/mL) and 
IL6 (10n g/mL) (both PeproTech). After 4 days in culture, blast cell colonies were 
35
analyzed under the microscope and counted. For the differentiation of hematopoietic 
precursors, day 6-14 EB derived cells were plated in methylcellulose medium. After 12-
14 days in culture, colonies were scored under Zeiss Axiovert25 microscope.  
Matrigel assay. On day 4, EBs were sorted into four populations based on Flk1/Venus 
expression using gating strategy shown in Fig 1B. 2x104 cells from each population were 
pre-cultured in gelatin-coated 96-well plate in DMEM + 20% FBS + 1% P/S for 20 hours. 
Matrigel-coated wells were prepared using the thin gel method. Briefly: 60 µl matrigel 
(Qiagen) was plated onto 96-well plate wells and let to polymerize for 30 minutes at 37ºC. 
Cells were trypsinized, transferred onto matrigel-coated wells, and cultured in EGM-2 
medium (Lonza) for 4 hours. Tubule formation was quantified using Angiogenesis 
Analyzer (Gilles Carpentier ImageJ News 2012) plugin for Fiji. 
RNA isolation, cDNA preparation, real-time RT-qPCR. Up to 106 cells were lyzed in TRI-
Reagent (MRC) and total RNA was isolated according to the manufacturer’s protocol. 1 
µg of total RNA was subjected to DNase (Invitrogen) treatment. RNA from sorted cell 
populations was isolated using RNeasy micro kit (Qiagen). cDNA was synthesized using 
oligo-dT (Invitrogen) and SuperScript III (Life Technologies) according to manufacturer’s 
protocol. qRT-PCR was performed using Fast Sybr Green master mix (Life Technologies) 
according to manufacturer’s instructions. Primers are listed in Supplementary Table 2. 
Whole mount staining. Whole mount staining of EBs was performed as described in 
(Yokomizo et al., 2012). Brief description in Suppl. materials. 
Statistical Analysis. Statistical analysis was performed using an unpaired Student’s t test, 
or one-way ANOVA with Bonferroni correction for multiple comparisons. Results were 
considered to be statistically significant at p value < 0.05 (*p<0.05, **p <0.01, ***p<0.001). 
All data shown as mean ± SEM. The number of biological replicates is indicated by the n 
value. Data analysis was done using GraphPad Prism (GraphPad Software). 
Results 
Hematopoietic and endothelial potential of Gata2 expressing cells 
Hematopoiesis in the mouse embryo and in ESC differentiation cultures is initiated by 
hemangioblast cells, which are identified by Flk1 expression and their bi-potential 
capacity to generate endothelial and hematopoietic progenitors (Choi et al., 1998; Huber 
et al., 2004). In human ESC differentiation cultures, hemangioblasts develop in response 
to BMP4 stimulation between 72 and 96 hours and represent a transient population that 
precedes the onset of the primitive hematopoietic program (Kennedy et al., 2007). To 
directly examine the relationship of Gata2 expression to hematopoietic differentiation of 
ESCs, we used a novel G2V reporter ESC line (Kaimakis et al., 2016) that facilitates 
tracing and isolation of live Gata2 expressing cells by Venus fluorescence expression 
(Suppl Fig 1), while preserving normal Gata2 endogenous protein levels. This is 
important since decreased Gata2 levels severely affect the production and expansion of 
HSCs and HPCs in the embryo, and affect HSC robustness in the adult (Ling et al., 2004; 
Rodrigues et al., 2005). To examine whether Gata2 expressing cells might possess 
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hemangioblast characteristics, G2V ESC differentiation was induced in the presence of 
BMP4 (Fig 1A) and cells analyzed at days 3-6. Four cell populations, Flk1+V-, Flk1-V+, 
Flk1+V+ and Flk1-V-, were sorted by flow cytometry (FACS) and evaluated by colony 
forming unit-cell (CFU-C) and matrigel assays to test the hematopoietic and endothelial 
potential.  
At day 3 and 4, the majority of Venus expressing (V+) cells co-expressed Flk1 (67% and 
76%, respectively) (Fig 1B). From day 5 onwards, the V+ single positive population 
became more prominent and Flk1+ cell frequency decreased (Fig 1B and 1C). 
Hematopoietic potential was tested at day 3-6 of differentiation (Fig 1D) and CFU-C were 
found only in cells expressing Venus. CFU-C were detected from day 4 onward and the 
main colony type observed was EryP (primitive erythroid). Although the majority of 
colonies were scored in the Flk1-V+ population (24±13; 16±11; 23±10 EryP/104 cells at 
day 4; 5; 6, respectively), EryP were also detected in the Flk1+V+ cells at day 4, indicating 
that the earliest hematopoietic potential emerges from Gata2 expressing cells.  
To test the endothelial potential of the sorted cells at day 4 of ESC differentiation (the 
time point with the highest EryP potential in the Flk1+V+ population), cells were plated in 
matrigel and tubule formation was quantified (Fig 1E and 1F). As expected, the highest 
endothelial potential was found in the Flk1+V- population (100 tubules/2x104 cells). The 
Flk1+V+ fraction also showed endothelial potential (30 tubules/2x104 cells), demonstrating 
that in addition to the hematopoietic potential, this subset is capable of endothelial 
differentiation. Together these data suggest a transient Gata2 expressing Flk1+ 
population emerging at day 4 and rapidly decreasing thereafter, that gives rise to the 
earliest primitive blood cells and harbors endothelial potential. Thus, it suggests that 
Gata2+ cells arising during the early stage of differentiation may contain cells with 
hemangioblast characteristics.  
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Figure 1. Gata2Venus expressing cells emerging in early differentiation culture possess 
primitive erythroid and endothelial potential. A) Scheme of embryonic stem cell (ESC) culture 
differentiation. ESCs were cultured in the presence of BMP4 from day 0 to 3. Embryoid bodies 
(EB) were dissociated, cells were FACS analyzed/sorted and tested in CFU-C (colony forming 
unit-cell) and matrigel assay at indicated time points. B) Dot plots with the gating strategy of flow 
cytometric analysis and sorting of ESCs for Flk1 and Gata2Venus expression at day 3-6 of culture 
(n=3). C) Quantification of FACS analysis in panel (B) showing changes in Flk1+Venus- (Flk1+V-); 
Flk1+Venus+ (Flk1+V+) and Flk1-Venus+ (Flk1-V+) cell frequency kinetics from day 3-6 of ESC 
differentiation (n=3). D) Bar graph showing EryP (primitive erythroid) colony output per 104 
Flk1+Venus- (F+V-); Flk1+Venus+ (F+V+); Flk1-Venus+ (F-V+) and Flk1-Venus- (F-V-) cell populations 
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isolated at day 4-6 culture (n=4). E) Representative images of cells showing endothelial tubules 
generated in matrigel cultures of Flk1+Venus- (F+V-); Flk1+Venus+ (F+V+); Flk1-Venus+ (F-V+) and 
Flk1-Venus- (F-V-) cell populations isolated at day 4 of ESC differentiation. Objective=4x. F) 
Quantification of tubule formation (tubules/2x104 cells) shown in panel (E) (n=3).  
Two temporally-defined waves of Gata2 expression are detected during ESC 
hematopoietic differentiation  
To understand the progression of the ESC differentiation towards hematopoietic lineage, 
the temporal dynamics of Gata2 expression was characterized. The frequency of V+ cells 
from day 4 to 14 of differentiation was examined by FACS (Fig 2, Suppl Fig 2A). V+ cells 
were detected throughout the time-course differentiation, and demonstrated wave-like 
dynamics with 2 peaks of increased V+ cell frequency. As compared to day 4, the 
percentage of V+ cells was significantly higher (5.5-fold) at day 6 (Fig 2A), and it 
decreased by day 7-10 as compared to day 6 of culture (3.3-fold). V+ cell frequency was 
higher again at day 11-12 as compared to day 10 of culture (2.3-fold at day 11). Venus 
and Gata2 RNA expression correlated with the V+ cell frequency showing 2 temporally-
defined expression peaks (Fig 2B). To exclude the possibility that the second Gata2 
expression peak occurs due to remaining undifferentiated cells, we analyzed the 
expression of pluripotency gene Nanog. Nanog RNA was significantly decreased after 
day 3 of differentiation and was not detectable at day 6 or day 12 at protein level (Suppl 
Fig 2B and 2C). Also, Brachyury expression, indicative of primitive streak/mesodermal 
commitment, showed the expected dynamics, with increased expression at day 3-6 and 
downregulated expression thereafter (Suppl Fig 2D), thus supporting the likelihood of two 
independent waves of induction of Gata2 expressing cells in ESC differentiation cultures. 
Gata2 functions in combinatorial manner with other key hematopoietic transcription 
factors (heptad factors) to direct HPC/HSC development  
(Wilson et al., 2010). The expression of heptad factors Gata2, Tal1, Lyl1, Lmo2, Fli1, 
Runx1 and Erg was tested (by qRT-PCR) in V+ and V- sorted cells at day 6 and day 12 
(Fig 2C). At both differentiation stages drastically higher expression of all the heptad 
factors was found in the V+ fraction, with very little/no expression in the V- fraction. As a 
control, the expression of a non-heptad ubiquitous transcription factor, Cbfb (Runx1 
binding partner) was assessed at day 6 in the same populations (Suppl Fig 2E). In 
contrast to the heptad factors, Cbfb was expressed similarly in V+ and V- cells as 
expected. Thus, these data show that Gata2 expressing cells exhibit a developmental 
gen hematopoietic gene expression profile.  
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Figure 2. Gata2Venus temporal expression defines primitive and definitive hematopoietic 
stages of ESC differentiation. A) Frequency of Venus expressing (V+) cells in day 4-14 
differentiated Gata2Venus ESC viable cells as measured by FACS (n=3). B) Real time qPCR 
analysis of Venus and Gata2 expression in day 4-14 differentiated Gata2Venus ESCs. Expression 
was normalized to b-actin, set as 100% for the sample with the highest expression level. 
40
Expression levels and % of maximum of other samples were calculated accordingly (n=3). C) Real 
time qPCR analysis for Gata2, Tal1, Lyl1, Lmo2, Runx1, Fli1 and Erg expression in FACS sorted 
Venus+ (V+) and Venus- (V-) populations isolated at day 6 (upper panel) and at day 12 (lower 
panel) of Gata2Venus ESC culture. Expression levels were normalized to b-actin (n=3). D) Real 
time qPCR analysis of Gata1, bH1 and bmajor expression in day 4-14 differentiated Gata2Venus 
ESCs. Expression was normalized to b-actin, set as 100% for the sample with the highest 
expression level. Expression levels and % of maximum of other samples were calculated 
accordingly (n=3). E) Confocal images (representative) of whole mount stained day 6 and day 12 
EBs (left and right panels, respectively) showing Venus (green) and CD31 (red) expression. 
Arrows indicate flat endothelial-like Venus+ cells in day 6 EB and round hematopoietic like Venus+ 
cells/clusters in day 12 EB. Size-bar=40 μm, 40x objective. F) Bar graph showing colony forming 
unit-cells (CFU-C) per 104 cells plated of Venus+ (V+) and Venus- (V-) cells isolated from day 6 and 
day 12 Gata2Venus differentiated ESCs (n=3). Colony types are indicated by color. CFU-
granulocyte, erythrocyte, monocyte, macrophage (GEMM); CFU-granulocyte-macrophage (GM); 
CFU-macrophage (M); CFU-granulocyte (G); burst-forming-unit erythroid (BFU-E) and CFU-
primitive erythroid (EryP). 
Sequential waves of Gata2 expressing cell generation correlate with functional 
primitive and definitive hematopoietic potential  
Hematopoiesis in the mouse embryo occurs in stage-specific waves, with a progressive 
generation of cells with more multipotential hematopoietic properties (reviewed in 
(Dzierzak and Speck, 2008; Kauts et al., 2016)). To elucidate whether the V+ cells in the 
two waves express genes indicative of primitive (bH1; functions in early erythropoiesis) 
and/or definitive (bmajor; functions in adult erythroid cells) hematopoietic programs (Palis 
et al., 2010), qRT-PCR was performed (Fig 2D). Gata1 (a pan-erythropoietic factor) was 
upregulated after the first peak of Gata2 expression at day 6-8, and downregulated 
thereafter (Fig 2D upper panel). As a read-out for Gata1 transcription factor function, its 
downstream target bH1 (embryonic globin) showed a peak of expression during the first 
wave of Gata2 expression and was significantly downregulated thereafter (Fig 2D middle 
panel). bmajor (adult globin) expression was detectable from day 8 onwards and showed 
high expression at day 12 of culture (Fig 2D lower panel) correlating with the second 
Gata2 expression peak.  
The morphology and localization of V+ cells were analyzed at the 2 stages of 
differentiation (day 6 and day 12) by confocal microscopy of whole EBs. In the mouse 
embryo, HPCs/HSCs emerge from CD31+ hemogenic endothelial cells (Boisset et al., 
2010), thus we immunostained the G2V EBs for CD31 to visualize the differentiating 
vasculature. CD31+, V+ and CD31+V+ cells were detected in the EBs at both time points 
(Fig 2E). At day 6, CD31+ cells were dispersed throughout the EBs with no distinct 
structural organization. Flat endothelial-like V+CD31+ cells were scattered in the EBs (Fig 
2E left panels). At day 12, CD31+ cells formed a lining around the EB cavities, and round 
hematopoietic-like V+ CD31+ cells were closely associated with the CD31+ lining (Fig 2E 
right panels). These imaging data indicate that Gata2 expressing cells in the day 6 and 
day 12 EBs are morphologically distinct, and thus, may possess different functions. 
To test the relationship between Gata2 expression, stage of ESC differentiation and 
hematopoietic function, cells from day 6 and day 12 EBs were harvested, FACS sorted 
into V+ and V- populations and analyzed by CFU-C assay. Hematopoietic progenitors 
were found exclusively in the V+ cell fractions (Fig 2F). Day 6 V+ cells gave rise to 39.4±5 
CFU-C/104 cells (HPC frequency 1:254), whereas day 12 V+ cells generated 17.7±3.6 
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CFU-C/104 cells (HPC frequency 1:564). The majority (82%) of day 6 cells had only EryP 
(primitive erythroid) potential. A very low frequency of macrophage, granulocyte and 
definitive erythroid (CFU-M, CFU-G, BFU-E) colonies were also observed. In contrast, 
day 12 gave rise to a variety of erythroid-myeloid colony types, including mixed 
multipotent colonies (CFU-GEMM). Moreover, based on the colony size, the colonies 
derived from day 12 progenitors exhibited significantly increased proliferation capacity 
compared to the hematopoietic cells isolated from day 6 EBs. No lymphoid cell potential 
was detected with our culture method in the V+ cells at day 12 of differentiation as 
assayed by OP9 co-culture (data not shown), and thus, Gata2 expressing cells possess 
definitive hematopoietic potential as described for erythroid-myeloid progenitors (EMP). 
Together these data indicate that Gata2-expressing cells proceed through at least 2 
different stages of induction in ESC cultures that correlate with distinct primitive and EMP 
definitive functional cell potentials and molecular programs. 
Figure 3. Gata2Venus cells progressively gain definitive hematopoietic characteristics. A) 
Flow cytometric dot plot analyzes of day 6, 8, 10, 12 and 14 differentiated Gata2Venus embryoid 
body (EB) derived cells showing cKit, CD31, CD41, CD45 and CD16/32 expression in Venus+ (V+ 
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upper panels) and Venus- (V- lower panels) cell populations (n=3). B) Graph showing the temporal 
kinetics of cKit+CD31+, cKit+CD41+, cKit+CD45+ and cKit+CD16/32+ cell frequencies in Venus+ (V+, 
green line) and Venus- (V-, black line) cell fractions of day 6, 8, 10, 12 and 14 Gata2Venus ESC 
differentiation cultures. Significant differences between indicated cell frequencies in V+ and V- 
populations are designated with asterisks (n=3). 
Gata2 expressing cells show progressive gain of definitive phenotypic 
characteristics during the waves of ESC differentiation 
To characterize the phenotype of V+ and V- cells during the waves of ESC differentiation, 
the expression of cell-surface markers cKit (expressed on all intra-aortic hematopoietic 
cluster cells), CD31 (expressed on all endothelial cells and intra-aortic hematopoietic 
cluster cells), CD41 (marks the earliest HPCs and megakaryocytes), CD45 (pan-
hematopoietic marker) and CD16/32 (marks EMP when co-expressed with cKit) was 
measured by FACS (Fig 3A and 3B). CD31+cKit+ cells were detected predominantly in 
V+ fraction (0.7%-13%), whereas very few V- cells (0.3%-2%) showed this phenotype. 
The percentages of CD31+cKit+ cells in the V+ fraction increased steadily from day 6 to 
day 10, decreased to a low point at day 12, and then rose again, suggesting a late wave 
of hematopoietic cell production. CD41 expression was detected in 4% of day 6 V+ cells 
and increased concomitantly with cKit co-expression to peak at day 8 (41±3.3% 
CD41+cKit+), followed by decreased percentages of these cells at day 10-14. 
Interestingly, cKit expression was mainly detected in V+CD41lo and not in V+CD41hi cells 
and is in line with published data showing that AGM HPCs/HSCs express CD41 at 
low/intermediate levels (Robin et al., 2011). Very few V- cells were CD41+ throughout all 
time points analyzed, thus suggesting that co-expression of Gata2, CD41lo and cKit 
define a HPC/HSC population during ESC differentiation. CD45 expression was barely 
detectable in V+ cells at day 6 of differentiation (1.3%). There was a profound increase 
and peak at day 10 with 46±2.2% of V+ cells CD45+cKit+ (as compared to the peak of 
CD41+cKit+ cells at day 8) and this was followed by decreased CD45+cKit+ cell 
percentages at day 12 and day 14. Very few V- cells were CD45+cKit+ (0.4-2.2%) 
throughout differentiation. Thus, CD45 is confirmed as a later marker of hematopoietic 
cells. In contrast to the other markers, CD16/32 was expressed in both, V- and in V+ cells 
at day 6 (15±2.3% and 21±5.0% respectively). This is expected and is in line with the in 
vivo results showing Gata2 independent HPCs (Kaimakis et al., 2016). However, as with 
the other hematopoietic markers, CD16/32 was co-expressed with cKit more abundantly 
in the V+ fraction, and cell frequencies peaked at day 10 (49±3.4%) followed by a rapid 
decline. Together these data demonstrate that Gata2 expression defines almost all 
phenotypic hematopoietic cells generated throughout ESC differentiation (both early and 
later) and that these phenotypic markers show wave-like kinetics.  
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Figure 4. Ly6a(Sca1)GFP expression distinguishes functional hematopoietic cells in the 
definitive stage of ESC differentiation. A) Frequency of Ly6a(Sca1)GFP expressing (G+) cells 
in day 4-14 differentiated Ly6a(Sca1)GFP embryoid bodies (EB) as measured by FACS (n=3). B) 
Blast colony (BL-CFU) potential in Ly6a(Sca1)GFP+ (G+) and Ly6a(Sca1)GFP- (G-) cells sorted 
from day 3 Ly6a(Sca1)GFP EBs (n=3). C) Representative FACS plot for expression of Flk1 and 
Ly6a(Sca1)GFP expression in day 3 Ly6a(Sca1)GFP EBs. D) Representative BL-CFU colony 
originating from a G- cell sorted from day 3 Ly6a(Sca1)GFP EBs (left). Representative fluorescent 
image of day 4 BL-CFC originating from a G- cell sorted from day 3 Ly6a(Sca1)GFP EBs (right). 
The emergence of G+ cells within the colony can be observed. E) CFU-C potential of day 7 (left 
panel) and 12 (right panel) G+ and G- cells sorted from Ly6a(Sca1)GFP EBs. Colony forming unit-
cell (CFU-C) number per 104 cells is shown (n=4). Colony types are indicated by color. CFU-
granulocyte, erythrocyte, monocyte, macrophage (GEMM); CFU-granulocyte-macrophage (GM); 
CFU-macrophage (M); CFU-granulocyte (G); burst-forming-unit erythroid (BFU-E) and CFU-
primitive erythroid (EryP). F) Graph showing time course of CFU-C frequency in day 3 to day 14 
Ly6a(Sca1)GFP EB-derived sorted G+ and G- cells. Significant differences between CFU-C/104 
G+ and G- cells are indicated (n=4). 
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The Ly6a(Sca1)GFP reporter distinguishes definitive hematopoietic cell potential 
after the Gata2Venus defined EMP stage 
Unlike the G2V reporter in the embryos which marks almost all hematopoietic cells from 
the earliest time of generation, the LG reporter in vivo marks fewer hematopoietic cells, 
and cells generated at later developmental time points. To examine whether the LG 
reporter shows different kinetics and marks the later wave of hematopoietic generation 
in ESC differentiation cultures, LG ESC line was established from the LG mouse model. 
FACS analysis of the temporal appearance of GFP-positive (G+) cells in the time course 
of ESC differentiation (Fig 4A) showed the presence of G+ cells already at day 3 (7%) 
and day 4 (10%), followed by a rapid 5-fold decrease. Percentages of G+ cells began to 
increase at day 7 showing a peak at day 9-10 of differentiation (3-fold increase; 6% at 
day 10). These two peaks of G+ cell frequency occurred approximately 2 days earlier 
than V+ cells (Fig 2A). 
To investigate whether GFP expression correlates with hematopoietic activity in the ESC 
differentiation culture, we performed hematopoietic colony forming assays. At early 
differentiation stages (day 3-4), bipotent endothelial/hematopoietic precursors, the 
putative hemangioblast, can be detected as blast colony forming cells (BL-CFC). BL-CFC 
culture, established with FACS sorted G+ and G- cells derived from day 3 EBs, revealed 
that significantly more blast colonies were formed in the G- fraction (215±11 in G-; 17±12 
in G+) (Fig 4B). Accordingly, only very few G+ cells (1±0.1% of the total live population) 
expressed Flk1 (Fig 4C). However, examination of BL colonies during growth phase 
showed a few G+ cells starting to emerge (Fig 4D), suggesting that LG expression in the 
hematopoietic lineage begins just after the hemangioblast stage. CFU-C assay with G+ 
and G- cells derived from later stage (day 7) EBs revealed that HPCs were found equally 
in both fractions (Fig 4E). However, at day 12 significantly more of these (including all 
the CFU-GEMMs) were found in the G+ population. Time course CFU-C assays (Fig 4F) 
demonstrated that from day 7 to 10 of differentiation, HPCs were contained in both 
fractions, at day 12 there were significantly more HPCs generated by G+ cells, and by day 
14 virtually all HPC activity was found in G+ cells. The frequency of hematopoietic cells in 
the G+ and G- fractions at day 6-14 of ESCs was determined by FACS for cKit and co-
expression of CD31, CD41, CD45 and CD16/32 (Fig 5). CD31+cKit+ cells were detected 
at day 6 at similar levels (6.9±0.4% and 6.9±1.3%) in G+ and G- fractions respectively. 
From day 10 onwards, the frequency of CD31+cKit+ cells increased in the G+ fraction 
(rising to 26.0±6.2%) as compared to the G- fraction. CD41+cKit+ cells were detected 
beginning at day 8 in G+ cells (0.9±0.2%) and frequencies gradually increased to day 14, 
when they were profoundly higher (14±3.0%). At all time points, CD41 expression was 
low in the G- fraction, thus CD41+cKit+ cell frequency in the G- fraction was negligible. 
CD45cKit expression showed a similar trend as CD41+cKit+ cells being detected in the 
G+ fraction from day 8 (0.2±0.1%) onwards, with a significantly higher frequency after day 
12 of culture and raising to 18±5.1% at day 14, as compared to the G- fraction, in which 
no/very few CD45+cKit+ cells were found. Phenotypic EMPs (cKit+CD16/32+ cells) were 
detected from day 6 onwards in both G+ and G- fractions (1.8±0.6% and 0.1±0.0% 
respectively). With progression of differentiation (day 10-12), the frequency of 
cKit+CD16/32+ cells increased considerably in the G+ fraction, while the frequency 
decreased in the G- fraction. These data indicate that LG specifically marks phenotypic 
hematopoietic cells in later stages of the ESC differentiation, e.g. from day 10-12 
onwards, and that a subset of hematopoietic progenitors is generated and/or acquire this 
marker later in the culture than the G2V defined EMP wave, thus potentially distinguishing 
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a third multipotent EMP definitive wave of hematopoietic emergence in the ESC 
differentiation cultures (Model, Fig 6). 
Figure 5. Ly6a(Sca1)GFP expression marks phenotypic hematopoietic cells after the 
Gata2Venus-defined EMP stage.  A) Flow cytometric dot plot analyzes of day 6, 8, 10, 12 and 
14 Ly6a(Sca1)GFP embryoid body (EB) derived cells showing cKit, CD31, CD41, CD45 and 
CD16/32 expression in Ly6a(Sca1)GFP-expressing (G+) and non-expressing (G-) cell fractions 
(n=4). B) Graph showing the temporal kinetics of cKit+CD31+, cKit+CD41+, cKit+CD45+ and 
cKit+CD16/32+ cell frequencies in Ly6a(Sca1)GFP-expressing (G+, red line) and non-expressing 
(G-, black line) fractions of day 6, 8, 10, 12 and 14 differentiated Ly6a(Sca1)GFP EBs. Significant 
differences between indicated cell frequencies in G+ and G- populations are designated with 
asterisks (n=4). 
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Figure 6. Gata2Venus and Ly6a(Sca1)GFP expression mark primitive and definitive 
hematopoietic progenitor generation stages in ESC differentiation cultures. Within the first 
few days of ESC differentiation, Gata2Venus expression defines cells with primitive hematopoietic 
potential. A subsequent decrease in Gata2Venus expressing cells is followed by the emergence 
of EMP-definitive potential in the second wave of Gata2Venus-expressing cells. In a later stage 
of ESC differentiation culture, Ly6a(Sca1)GFP and Gata2Venus expression distinguishes a third 
wave of hematopoietic emergence that defines multipotent definitive hematopoietic cells. 
Discussion 
In this study, we show that ESC differentiation progresses through three stages of 
functional hematopoietic cell production that can be discriminated by the temporal 
expression of the G2V or LG reporters. These reporters are excellent in vivo indicators 
of normal temporal and spatial generation of hematopoietic cells in the mouse embryo, 
ensuring high fidelity in their use to examine the stages of hematopoietic emergence in 
vitro. These novel reporter ESC lines, when enriched during the differentiation culture, 
demonstrate functional hematopoietic properties that are analogous to the cells 
generated in the three in vivo waves of hematopoietic emergence found in the mouse 
embryo. 
Hematopoiesis in the mouse embryo starts in the YS with a transient wave of primitive 
hematopoiesis. This program is characterized by a short lived bi-potential Flk1+ 
hemangioblast that gives rise to the earliest blood cells and entotheliium (Choi et al., 
1998; Kennedy et al., 1997; Palis et al., 1999; Shalaby et al., 1997). Our analysis of early 
G2V EB differentiation reveals a transient V+Flk1+ population that differentiates into 
endothelial and primitive erythroid cells. In contrast, no Flk1 expression or hemangioblast 
function is found in the G+ cells of LG EB. Thus the earliest functional hematopoietic cells 
in the ESC cultures are defined by Gata2 expression. Gata2, and also Gata1, are first 
detected in the YS mesoderm at E7 resulting in high expression of the developmentally 
distinct embryonic globin from E7.5, that is not detected later in the adult erythroid cells 
(Silver and Palis, 1997). In the embryo, Gata2 is involved in the initial activation of Gata1, 
and when Gata1 is expressed, it subsequently suppresses Gata2. This is referred as the 
Gata factor switch (Ferreira et al., 2005). Our kinetic analysis of Gata factor expression 
is consistent with this switch. As a readout for Gata function, high level of embryonic 
globin is detected at day 6, e.g. during the first Gata2 expression peak, but not thereafter 
(day 12-14). This agrees with the single cell transcriptomic data in which a 
pseudotemporal ordering of cells (posterior Flk1+ mesodermal cells arising from the 
posterior primitive streak) in the E7.5-7.75 embryo show upregulation of Gata1, 
embryonic globin and Itga2b after Brachyury detection indicative of primitive streak 
specification (Scialdone et al., 2016). Therefore, the early stage of our EB differentiation 
culture as defined by the first Gata2 expression peak related with Gata1, embryonic 
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globin and CD41 expression, closely follows the formation of early mesoderm in 
gastrulating embryos. 
Interestingly, EryP colonies and the expression of embryonic globin declined in the 
culture in parallel with the onset of the second Gata2 expression wave that is 
accompanied by expression of adult globin and the appearance of multipotent EMPs. 
Thus, the Gata2 expression peaks discriminate functional primitive and EMP-definitive 
stages in the ESC differentiation. It is likely that the first and second wave cells are 
derived from independent cohorts of cells as supported by the data of (Scialdone et al., 
2016) and from the human ESC differentiation cultures of (Ditadi et al., 2015; Sturgeon 
et al., 2014), but this is in contrast to the day 3 differentiation cultures of (Pearson et al., 
2015) suggesting that all waves of hematopoietic activity and in vivo repopulating cells 
(albeit low-level repopulating) arise in these early cultures. Additionally, the temporal 
dynamics of Gata2 defined primitive/definitive stages are consistent with studies from 
other groups reporting waves of distinct hemogenic endothelium and hematopoietic cell 
generation in mouse and human ESC differentiation cultures (Nakano et al., 1996; Rafii 
et al., 2013; Zambidis et al., 2005). Our results show for the first time that these stage-
specific hematopoietic cells can be traced and isolated using a single relevant reporter. 
Morphological observation of the Gata2+ cells in the differentiating EBs corroborates both 
developmental and functional stage changes. Whole mount imaging of day 12 (but not 
day 6) EBs show the presence of CD31+ cells lining vascular tubules and the close 
association of clusters of V+CD31+ cells, mainly near the cavities of the EBs. This 
observation is supported by our FACS data showing an increased frequency of 
cKit+CD31+V+ cells after day 6 of differentiation. This could represent the endothelial-to-
hematopoietic-transition occurring in E8.25-E11 circulation deficient YS where EMPs 
emergence from cKit+ clustering was observed (Frame et al., 2016). However, we 
previously showed by immunostained E10.5 G2V AGM tissue that endothelial and 
hematopoietic cluster cells of the aorta are CD31+V+ (Kaimakis et al., 2016), indicating a 
structural resemblance between the day 12 EBs and the dorsal aorta. Also, a recent study 
with day 23-33 differentiated human ESCs showed similar aortic and cluster-like 
structures (Ng et al., 2016). All together these data show that the second wave defines 
EMP development, which is morphologically close to in vivo definitive hematogenesis.  
In the mouse embryo, although all HSCs are Gata2+, a few Gata2 independent 
progenitors are generated (Kaimakis et al., 2016). HPC activity is enriched in the GATA2 
expressing fraction of human ESC differentiation cultures (Huang et al., 2016). Here we 
have shown that the functional hematopoietic activity in the G2V EBs is exclusively found 
in the V+ population. However, some phenotypic HPCs are found in the V- fraction as 
assayed by FACS. High enrichment of hematopoietic activity of V+ cells is further 
highlighted by dramatically higher expression of all heptad hematopoietic transcription 
factors as compared to V- cells suggesting that V+ cells are more potent/robust. 
Surface marker analysis of G2V ESC-derived cells revealed that the highest frequency 
of phenotypic V+ hematopoietic cells is detected at day 8 (cKit+CD41+ cells) and at day 
10 (cKit+CD45+; cKit+CD16/32+; cKit+CD31+ cells), and thereafter the frequency is greatly 
reduced. This wave-like activity is in line with several human ESC differentiation studies 
that use gene expression profiling and surface markers suggesting waves of 
hematopoietic generation (Irion et al., 2010; Nakano et al., 1996; Rafii et al., 2013; 
48
Zambidis et al., 2005). HPC potential in our cultures continues at day 12 and thereafter, 
and the definitive HPC potential specifically expresses LG. LG expression did not report 
hemangioblast stage primitive progenitors. However, in BL-CFC rare G+ cells were found. 
During the first stage of EB differentiation (e.g. day 6-10) HPCs are found in both, G+ and 
G- fractions. After day 12, HPC activity is significantly enriched in the G+ cells. These data
are in contrast to HPC activity in the differentiated G2V ESCs where all HPCs are V+
throughout the differentiation. Distribution in progenitor activity in the LG EBs is
consistent with the distribution of HPC activity in the LG mouse embryos. In the LG YS,
most HPCs are G-. This is in contrast to the E10.5/E11.5 AGM lymphoid progenitors and
multipotent HPCs/HSCs, that are found in the G+ population at much higher frequency
than in the G- fraction (Li et al., 2014; Solaimani Kartalaei et al., 2015). LG expression
reports hemogenic endothelial cells and all emerging HSCs in the E10.5 aorta in vivo
(Boisset et al., 2010; de Bruijn et al., 2002). Thus, LG expression specifically reports
aortic HSCs and cells with lymphoid potential, but not the YS stage progenitors. Taken
together, these data propose that in the ESC differentiation culture the LG reporter
distinguishes definitive aorta-like hematopoietic progenitors that appear/persist in the
culture after the EMP stage defined by the G2V expression.
In conclusion, we demonstrate that three waves of hematopoietic generation can be 
prospectively traced and isolated by the G2V and LG reporter expression in ESC 
differentiation cultures. Further experiments will elucidate whether the late waves of 
hematopoietic cells generated in the G2V and LG ESC cultures possess lymphoid, and 
even more robust hematopoietic potentials. Such findings will facilitate better 
understanding of the hematopoietic development in PSC differentiation cultures, and may 
ultimately enable the recapitulation of physiologic HSC emergence for the de novo 
generation of transplantable HSCs for therapeutic strategies.  
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Supplementary data 
Supplementary figure 1. Validation of Gata2Venus ESC reporter. A) FACS dot plots showing 
percentage of Venus expressing cells in day 6 Gata2Venus (G2V, left) ESC differentiation 
cultures. Differentiated wild type (WT, right) ESCs were used as a negative control. B) Western 
blot analysis of whole cell extracts of pre-sorted or Venus- (V-) and Venus+ (V+) populations from 
day 6 differentiated Gata2Venus ESC cultures. A Gata2 protein band (40 kDa) is observed in 
unsorted and V+ cells. -actin is the protein normalization control. Representative plot (n=2). C) 
Quantification of Gata2 protein in Western blot shown in panel B. Values represent Gata2 protein 
quantity relative to b-actin expression. Mean ± SEM (n=2). 
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Supplementary Figure 2. Gata2Venus expression kinetics during ESC hematopoietic 
differentiation.  A) FACS dot plots showing Venus+ cell frequency in day 4-14 Gata2Venus ESC 
differentiation cultures (n=3).  B) Real time qPCR analysis of Nanog expression in day 3-12 
Gata2Venus ESC differentiation cultures. Expression was normalized to b-actin and set as 1 in 
the day 3 sample, and the other samples were calculated accordingly (n=3).  C) Western blot 
analysis of Nanog protein expression in day 0, 6 and 12 differentiated Gata2Venus ESCs. b-actin 
was used as the protein normalization control. Representative plot (n=2).  D) Real time qPCR 
analysis of Brachyury expression in day 0, 3, 6 and 12 differentiated Gata2Venus ESCs. 
Expression was normalized to b-actin and set as 1 in day 0 sample, and the other samples were 
calculated accordingly. Representative data.  E) Real time qPCR analysis of Cbfb expression in 
FACS sorted Venus+ (V+) and Venus- (V-) cells derived from day 6 ESC differentiation cultures. 
Gene expression was normalized to b-actin expression (n=3). 
Data shown as mean ± SEM, if not stated otherwise. ***p<0.001. 
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Supplementary Figure 3. Myeloid potential of Gata2Venus ESC derived Venus+ cells. 
Representative photos of CFU-C colonies (left) and May-Grünwald/Giemsa staining of 
cytospinned colony cells (right) from Venus+ cells derived from day 6 or day 12 Gata2Venus 
differentiated ESCs. Objective=4x (left panels), =40x (right panels). CFU-granulocyte, erythrocyte, 
monocyte, macrophage (GEMM); CFU-granulocyte-macrophage (GM); CFU-macrophage (M); 
CFU-granulocyte (G); burst-forming-unit erythroid (BFU-E) and CFU-primitive erythroid (EryP). 
Ed=definitive erythrocyte. 
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Supplementary experimental procedures 
Establishment and maintenance of ESC lines. ESC lines (WT from WT 129/Ola mice, 
G2V from Gata2Venus mice (Kaimakis et al. 2016) and LG from Ly6a(Sca1)GFP mice 
(de Bruijn et al. 2002)) were established as described by Bryja et al., (2006). Blastocysts 
were isolated at E3.5 and placed onto irradiated mouse embryonic fibroblasts (MEFs) 
and cultured in SR-ES medium (Knockout DMEM supplemented with 20% Knockout 
Serum Replacement (Gibco), 1% penicillin/streptomycin (P/S) (Gicbo), 2 mM L-glutamine 
(Gicbo), 1x NEAA (Gibco), 100 mM b-mercaptoethanol (Sigma) and recombinant mouse 
LIF (1000 U/ml) (Chemicon International)). After an attachment phase of 2 days, the 
medium was changed every two days to allow for expansion of the inner cell mass (ICM). 
After sufficient outgrowth, the ICM was trypsinized and transferred to a 12-well format 
coated with inactivated MEFs. Afterwards, the ESCs were maintained in DMEM (Lonza) 
+ 15% FBS (HyClone), 2mM GlutaMAX, 1mM Na-pyruvate, 1% P/S, 50µM b-
mercaptoethanol (all Gibco), 0.1mM NEAA (Lonza) and 1000U/ml LIF (Sigma) at 37°C
in the presence of 5% CO2.
Protein extraction and Western Blotting. Cells were washed 2x with PBS and re-
suspended in ice cold RIPA buffer + protease and phosphatase inhibitors (Thermo 
Fisher) and incubated for 30 minutes on ice. Samples were homogenized by sonication 
and centrifuged at 13 000 rpm for 15 minutes, total protein in the supernatant was 
quantified using BSA kit (BioRad) following the manufacturer’s instructions. Total protein 
concentration was calculated based on a BSA standard curve. Equal amounts of protein 
for each sample were boiled (95°C for 5 minutes) in SDS sample buffer (BioRad). 
Proteins were separated in SDS-polyacrylamide gel (NuStep) and blotted for 30 minutes 
at 20 volts on a nitrocellulose membrane (Amersham). The membrane was blocked with 
5% semi-skimmed milk in TBS-Tween 20 (TBS-T) immunostained overnight at 4°C in 
2.5% semi-skimmed milk in TBS-T. After 3 x 5 minute washes with TBS-T the membrane 
was immunostained with secondary antibody at RT for 1 hour. Membranes were 
analyzed with Odyssey FC (Li-Cor) using Image Studio LiteTM (Li-Cor) software. Used 
antibodies are listed in Supplementary Table 1. 
Whole mount staining and confocal imaging. Fixing: EB were washed with PBS, fixed in 
PBS + 2% PFA (Sigma) for 10 minutes on ice following triple washing in PBS for 10 
minutes on ice. Dehydration: dehydration was performed 1x in 50% methanol + PBS and 
2x in 100% methanol on ice for 10 minutes. Rehydration: EBs were incubated 1x in 1:1 
methanol + PBS and 1x in 100% methanol on ice for 10 minutes and washed 1x with 
cold PBS on ice for 10 minutes. Blocking: EBs were incubated in PBS + 1% semi 
skimmed milk + 0.005% Tween X100 (Sigma) (PBS-MT) + 10% bovine serum albumin 
(BSA) (Sigma) and 0.1% goat serum on ice for 4-6 hours. Primary and secondary 
antibody incubations were performed overnight at 4°C in PBS-MT solution following 3x 
washing with PBS-MT on ice each for at least 2 hours. Dehydration: EBs were rinsed in 
PBS-T and incubated for 10 minutes on ice first in 1:1 methanol/PBS and then in 100% 
methanol. Clearing and mounting:  EBs were transferred onto a fast well and washed 4 
x for 30 seconds in 100% methanol following clearing first 4x for 30 seconds in 1:1 benzyl 
alcohol + benzyl benzoate (BABB) + methanol following in 100% BABB. Fast well was 
covered with coverslip and EBs were imaged in 100% BABB with Leica SP5 confocal 
microscope. Antibodies are listed in Supplementary Table 1. 
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Cytospin and May-Grünwald/Giemsa staining. Single colonies from methylcellulose 
culture were picked, washed 1x with PBS + 10% FBS. Cells were re-suspended in 50 µl 
PBS and transferred into sample chamber containing a glass slide. Samples were 
centrifuged for 5 minutes at 200 rpm. Cells were stained with Rapid Romanowsky Stain 
Pack kit (TCS Biosciences) according to the manufacturer’s protocol. Slides were 
washed 2x in tap water and examined under Zeiss Axioskop2 microscope. 
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Supplementary Table 1. Antibody list 
Supplementary Table 2. Real time qPCR primer list 
qRT-PCR forward 5’-3’ reverse 5’-3’ 
b-actin CACCACACCTTCTTACAATGAG	 GTCTCAAACATGATCTGGGTC	
Gpr56 TCTGCTCTGGCTTGTGTCTTC	 AGGTTCATGTGGACTTTGATGG	
Gpr97 CTGGGATATGGCTAAAGGAGAC	 AAGGCGAAGAAGGTCAAGTG	
Gpr114 TCACTGCTCAATAACTATGTCC	 ACTGTATACCCTTCCAGACTC	
bH1 AGTCCCCATGGAGTCAAAGA	 CTCAAGGAGACCTTTGCTCA	
bmajor CTGACAGATGCTCTCTTGGG	 CACAACCCCAGAAACAGACA 
Gata1 TGCCTGTGGCTTGTATCA	 TGTTGTAGTGGTCGTTTGAC	
Runx1 TTTGATGGCTCTATGGTAGGTG	 CAGGTAGCGAGATTCAAAGA 
Brachyury TGTCCTCCCTTGTTGCCTTAGAGT AGTAGGCATGTTCCAAGGGCAGAA 
Cbfb CAGGAAGATGCATTAGCACAA AGATCATCACCGCCACCTAA 
Fli1 ATGGACGGGACTATTAAGGAGG GAAGCAGTCATATCTGCCTTGG 
Nanog CACAGTTTGCCTAGTTCTGAGG GCAAGAATAGTTCTCGGGATGAA 
Tal1 TCCCCATATGAGATGGAGATT ATTGATGTACTTCATGGCAAG 
Lyl1 CAGGACCCTTCAGCATCTTC ACGGCTGTTGGTGAACACTC 
Erg GGCAGCTACATGGAGGAGAA TATTCTTTCACCGCCCACTC 
Lmo2 ATGTCCTCGGCCATCGAAAG CGGTCCCCTATGTTCTGCTG 
Venus ATCTTCTTCAAGGACGACGG GGCTGTTGTAGTTGTACTCC 
FACS antibodies Provider, cat# Dilution 
CD41-ef450 eBioscience, 48-0411 1:100 
CD45-AF700 BioLegend, 103127 1:400 
CD31-PE BD Biosciences, 553373 1:1000 
CD16/32-PE eBioscience, 12-0161 1:200 
cKit-APCef780 eBioscience, 47-1171-80 1:800 
Flk1-PE BD Biosciences, 3221709 1:600 
Western Blot antibodies 
Gata2 Santa Cruz, sc9008 1:200 
Nanog Chambers lab (Edinburgh) inhouse 1:2000 
b-actin Santa Cruz 1:1000 
Whole mount antibodies 
GFP (used for Venus) MBL, MBL 598 1:2000 
CD31-biotin BD Biosciences, 553371 1:500 
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Introduction 
Hematopoietic stem cells (HSC), the cells that provide life-long maintenance of the adult 
hematopoietic system, are generated via a transdifferentiation process, known as the 
endothelial to hematopoietic cell transition (EHT) reviewed in Kaimakis et al., (2013). In 
that stepwise process, specialized vascular endothelial cells, known as the hemogenic 
endothelial cells (HEC) suppress their endothelial program to turn on the hematopoietic 
identity. In mice, the first HSCs are generated in the aorta-gonad-mesonephros (AGM) 
region at embryonic day (E) 10.5 (Medvinsky and Dzierzak, 1996; Muller et al., 1994). 
Their development is temporally associated with the appearance of hematopoietic 
clusters in the endothelium of the dorsal aorta (de Bruijn et al., 2000; Garcia-Porrero et 
al., 1995; North et al., 1999). Vital imaging of the mouse embryonic aorta at the time of 
the first HSC emergence has revealed the transition of morphologically flat endothelial 
cells into round hematopoietic cells that are bulging out from the wall of the aorta into the 
lumen (Boisset et al., 2011). The use of elegant tracing methods supported by 
transplantation of stringently enriched populations, have provided further evidence of the 
endothelial origin of the HSCs (Chen et al., 2009; de Bruijn et al., 2002; North et al., 2002; 
Zovein et al., 2008). The emergence of round hematopoietic cells from flat endothelial 
cells has also been observed in the zebrafish model, thus suggesting that the 
development of HSCs through EHT is a process that is conserved between vertebrate 
species (Bertrand et al., 2010; Kissa and Herbomel, 2010). 
Several markers/the combination of different markers has facilitated studies examining 
the emergence of HSCs. The appearance of newly generated HSCs via EHT has been 
visualized in the Ly6a (Sca1) GFP fluorescent reporter transgenic embryos. GFP reporter 
marks all embryonic and adult HSCs (Chen et al., 2011; de Bruijn et al., 2000; Li et al., 
2016; Ma et al., 2002; Ottersbach and Dzierzak, 2005), therefore, serves as an excellent 
reporter for observing the emergence of HSCs. Vital time-lapse imaging of thick Lya6A-
GFP E10.5 embryo sections, that were immunostained with endothelial (CD31) and 
hematopoietic (cKit, CD41) markers, revealed the bulging of some GFP+cKit+CD41+ cells 
into the lumen of the aorta. They were directly transdifferentiating from the CD31+GFP+ 
cells, where GFP specifically distinguished the HECs from other endothelial cells, thus 
revealing the EHT process in real time (Boisset et al., 2011). 
Although marker expression of cells going through EHT has given some insight into this 
process, and allows for the enrichment of emerging HSCs, the precise molecular program 
of each step in this process has not been characterized extensively. Thus, it is as yet 
unclear what drives the emergence of HSCs from HECs. A recent transcriptome 
sequencing of the Ly6A-GFP E10.5 AGM sorted EHT cell subsets (endothelial cells, 
CD31+GFP-; HECs, CD31+GFP+; differentiated hematopoietic cells, CD31+cKit+GFP- and 
HPCs/HSCs, CD31+cKit+GFP+) has identified 530 differentially expressed genes. Gpr56 
was identified as the top differentially expressed novel gene in the HEC to HSC transition 
(Solaimani Kartalaei et al., 2015). As a surface receptor, is it of interest to study as a 
candidate signaling molecule involved in EHT.  
Gpr56 is a member of the largest family of cell surface receptors that mediate various 
external stimuli as well as signals from other cells. The G protein coupled receptors 
(GPCR) share a conserved seven transmembrane (7TM) polypeptide chain and use a 
trimeric GTP-binding protein (G protein) to relay the signal to intracellular target proteins 
(Rosenbaum et al., 2009) (Figure 1). About 150 genes encode for orphan GPCRs, 
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meaning that their ligands are unknown. The largest group of orphan GPCRs is the 
adhesion receptor group. Adhesion GPCRs have an extremely long N-terminal tail that 
almost always contains a GPCR proteolytic site (GPC) motif (Paavola and Hall, 2012). 
The GPC site harbors similarities with known self-cleaving domains proteins (Paulus, 
2000). The physiological significance of the large N-terminus remains largely unknown, 
however, mutations in it often result in disease (Piao et al., 2004). Interestingly, it has 
been shown that removal of the N-terminus causes the constitutive activation of adhesion 
GPCRs (Paavola et al., 2011; Ward et al., 2011).  
Figure 1. Schematic illustration of the Gpr56 structure and proposed activation 
mechanism. A) Gpr56 has a conserved seven transmembrane (7TM) polypeptide region (black) 
and a long N-terminal tail (red). Gpr56 uses trimeric GTP-binding protein (G-protein, yellow) to 
relay the signal. The long N-terminal tail is cleaved from the 7TM region at the GPCR proteolytic 
site (GPS, blue), but the two halves of the receptor remain non-covalently associated, and the 
receptor is inactive. B) The binding of the N-terminal tail by an adhesive ligand (such as Collagen 
III) (Luo et al., 2011a) (turquoise) can lead to receptor’s conformational changes causing the
removal of the N-terminal tail from the 7TM region leading to the induction of receptor signaling
via activation of RhoA. Gpr56 expression and signaling has been associated with several
functions, such as cell migration/adhesion, apoptosis/survival, proliferation/quiescence and
differentiation/stemness (Saito et al., 2013; Shashidhar et al., 2005; Xu et al., 2006; Xu and Hynes,
2007; Yang et al., 2011; Solaimani Kartalaei et al., 2015).
Gpr56 is one of the approximately 30 orphan adhesion GPCRs (Langenhan et al., 2013). 
Gpr56 function is mainly studied in the context of brain development, as its high 
expression has been observed in the developing mouse neocortex and neural stem cells, 
where the RhoA dependent activation leads to actin fiber reorganization and suppression 
of their migration (Bae et al., 2014; Iguchi et al., 2008; Piao et al., 2004). Mutations in 
Gpr56 cause a severe brain malformation known as the bilateral frontoparietal 
polymicrogyria (BFPP). Gpr56 is required for normal oligodendrocyte development as 
loss of Gpr56 impairs axon myelination through impaired oligodendrocyte maturation 
(Ackerman et al., 2015; Giera et al., 2015). The expression levels of Gpr56 have been 
correlated with several cancer types and their progression. It has been proposed that 
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Gpr56 acts as a tumor growth suppressor, as its downregulation leads to melanoma 
metastasis (Xu et al., 2006). On the other hand, high Gpr56 levels have also been shown 
to induce melanoma progression (Ke et al., 2007). Furthermore, high Gpr56 expression 
levels have been found in epithelial ovarian cancer patients (Liu et al., 2017), in glioma 
cells where they induce growth and metastasis (Shashidhar et al., 2005) and in leukemic 
stem cells contributing to acute myeloid leukemia (AML) progression (Daria et al., 2016). 
Gpr56 has been identified as a candidate target molecule of the ectopic viral integration 
site-1 (EVI1) transcription factor positive AML cells, where it regulates cell adhesion and 
anti-apoptotic function (Saito et al., 2013). EVI1 positive cancers are known for their poor 
prognosis and clinical outcome (Barjesteh van Waalwijk van Doorn-Khosrovani et al., 
2003). Thus Gpr56 serves as a potential drug target. The role of Gpr56 in different 
diseases is mainly associated with adhesion and cell migration, however, the precise 
function seems to be cell type specific. 
 
Gpr56 has been suggested to interact with several extracellular molecules, such as 
tetraspanins (CD9, CD81) and a major ECM crosslinking protein transglutaminase 2 
(TG2) (Xu et al., 2006). The biological meaning of the interactions with tetraspanins is 
still unknown. The Gpr56-TG2 interaction has been proposed to be anti-metastatic and 
suppress the growth of tumor cells (Xu and Hynes, 2007; Yang et al., 2011). Another 
proposed binding partner is Collagen III, which in the development of cerebral cortex, 
binds to the N-terminus of Gpr56, resulting in the coupling to Gα12/13 and the activation of 
RhoA pathway (Luo et al., 2011b). Collagen III is the major collagen in connective tissues. 
The homozygous deletion of the Collagen III encoding gene in mice (Col3a1) results in 
perinatal lethality in 90% of the mice caused by the rupture of the major blood vessels 
(Liu et al., 1997) as seen in patients with type IV Ehlers Danlos syndrome (Pope et al., 
1975), and cobblestone-like malformation of the cerebral cortex (Bahi-Buisson et al., 
2010) a highly similar phenotype to the Gpr56 knockout mice (Li et al., 2008). Besides 
the central nervous system, Collagen III binds Gpr56 in pancreatic β-cells, where it is 
required for normal β-cell function (Duner et al., 2016). Whether any of these ligands act 
as Gpr56 activators in hematopoietic cells, remains to be addressed.  
 
The expression of Gpr56 in HSC has been reported long ago (Terskikh et al., 2001), 
however its function in hematopoietic development is largely unexplored. Studies with 
Gpr56 knockdown mice have given insight into Gpr56 requirement for HSC biology. Saito 
et al has detected decreased bone marrow HSC numbers and impaired HSC 
reconstitution ability in the Gpr56-/- mice suggesting that Gpr56 is involved in the 
maintenance of the adult HSC quiescence and in the interactions with the bone marrow 
niche (Saito et al., 2013). On the other hand, although Rao et al detected Gpr56 mRNA 
expression in the E11 AGM and E14 fetal liver HSCs by quantitative RT-PCR, their 
functional studies with Gpr56-/- derived embryonic HSCs revealed no hematopoietic 
defects or significant differences in the potential of HSCs (Rao et al., 2015). It is important 
to note that the strategy to generate Gpr56-/- mouse model aimed to delete exons 2 and 
3, which harbor translational start sites. However, murine Gpr56 has an alternative splice 
variant (S4) translated from exon 4. Thus, it is possible that the Gpr56-/- mice have 
residual Gpr56 protein expression that is sufficient to overcome profound hematopoietic 
defects (Rao et al., 2015). Corroborating with the Gpr56 expression pattern in HSCs 
detected by Rao et al, in situ hybridization by us shows Gpr56 expression in the Ly6A-
GFP+ E10.5 AGM hematopoietic cells (Solaimani Kartalaei et al., 2015). Knockdown 
experiments in zebrafish show that phenotypic HPCs/HSCs are abolished upon Gpr56 
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morpholino injection and this phenotype is rescued by mouse and human Gpr56 cDNA 
injection (Solaimani Kartalaei et al., 2015). Thus these data strongly suggest that Gpr56 
signaling axis functions in the development of definitive hematopoiesis, however, its 
precise role and temporal requirement remains to be explored. 
In this study, we take advantage of a novel Gata2Venus (G2V) reporter mouse embryonic 
stem cell (ESC) model, that allows the isolation of live Gata2+ cells by Venus 
fluorochrome expression, to investigate the requirement of Gpr56 in early hematopoiesis. 
ESCs serve as a valuable tool to recapitulate aspects of early embryonic development, 
including EHT (Lancrin et al., 2009; Tamplin et al., 2015). The Gata2 transcription factor 
belongs to the heptad transcription complex of hematopoietic transcription factors 
(Wilson et al., 2010) that function as transcriptional hubs for the progression of EHT. In 
the mouse genome, there is a heptad factor consensus region located 37 kb upstream 
of the Gpr56 translational start site (Gpr56-37 enhancer) and enrichment of Gata2 and 
the heptad factors has been indicated at the Gpr57-37 enhancer (Solaimani Kartalaei et 
al., 2015). Also, Gpr56 expression is negatively affected upon the deletion of Gata2 
regulatory element (+9.5 cis element) that is required for the generation of HSCs (Gao et 
al., 2013). Previous studies by us and others demonstrate that the Gata2 transcription 
factor has a pivotal role in hematopoiesis (de Pater et al., 2013; Kaimakis et al., 2016; 
Ling et al., 2004; Rodrigues et al., 2005; Tsai et al., 1994; Tsai and Orkin, 1997). Our lab 
generated a G2V reporter knock-in mouse model and fo und that all AGM HSCs and most 
hematopoietic progenitor cells (HPC) are Venus+ (Kaimakis et al., 2016). By 
differentiating G2V ESCs, we have shown that G2V expression facilitates the isolation 
of all functional HPCs generated in the ESC differentiation culture (Kauts et al., 
submitted). As Gpr56 is a downstream target of Gata2, the novel G2V hematopoietic 
reporter ESC line serves as an advantageous tool to study the role of Gpr56 in 
hematopoietic development. Here we show that Gpr56 is increasingly expressed 
during hematopoietic commitment of ESCs and suggest that Collagen III, the putative 
ligand of Gpr56, serves as a positive regulator of hematopoiesis, possibly via Gpr56 
signaling. Our studies with Gpr56 knockout ESCs reveal a functional redundancy 
between Gpr56 and Gpr97, and demonstrate that Gpr56 is required for the 
generation of multipotent hematopoietic progenitors.    
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Materials and methods 
Maintenance of ESC lines. WT and G2V (derived as described in (Kaimakis et al., 2016)) 
ESC lines (129/Ola background) were maintained on gelatinized tissue culture plates in 
a 12-well format on mouse embryonic feeders (MEF) in DMEM (Lonza) + 15% FBS 
(HyClone), 2mM GlutaMAX, 1mM Na-pyruvate, 1% P/S, 50µM b-mercaptoethanol (all 
Gibco), 0.1mM NEAA (Lonza) and 1000U/ml LIF (Sigma) at 37°C in the presence of 5% 
CO2. Cell medium was refreshed daily and cells were passaged by trypsinization every 
other day.  
Establishment of G2V hematopoietic reporter GPCR knockout cell ESC lines: 
CRISPR/Cas9 technology. CRISPR/Cas9 technology was performed as described in 
(Ran et al., 2013). Guide RNAs (gRNA) (sequences listed in Supplementary Table 1) 
were designed to target the exon 2 of the Gpr56 and Gpr97 genes, and exons 1+2 in 
Gpr114 (Supplementary Fig1). BbsI cohesive ends were added on the 5’ of each strand. 
The insert gRNA duplex was prepared by annealing, followed by ligation into the 
pSpCas9(BB)-2AGFP (PX458, Addgene) vector. Bacterial transformation was performed 
followed bacterial plasmid DNA isolation (miniprep). Correct gRNA integration was tested 
by BbsI restriction (BbsI site is lost after successful integration) and positive clones were 
sequenced. Clones with correct integration were subjected to high yield bacterial DNA 
isolation (maxiprep).  
ESC transfection. Gata2Venus ESC transfection was performed using DreamFectStem 
(Oz Biosciences) according to manufacturer’s instructions. The cells were seeded on 
MEFs on a 24-well plate one the day before the transfection. On the day of transfection, 
medium was changed to growth medium with no P/S and +5% FBS. 0.5 µg of total Psp-
Cas9-2A-GFP plasmid containing preferred gRNA, combination of different gRNAs or no 
gRNA for Gpr56-97-115 wild type control, was added to 50 µl DMEM and mixed with 
another 50 µl of DMEM containing 2 µl of DreamFectStem and incubated at RT for 20 
minutes. The mixture was then added dropwise to the cells. Medium was changed to full 
growth medium after 4-6 hours. Following 48-72 hours, cells were harvested by 
trypsinization and single GFP expressing cells were FACS sorted onto 96-well plate 
containing MEFs. After approximately 5 days of culture, single colonies were trypsinized 
and transferred to a 12-well plate. After extra 5 days of culture, the cells were split into a 
6-well plate. When the well reached 80% confluency, ½ of the cells were harvested for
protein analysis, ¼ for RNA analysis and the rest was frozen down and stored in liquid
nitrogen. Following protein and RNA analysis, clones with desired gene/protein
expression profile were subjected to karyotyping.
ESC differentiation. ESC differentiation was performed as described in (Keller et al., 
2002). ESCs were harvested by trypsinization and MEF depleted by incubating in IMDM 
+ 15% FSC (HyClone) + 1 % P/S (Gibco) for 30 minutes. EB formation was induced by
culturing 25 000 cells/ml on a shaker at 40 rpm. On day 3, the EB medium containing
IMDM +15% FBS (HyClone), +1% P/S, 2mM GlutaMAX (Gibco), 50 µg/ml ascorbic acid
(Sigma), 4x10-4 M monothgioglycerol (Sigma), 300 µg/ml transferrin (Roche) was
supplemented with 5% proteome free hybridoma medium (Gibco). From day 6 onwards,
100 ng/ml SCF, 1 ng/ml IL-3 and 5 ng/ml IL-11 were added and cell medium including
fresh cytokines was changed every other day. Y-27632 inhibitor (at concentration of
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10µM) and Collagen III (at concentration of 0.84nM or 8.4nM, as indicated) treatments 
were started at day 4 of culture, fresh reagents were added every other day. 
FACS analysis/sorting. EBs were washed 1x with PBS and incubated in TrypLE Express 
(Gibco) at 37°C for 3-5 minutes. Enzyme was deactivated by adding PBS + 10% FBS + 
1% P/S and homogenous single-cell suspension was obtained by re-suspending with a 
P1000 pipette or mechanically crushing the EBs on a nylon mesh. G2V expression could 
be readily detected in the cells. cKit-PE antibody (BD Biosciences, dilution 1:600) staining 
was performed on ice for 30 minutes at a concentration of 106 cells/100 μl. Dead cells 
were excluded with Hoechts33342 (Invitrogen). Cells were sorted on FACS Aria III SORP 
or Fusion. Data analysis was performed with FlowJo software (Tree star). 
RNA isolation, cDNA preparation, real-time qRT-PCR. RNA was isolated using RNeasy 
micro kit (Qiagen). cDNA was synthesized using oligo-dT (Invitrogen) and SuperScript III 
(Life Technologies) according to manufacturer’s protocol. qRT-PCR was performed using 
Fast Sybr Green master mix (Life Technologies) according to manufacturer’s 
instructions. Primers are listed in Supplementary Table 2. 
Protein extraction and Western Blotting. Cells were washed 2x with PBS and re-
suspended in ice cold RIPA buffer + protease and phosphatase inhibitors (Thermo 
Fisher) and incubated for 30 minutes on ice. Samples were homogenized by sonication 
and centrifuged at 13 000 rpm for 15 minutes, total protein in the supernatant was 
quantified using BSA kit (BioRad) following the manufacturer’s instructions. Total protein 
concentration was calculated based on a BSA standard curve. Equal amounts of protein 
for each sample were boiled (95°C for 5 minutes) in SDS sample buffer (BioRad). 
Proteins were separated in SDS-polyacrylamide gel (NuStep) and blotted for 30 minutes 
at 20 volts on a nitrocellulose membrane (Amersham). The membrane was blocked with 
5% semi-skimmed milk in TBS-Tween 20 (TBS-T) immunostained overnight at 4°C in 
1%/1.5%/2.5% (for Gpr97/Gpr56/b-actin detection, respectively) semi-skimmed milk in 
TBS-T. Incubation for b-actin detection for performed at RT for 2 hours. After 3 x 5 minute 
washes with TBS-T the membrane was immunostained with secondary antibody at RT 
for 1 hour. Membranes were analyzed with Odyssey FC (Li-Cor) using Image Studio 
LiteTM (Li-Cor) software. The following primary antibodies were used: Gpr56 mouse 
monoclonal (Millipore, dilution 1:250), Gpr97 goat anti mouse (Santa Cruz, dilution 
1:1000), b-actin anti-mouse-HRP conjugated (Santa Cruz, dilution 1:1000). 
Hematopoietic progenitor assay. For the differentiation of hematopoietic precursors, the 
Venus+ population was sorted from day 12 EB derived cells. Sorted cells were plated in 
methylcellulose medium (Stem Cell Technologies). After 12-14 days in culture, colonies 
were scored under Zeiss Axiovert25 microscope and results calculated as colonies per 
104 Venus+ cells.  
Statistical Analysis. Statistical analysis was performed using an unpaired Student’s t test. 
Results were considered to be statistically significant at p value < 0.05 (*p<0.05, **p 
<0.01). All data are shown as a mean ± SEM. The number of biological replicates is 
indicated by the n value. Data analysis was done using GraphPad Prism (GraphPad 
Software). 
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Results 
Gpr56 expression is specific for ESC-derived hematopoietic cells 
We first assessed the expression dynamics of Gpr56 during mouse G2V ESC 
hematopoietic differentiation. Gene and protein expression analysis showed a trend of 
Gpr56 transcript (Fig 2A) and Gpr56 protein (Fig 2B) upregulation at day 12 of 
differentiation culture, suggesting that Gpr56 may function in hematopoietic commitment. 
To assess whether Gpr56 expression is detected in hematopoietic cells, day 6 
(represents primitive hematopoietic cells)  and day 12 (definitive) (Kauts et al., submitted) 
differentiated Venus expressing (Venus+) and non-expressing (Venus-) G2V ESCs were 
sorted. A significantly higher Gpr56 transcript expression was found in the Venus+ 
fraction at day 6, the same trend was observed at day 12 (Fig 2C). Western blot analysis 
confirmed the profoundly higher Gpr56 protein expression in day 6 Venus+ fraction (Fig 
2D). Thus, suggesting that Gpr56 is specifically expressed in Gata2 expressing cells that 
possess hematopoietic characteristics.  
GPCR signaling affects HPC generation 
Gpr56 signals via RhoA by coupling to Gα12/13 (Luo et al., 2011a). We used Y-27632, a 
selective inhibitor of Rho associated protein kinases (ROCK1 and ROCK2) as an 
antagonist to GPCR to assess Gpr56 requirement in the generation of HPCs. The Y-
27632 (10µM) treatment of day 12 differentiated G2V ESCs resulted in diminished 
hematopoietic progenitor potential as described by colony forming unit cell (CFU-C) 
activity of the Venus+ cells (Fig 2E) (9 fold as compared with untreated sample). 
Importantly, no bi-or multipotent progenitors were generated upon GPCR inhibition. 
When the expression of hematopoietic genes βH1 and βmajor (encoding for embryonic 
and adult globin, respectively) and Gata1 in the total EB-derived cell population showed 
a trend of downregulation upon Y-27632 treatment (Fig 2F), the levels of Runx1 were 
mainly unchanged. Thus, suggesting an involvement of ROCK signaling in HPC and 
erythroid differentiation.  
Collagen III, a putative ligand of Gpr56, is a positive stimulator of ESC 
hematopoietic differentiation 
The ligand of Gpr56 in the hematopoietic system remains to be characterized. It has been 
proposed that Collagen III (Col III) binds and activates Gpr56 in the neural system (Luo 
et al., 2011a) and Col3a1 was found to be most highly expressed in AGM ECs in the 
RNA Sequencing datasets (Solaimani Kartalaei et al., 2015). Hence, we supplemented 
the G2V ESC differentiation cultures with Col III to assess the hematopoietic cell output 
at day 12 of culture. A CFU-C assay revealed that an increased number of CFU-Cs were 
generated when Col III was present (1.4-fold increase as compared to untreated control) 
(Fig 2E and Supplementary Fig 1), and there was an increase in the bi-and multipotent 
progenitors (CFU-GM and CFU-GEMM). Gata1, and as a result of its function, βmajor 
expression were significantly upregulated upon Col III treatment, whereas βH1 and 
Runx1 showed only a slight trend of upregulation. The increased expression of βmajor, 
βH1 and Gata1 was concentration dependent. A role for Col III in the hematopoietic 
development/differentiation, was also supported by its expression in hematopoietic 
supportive stromal cell lines (Fig 2G). Col31a gene showed high expression in OP9 
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stromal cells, which have been used efficiently to induce hematopoietic differentiation of 
pluripotent stem cells and promote EHT (Lynch et al., 2011). AM201B4 and UG261B6 
cell lines, derived from the AGM region of mouse embryos, that have been reported to 
support HSCs but not their generation (Oostendorp et al., 2002a; Oostendorp et al., 
2002b), were also found to express Col31a, but at lower level. Together, these data 
suggest that Col III may be a novel dose dependent positive regulator of hematopoiesis, 
and that hematopoietic induction may occur via the Col III-Gpr56 axis.  
Figure 2. Gpr56 expression in the differentiating ESCs is hematopoietic specific. A) qRT-
PCR gene expression analysis of Gpr56 in undifferentiated day 0 (d0), day 6 and day 12 
Gata2Venus (G2V) ESCs. Gpr56 expression levels were normalized to b-actin (n=3). B) A 
representative Western Blotting analysis of Gpr56 (52kDa) protein expression in undifferentiated 
(day 0) and day 12 differentiated G2V ESCs. b-actin (42 kDa) was used as a loading control. 15 
µg of total protein was loaded per lane. C) qRT-PCR gene expression analysis of Gpr56 in Gata2 
expressing (Venus+) and non-expressing (Venus-) fractions flow cytometrically (FACS) sorted 
from day 6 and day 12 differentiated G2V ESCs. Gpr56 expression levels were normalized to b-
actin (n=3). D) Western Blotting analysis of Gpr56 protein expression in total population (pre-sort), 
Venus+ and Venus- cells FACS sorted from day 6 differentiated G2V ESCs. b-actin was used as 
a loading control. Total protein from 0.7x106 cells was loaded per lane (n=2). E) Representative 
hematopoietic colony forming unit-cell (CFU-C) analysis of Venus+ cells sorted from day 12 
differentiated untreated (control), 10 µM Y-27632 or 0.84 nM Collagen III (Col III) stimulated G2V 
ESCs. CFU-C potential per 104 Venus+ cells is shown. Colony types are indicated by color. CFU- 
granulocyte, erythrocyte, monocyte, macrophage (GEMM); CFU-granulocyte-macrophage (GM); 
CFU-macrophage (M); CFU-granulocyte (G); burst-forming-unit erythroid (BFU-E) and CFU-
primitive erythroid (EryP) (n=4). F) qRT-PCR gene expression analysis of Gata1, bmajor (adult 
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globin), bH1 (embryonic globin) and Runx1 hematopoietic genes in day 12 differentiated untreated 
(control), 10 µM Y-27632, 0.84nM Col III or 8.4nM Col III treated G2V ESCs. Expression was 
normalized to b-actin, set as 100% for the sample with the highest expression level. Expression 
levels and % of maximum of other samples were calculated accordingly (n=3). G) qRT-PCR gene 
expression analysis of Col3a1 in AM201B4 and UG201B6 embryonic cell lines derived from aorta-
gonads-mesonephros region (Oostendorp, 2002; Oostendorp, 2002) and in OP9 stromal cell line. 
Expression in NIH3T3 fibroblastic cell line was used as a positive control. Col3a1 expression 
levels were normalized to b-actin (n=3). 
Gpr56 and Gpr97 expression is redundant 
Our data indicate that ESC hematopoietic differentiation is negatively affected upon 
GPCR signaling inhibition by Y-27632. To specifically study the role of Gpr56 in 
hematopoiesis, we took advantage of the CRISPR/Cas9 technology to delete Gpr56 in 
G2V reporter ESCs. We generated two clones of Gpr56 KO G2V ESCs (56 KO1 and 56 
KO2) and 2 clones of mock controls (56 WT1 and 56 WT2). Reduced mRNA expression 
levels as compared with 56 WT2 cells, and lack of Gpr56 protein in 56 KO1 and 56 KO2 
lines was confirmed by qRT-PCR and Western Blotting (Fig 3A-B).  Surprisingly, the 
hematopoietic output, as measured by the frequency of Venus+ cells at day 12 of 
differentiation culture, showed a slight (1.6-fold), but significant increase in the 56 null 
G2V ESCs (56 KO2 vs 56 WT2) (Fig 3C). This was accompanied by significantly higher 
CFU-C frequency of the Venus+ cells (total CFU-C count 3.8 fold higher in 56 KO2 vs 56 
WT2) (Fig 3D). These data suggest that Gpr56 could be a negative regulator of 
hematopoietic differentiation.  
Based on previous contradictory data of (Rao et al., 2015), who reported no 
hematopoietic defects in a Gpr56 KO mouse model; and zebrafish data showing that 
Gpr56 is a novel positive HSC/HPC regulator (Solaimani Kartalaei et al., 2015), we 
proposed that the function of Gpr56 may be redundant. In the mouse genome, Gpr56 is 
located on chromosome 8, with 2 other adhesion GPCRs: The Gpr114 located 77 kb 
upstream and Gpr97 48 kb downstream from Gpr56. And, importantly, our RNA 
Sequencing datasets revealed that Gpr97 (and to a lesser extent Gpr114) was 
upregulated in EHT (Solaimani Kartalaei et al., 2015). To assess, whether the higher 
CFU-C and Venus+ hematopoietic cell frequency in the 56 KO cells was observed due to 
a compensatory mechanism by redundant GPCRs, the G2V ESCs were differentiated for 
6 days, and Venus+ and Venus- cells were sorted. qRT-PCR analysis revealed that Gpr97 
showed a profoundly higher expression in the Venus+ fraction (Fig 3E). Same trend, 
however, at much lower level, was observed for Gpr114. Thus, Gpr97 (and to lesser 
extent Gpr114) are expressed in the same cells as Gpr56. We next analysed whether 
the levels of these receptors were affected by the deletion of Gpr56 in the total population 
of undifferentiated 56 KO G2V ESCs. qRT-PCR showed a 25-fold Gpr97 mRNA 
expression level increase in 56 KO1 and 56 KO2 lines (Fig 3F). No upregulation of 
Gpr114 was observed (data not shown) likely due to overall very low expression of 
Gpr114 in ESCs, and also in the hematopoietic sites of the mouse embryo (Solaimani 
Kartalaei et al., 2015). These data suggest that there is a redundancy between Gpr56 
and Gpr97, and, that strong compensatory mechanisms leading to higher hematopoietic 
progenitor output, are seen due to the upregulation of Gpr97 when Gpr56 is not present 
(Fig 2G).  
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Figure 3. Gpr56 and Gpr97 redundancy. A) A representative qRT-PCR gene expression 
analysis of undifferentiated Gata2Venus (G2V) ESCs encoding wild type Gpr56 gene (56 WT2) 
that were transfected with Cas9-GFP vector without gRNA, and in 2 clones of G2V ESCs that 
were targeted with Cas9-GFP vector together with Gpr56 specific gRNA (56 KO1, 56 KO2). Gpr56 
expression levels were normalized to b-actin. B) A representative Western Blotting analysis of 
Gpr56 (52kDa) protein expression in embryonic head that was used as a positive control (embr. 
head) and in two clones of Gpr56 WT and Gpr56 KO G2V ESCs. 10 µg of total protein was loaded 
per lane. b-actin (42 kDa) was used as a loading control. C) Frequency of Gata2 expressing 
(Venus+) cells in day 12 differentiated Gpr56 WT2 and Gpr56 KO2 G2V ESCs (n=3). D) 
Hematopoietic colony forming unit-cell (CFU-C) analysis of Venus+ cells sorted from day 12 
differentiated Gpr56 WT2 and Gpr56 KO2 G2V ESCs. CFU-C potential per 104 Venus+ cells is 
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shown. Colony types are indicated by color. CFU-granulocyte, erythrocyte, monocyte, 
macrophage (GEMM); CFU-granulocyte-macrophage (GM); CFU-macrophage (M); CFU-
granulocyte (G) and burst-forming-unit erythroid (BFU-E) (n=3). E) qRT-PCR gene expression 
analysis of Gpr97 and Gpr114 in total cells (pre-sort), Gata2 expressing (Venus+) and non-
expressing (Venus-) cell fractions FACS sorted from day 6 differentiated G2V ESCs. Gene 
expression levels were normalized to b-actin (n=2). F) A representative qRT-PCR gene 
expression analysis of Gpr97 in undifferentiated Gpr56 WT2, Gpr56 KO1 and Gpr56 KO2 G2V 
ESCs. Gpr97 expression levels were normalized to b-actin. G) A schematic representation of 
mouse chromosome 8 locus harboring Gpr56; Gpr97 and Gpr114 genes. Due to redundancy by 
Gpr97, the deletion of Gpr56 results in induction of Gpr97 expression and function.  
Gpr56 function is required for normal hematopoietic differentiation 
In order to generate Gpr56 KO cells that lacks the redundant function of other GPCRs at 
this locus, Gpr97 and Gpr114 were deleted. Therefore, we targeted the G2V ESCs with 
guide RNAs specific for Gpr56, Gpr97 and Gpr114, to block their protein expression 
(Supplementary Fig 2). No Gpr56 protein, and reduced levels of Gpr97 protein were 
found in the KO G2V ESCs (56-97-114 KO) as compared with the mock control cells (56-
97-114 WT) (Fig 4A). Quantification of Gpr97 protein expression showed 2-fold
decreased levels, thus suggesting that the Gpr56-97-114 KO ESCs only have one
deleted Gpr97 allele (Fig 4B). We could not detect Gpr114 protein in Gpr56-97-114 WT
cells, and the RNA levels were very low, thus we were not able to confirm whether it was
knocked out. Due to very low initial level we neglected its expression/function in further
experiments.
We differentiated the Gpr56-97-114 WT and Gpr56-97-114 KO G2V ESCs and analysed 
the hematopoietic cell output. FACS analysis revealed that there were significantly (2-
fold) less hematopoietic cells generated at day 12 of differentiation from the Gpr56-97-
114 KO G2V ESCs as demonstrated by decreased frequency of Venus+ cells (Fig 4C). 
This is in contrast to the Venus+ cell frequency increase observed in Gpr56 KO cells. 
Interestingly, we noticed significantly increased frequency of cKit (CD117) expressing 
cells in the day 12 differentiated Gpr56-97-114 KO G2V ESCs as compared to the Gpr56-
97-114 WT ESCs (Fig 4D-E) and overall increased viable cell numbers (Fig 4F). When
we visually assed the day 12 differentiated EBs generated from Gpr56-97-114 WT, Gpr56
KO2 and Gpr56-97-114 KO cells, the latter failed to show globin expression, which is
indicated by red colour of the EBs (Fig 4G), thus, suggesting that erythropoietic
differentiation is affected. These data are in line with the decreased globin mRNA levels
upon Y-27632 treatment (Fig 2F). Red color was also observed in the 56 KO2 EBs, as
expected based on the presence of BFU-E colonies in the day 12 EB derived Venus+
cells (Fig 2D). When we assessed the hematopoietic potential of the generated Venus+
cells, we detected significantly (4.1 fold) lower CFU-C yield. Importantly, there were no
bi- or multipotent colonies (CFU-GM; CFU-GEMM) generated from the Gpr56-97-114 KO
cells (Fig 4H) demonstrating that hematopoietic progenitor cell generation is abrogated,
and most severely affected is the definitive multipotent compartment which represents
the cells that are most similar to the HSCs.
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Figure 4. Gpr56 function is required for the generation of multipotent definitive 
hematopoietic progenitors. A) To generate a triple knockout cell line, we used CRISPR/Cas9 
to target Gpr56, Gpr97 and Gpr114 genes in the Gata2Venus (G2V) reporter ESCs. A 
representative Western Blotting protein expression analysis of Gpr56 and Gpr97 in 
undifferentiated G2V ESCs encoding wild type Gpr56, Gpr97 and Gpr114 genes (Gpr56-97-114 
WT) that were transfected with Cas9-GFP vector without gRNA, and in G2V ESCs with that were 
targeted with Cas9-GFP vector together with Gpr56, Gpr97 and Gpr114 specific gRNAs (Gpr56-
97-114 KO). b-actin was used as a loading control. 15 µg of total protein was loaded per lane. B)
Quantification of Gpr97 protein expression in panel A. Values represent Gpr97 protein quantity
relative to b-actin expression. C) Quantification of Venus expressing cell frequency in day 12 
differentiated Gpr56-97-114 WT and Gpr56-97-114 KO G2V ESCs (n=6). D) Representative 
FACS histogram of cKit expression in day 12 differentiated Gpr56-97-114 WT (black line) and 
Gpr56-97-114 KO (green line) G2V ESCs. E) Quantification of FACS data in panel D, n=4.  F) 
Quantification of total live cell number in day 12 differentiated Gpr56-97-114 WT and Gpr56-97-
114 KO G2V ESCs (n=4). G) Representative picture of day 12 differentiated Gpr56-97-114 WT, 
Gpr56 KO2 and Gpr56-97-114 KO G2V ESCs. Red color indicates globin expression. H) 
Hematopoietic colony forming unit-cell (CFU-C) analysis of Venus+ cells sorted from day 12 
differentiated Gpr56-97-114 WT and Gpr56-97-114 KO G2V ESCs. CFU-C potential per 104 
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Venus+ cells is shown. Colony types are indicated by color. CFU-granulocyte, erythrocyte, 
monocyte, macrophage (GEMM); CFU-granulocyte-macrophage (GM); CFU-macrophage (M); 
CFU-granulocyte (G); burst-forming-unit erythroid (BFU-E) and CFU-primitive erythroid (EryP) 
(n=4). 
Discussion 
Whole transcriptome analysis of EHT provides valuable information to identify the key 
players in the gene regulatory networks that orchestrate the development of HSCs. A 
recent RNA Seq dataset revealed Gpr56 as a possible new positive regulator of 
HSC/HPC emergence in EHT (Solaimani Kartalaei et al., 2015). Gpr56 signaling in 
hematopoiesis has been poorly studied and many aspects of its function and regulation 
remain to be addressed. Here we have taken advantage of a G2V reporter mouse ESC 
line, where the expression of Gata2 (direct regulator of Gpr56) can be traced by Venus 
fluorochrome expression. We have previously shown that all functional HPCs are found 
in the Gata2 expressing fraction, and thus, can be isolated by Venus reporter (Kauts et 
al., submitted). In vivo studies of the midgestation AGM are limited due to the extremely 
low cell numbers, thus hampering (biochemical) studies, therefore G2V reporter ESC line 
is an advantageous tool to study the involvement and role of Gpr56 in the establishment 
of HSCs/HPCs.  
Consistent with Gpr56 expression in the HSCs/HPCs (Rao et al., 2015; Saito et al., 2013; 
Solaimani Kartalaei et al., 2015), we found Gpr56 to be co-expressed with Gata2+ 
hematopoietic progenitors and its expression upregulated during the commitment of 
definitive hematopoietic progenitors, therefore supporting the hypothesis that Gpr56 
functions as a positive regulator of the HPC/HSC development. The signals which 
stimulate Gpr56 in the blood cells, are not known. Several interacting partners, including 
Collagen III, have been suggested, but their signaling has not been studied in 
hematopoietic cells. Rao et al., reported Collagen III encoding gene Col3a1 expression 
by qRT-PCR in the E11 AGM mesenchymal cells (Rao et al., 2015), thus demonstrating 
the spatiotemporal vicinity of Collagen III to the developing HSCs/HPCs. We detected 
Col3a1 expression in other stromal cells that are used as a hematopoiesis inductive 
environment in embryonic and induced pluripotent stem cell hematopoietic differentiation 
approaches, further indicating for its possible role as a stimulator of hematopoiesis. 
Moreover, Collagen III seems to have a positive effect on the hematopoietic 
differentiation as it induced hematopoietic gene expression in ESC differentiation and 
increased the definitive hematopoietic potential of Venus+ cells. Thus, these data suggest 
that Collagen III is a positive regulator of hematopoietic differentiation, possibly via the 
Collagen III-Gpr56 axis. Our further experiments with Gpr56 KO cells aim to confirm the 
specificity of Collagen III-Gpr56 signaling. Also, biochemical analysis of Gpr56 
expressing Venus+ hematopoietic progenitors will allow us to identify possible new 
ligands of the Gpr56 receptor that could be used as external stimulators of pluripotent 
stem cell hematopoietic differentiation in order to establish protocols for the in vivo HSC 
generation. 
To investigate the requirement of Gpr56 for the hematopoietic development, we 
established Gpr56 KO G2V reporter ESCs, and to our surprise, found that there were 
significantly more Gata2 expressing cells generated in their hematopoietic differentiation, 
and those cells gave rise to 4-fold more definitive hematopoietic colonies. Consistent with 
our data, Rao et al investigated hematopoiesis in Gpr56-/- mice and did not report negative 
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effect on embryonic HSC/HPC development, maintenance, or reconstitution ability (Rao 
et al., 2015). Strikingly, we observed that the expression of another GPCR, Gpr97 was 
upregulated in both of our Gpr56 KO ESC clones, demonstrating for the first time a direct 
redundancy between Gpr56 and Gpr97. Functional redundancy between other adhesion 
GPRC has been proposed previously. Gpr65, a pH sensing GPCR, has a critical role in 
glucocortical-induced thymocyte apoptosis (Malone et al., 2004; Tosa et al., 2003), 
however, Gpr65 KO mice show no immune defects, thus suggesting for a redundancy by 
other GPCR with similar expression pattern, such as G2A (Radu et al., 2006). Increased 
Gpr97 expression was detected during EHT specifically in the HSC compartment 
(Solaimani Kartalaei et al., 2015). Upon deletion of Gata2 cis-regulatory element at 9.5 
kb downstream of its promoter (+9.5 element), Gpr97 transcript levels were decreased 
more than 100 fold (Gao et al., 2016). In line with this study, we detected Gpr97 
specifically in the Venus expressing cells, thus suggesting that Gpr97 and Gpr56 are 
expressed in the same hematopoietic cells and upon the deletion of Gpr56, 
compensatory mechanisms are activated that result in higher progenitor output. Further 
studies are needed to specify the direct mechanisms activated upon Gpr56 ablation, and 
whether this phenomenon could be rescued by Gpr56 expression. Also, it is attractive to 
propose that the compensatory mechanisms caused by functionally redundant Gpr56 
and Gpr97 may be the causing the loss of abnormalities in the Gpr56 KO embryos (Rao 
et al., 2015). When Gpr97 was knocked down in Gpr56 KO ESC, the hematopoietic 
program was severely abrogated. These data corroborate the proposed redundancy 
between Gpr56 and Gpr97 and demonstrate that Gpr97 knockdown is sufficient to 
suppress normal HPC development in the absence of Gpr56 activity.  
Double knockdown of Gpr56 and Gpr97 mainly affected the generation of bi- and 
multipotent progenitor compartment, some unipotent cells were detected, thus 
suggesting that Gpr56 function may be specifically required for the 
generation/maintenance of definitive multipotent progenitors. Previously published data 
suggest that Gpr56 may function in the maintenance of stem cell properties. 
Overexpression of constitutively signaling Gpr56 mutant form in neutrophil cell line 
resulted in a blockage of differentiation, thus demonstrating that Gpr56 is keeping 
progenitor cells in undifferentiated state (Solaimani Kartalaei et al., 2015). This is in line 
with Gpr56 activity in adult bone marrow, where it sustains the HSC pool (Saito et al., 
2013). Gpr56 seems to have a similar role of sustaining stemness properties also in 
cancer stem cells, where high Gpr56 expression in the AML cells has been noted to 
correlate with higher repopulating activity of the cells (Daria et al., 2016; Pabst et al., 
2016). Taken together, these data suggest that lower multipotent CFU-C activity in 
Gpr56-97-114 KO cell differentiation may be seen due to the abrogated maintenance 
mechanism of the progenitor/stemness properties in the generated progenitor cells.    
Interestingly, we detected increased frequency of cells with high cKit expression in the 
double knockout cell line. cKit is a receptor tyrosine kinase that is essential for 
hematopoiesis. It is expressed in HSCs and in lineage progenitor cells and is 
downregulated in most of the mature lineage cells, except for mast cells that retain high 
cKit expression. Our hematopoietic progenitor assay data agree with this expression 
pattern as a complete loss of bi- and multipotent hematopoietic progenitors upon Gpr97 
knockdown in the Gpr56 KO cells was observed, however, the CFU-G fraction, which 
contain mast cells, was only marginally affected. cKit receptor has been reported to 
directly interact with other growth factor receptors, such as the receptors for GM-CSF, 
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Epo, IL-7 and IL-33 (Drube et al., 2010; Jahn et al., 2007; Lennartsson et al., 2004; Wu 
et al., 1995). Thus, one possible way how to explain the higher frequency of cells 
expressing high cKit levels is that Gpr56 is involved in the maintenance of normal cKit 
expression levels by directly interacting with cKit receptor. Our ongoing experiments will 
investigate the Gpr56-cKit interactions and aim to reveal whether one means by which 
Gpr56 controls hematopoiesis is via cKit regulation.  
We detected profoundly increased viable cell counts upon Gpr56-97-114 deletion in the 
differentiating cells. This may be a secondary effect caused by higher frequency of cKit 
expressing cells, as SCF-cKit axis regulates cell growth and proliferation. However, stem 
cells are slowly cycling cells (Fig 2 Chapter 1) and the expression of Gpr56 in stem cells 
has been associated with the maintenance for their quiescence. Also, Gp56 has been 
proposed to suppress cancer cell growth in vivo. Thus, the higher viable cell number seen 
in the Gpr56-97-114 KO cells may be seen due to decreased numbers of quiescent 
stem/progenitor cells and subsequently, higher proportion of proliferating non 
progenitor/stem cells.  
Our study proposes that Gpr56 is involved in the regulation of HPC generation, possibly 
via Collagen III signaling axis, and reveals a functional redundancy between Gpr56 and 
Gpr97. Our data suggest that Gpr56 may be involved in the maintenance of 
stem/progenitor cell properties, however, the precise role of how Gpr56 signaling 
functions in hematopoietic cells needs further investigation. Gpr56 signaling is activated 
via the cleavage and additional binding of its long N-terminal tail by an adhesive ligand 
to relieve the inhibitory influence of the N-terminal tail (Figure 1). The removal of the N-
terminus results in the generation of a constitutively active form of Gpr56 (Paavola et al., 
2011). Our ongoing experiments aim to generate an ESC line expressing inducible 
constitutively signaling Gpr56 form to analyze the temporal requirement of Gpr56 
signaling for HPC/HSC generation. This approach facilitates studying the downstream 
pathways that are activated by Gpr56 signaling and potentially, will reveal the mechanism 
of how Gpr56 functions in EHT to induce HSC/HPC emergence. Moreover, we aim to 
investigate whether overexpression of Gpr56 has a positive effect on hematopoietic 
differentiation of pluripotent stem cells, possibly allowing the generation of repopulating 
HSCs in vitro, which has been a long term goal in blood research. 
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Supplementary data 
Supplementary Figure 1. Hematopoietic progenitor potential of Collagen III treated G2V 
ESCs. Hematopoietic colony forming unit-cell (CFU-C) analysis of Venus+ cells sorted from day 
12 differentiated G2V ESCs. Data from 3 biological replicates are presented. Colony types are 
indicated by color. CFU-granulocyte, erythrocyte, monocyte, macrophage (GEMM); CFU-
granulocyte-macrophage (GM); CFU-macrophage (M); CFU-granulocyte (G); burst-forming-unit 
erythroid (BFU-E) and CFU-primitive erythroid (EryP). 
Supplementary Figure 2. Generation of Gp56-97-114 knockout G2V ESCs by CRISPR/Cas9 
strategy A schematic representation of the Gpr114, Gpr56 and Gpr97 locus on mouse 
chromosome 8. Guide RNAs (gRNA) targeting exon 1+2 on Gpr114 and exon 2 on Gp56 and 
Gpr97 were used to disrupt the locus by Non-Homologous End Joining DNA repair pathway, which 
may lead to the deletion of the complete locus, or specific fragments, or a frameshift, ultimately 
causing a loss of Gpr56, Gpr97 and Gpr114 protein expression.  
Supplementary Table 1. CRISPR/Cas9 gRNA sequences 
Gpr56 exon 2 Top CACCGTCTGTTGGGTCTGGTTCCGC 
Bottom AAACGCGGAACCAGACCCAACAGAC 
Gpr97 exon 2 Top CACCGGAATGTCTGCCGTCGGCTTC 
Bottom AAACGAAGCCGACGGCAGACATTCC 
Gpr114 exon 1+2 Top CACCGCTTGAGCAGCCCGTAGGCCG 
Bottom AAACCGGCCTACGGGCTGCTCAAGC 
Guide RNAs (gRNA) designed to target the exons that harbour ATG start sites in Gpr56, Gpr97 
and Gpr114 genes (top) and their deduced reverse complement sequences (bottom). The gRNA 
sequences (black) contain overhangs (red) for ligation into the pair of BbsI sites in the pSP-Cas9-
A2-GFP plasmid. A G-C base pair (blue) is added at the 5′ end of the guide sequence to facilitate 
transcription from the U6 promoter that is contained in the pSP-Cas9-A2-GFP plasmid directly 
upstream from the ligated gRNA sequence. 
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Supplementary Table 2. qRT-PCR primer sequences 
qRT-PCR	 forward 5’-3’ reverse 5’-3’ 
b-actin CACCACACCTTCTTACAATGAG GTCTCAAACATGATCTGGGTC 
Gpr56 TCTGCTCTGGCTTGTGTCTTC	 AGGTTCATGTGGACTTTGATGG	
Gpr97 CTGGGATATGGCTAAAGGAGAC	 AAGGCGAAGAAGGTCAAGTG	
Gpr114	 TCACTGCTCAATAACTATGTCC	 ACTGTATACCCTTCCAGACTC	
bH1	 AGTCCCCATGGAGTCAAAGA	 CTCAAGGAGACCTTTGCTCA	
bmajor	 CTGACAGATGCTCTCTTGGG	 CACAACCCCAGAAACAGACA 
Gata1	 TGCCTGTGGCTTGTATCA	 TGTTGTAGTGGTCGTTTGAC	
Runx1	 TTTGATGGCTCTATGGTAGGTG	 CAGGTAGCGAGATTCAAAGA 
Col3a1 GAATCTGTGAATCATGTCCAACTG CCACCCATTCCTCCCACTC 
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Abstract 
Mast cells are tissue resident immune cells. Aberrant or uncontrolled activation of mast 
cells can result in a wide range of common, distressing and sometimes life-threatening 
disorders, including asthma, psoriasis, anaphylaxsis and mastocytosis (Figure 1) 
(Theoharides et al., 2016; Theoharides et al., 2015). Drug discovery efforts have been 
hampered by the cell culture systems which have used immature (cancer-derived) cell 
lines or primary cells that provide low efficiency yield and reproducibility, and require a 
12-week culture period before mature mast cells are obtained (Holm et al., 2006; Saito
et al., 2006; Shimizu et al., 2002; Wang et al., 2006). To address this problem, we
developed a novel method for the rapid and robust production of mature mast cells from
pluripotent stem cells (PSC) - which represent an unlimited source. Our protocol utilizes
an advantageous Gata2Venus reporter (Kaimakis et al., 2016) that marks and enables
the isolation of all mast cells and precursors as they are produced from PSCs. Highly
proliferating mast cells emerge after less than 2 weeks of culture. These mast cells are
fully functional and degranulate after activation. Unlike primary tissue-derived mast cells,
this approach will enable the production of sufficient numbers of physiologically relevant
human mast cells for high-throughput drug discovery and, in combination with patient-
specific iPSCs, the study of mast cell-associated hematological disorders, thus opening
the field for personalized medicine.
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Results 
Mast cells are the key effectors in common immunological disorders affecting worldwide 
populations. These include allergies, autism, asthma, eosinophilic esophagitis, celiac 
disease, mastocytosis, atopic dermatitis and psoriasis. To date, treatment options 
focusing on the modulation of mast cells are limited and development of new therapies 
are hampered by challenges in generating sufficient phenotypically mature mast cells for 
biomedical discovery and drug screening (Holm et al., 2006; Saito et al., 2006; Shimizu 
et al., 2002; Wang et al., 2006). Currently, direct isolation of mast cells is inefficient and 
results in an altered phenotype. The ex vivo generation of mast cells from blood 
precursors involves extended culture periods, expensive reagents and low/variable yields 
(Table 1).  
Pluripotent stem cells (PSC) offer an alternative source for obtaining mature mast cells 
for research. However, the published protocols are again laborious and time-consuming, 
as mast cells emerge after extensive 4-8 weeks of mouse ESC culture (Moller et al., 
2007; Tsai et al., 2002; Westerberg et al., 2012) and only after 10 weeks of human ESC 
culture (Kovarova et al., 2010) (Table 1). Further prolonged culture is needed to increase 
mast cell yield, as the cells are cumulatively harvested, and do not enable prompt 
production of large numbers of mast cells. Thus, the lack of an efficient protocol to rapidly 
obtain large numbers of mature mast cells for research has severely hampered drug 
development and progress in understanding and treating mast cell-related disorders. 
Here we report a novel method for the rapid (12-14 days) and abundant production of 
functionally mature mast cells from PSCs (mouse and human) that relies on a 
Gata2Venus (G2V) reporter.  
Figure 1. Mast cell activation. 
Mast cells are white blood cells 
that play a key role in 
inflammatory processes 
(Theoharides et al., 2016; 
Theoharides et al., 2015). They 
express ckit (CD117) and 
FcεRIα (IgE high affinity 
receptor) and contain 
cytoplasmic granules rich in 
proteases. When they are 
activated by an allergen, 
degranulation is triggered 
resulting in chemical mediator 
release and inflammation. 
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Table 1. Duration of cultures used for mast cell generation from different cell/tissue 
sources. 
Source Culture time Ref 
hPB 12 weeks (Saito et al., 2006; Wang et al., 2006) 
hCB 12 weeks (Holm et al., 2006) 
hBM 12 weeks (Shimizu et al., 2002) 
WT mESC 4-8 weeks (Moller et al., 2007; Tsai et al., 2002; 
Westerberg et al., 2012) 
WT hESC 10 weeks (Kovarova et al., 2010) 
G2V mESC 14 days This study 
G2V hESC/iPSC 12 days This study 
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Duration of cultures for human mast cell generation from progenitors isolated from primary tissue 
sources such as peripheral blood (hPB), cord blood (hCB) and bone marrow (hBM) and from wild 
type (WT) and Gata2Venus (G2V) reporter mouse embryonic stem cells (mESC) and human ESC 
(hESC) or induced pluripotent stem cells (iPSC).  
The rationale for this reporter is that the Gata2 transcription factor is highly expressed 
in mast cells (Jippo et al., 1996) and its expression is essential for mast cell precursor 
development (Tsai and Orkin, 1997),  expansion (Tsai and Orkin, 1997), and the 
function of mature mast cells (Masuda et al., 2007). We have previously shown that 
Venus reporter expression in the mouse G2V ESCs (Kauts et al., submitted) and 
embryos (Kaimakis et al., 2016) mirrors that of Gata2 without affecting its expression 
levels, and that Gata2 is expressed in all hematopoietic stem cells (HSC) and 
progenitors (HPC) (Kaimakis et al., 2016). Gata2 is downregulated when immature 
HPCs differentiate into mature lineage cells, with the exception of mast cells, thus 
making it a specific reporter for this lineage. 
Our recent data show that all the functional erythroid-myeloid progenitors (EMPs) 
generated in the G2V ESC differentiation cultures are Gata2-expressing and the 
highest frequency of EMPs is found at day 10 of culture (Kauts et al., submitted). To 
induce EMP development, mouse G2V ESCs were differentiated to embryoid bodies 
(EB) for 10 days (Fig 2A). Venus+ cells were sorted (1.6 % of total live EB-derived cells) 
and cultured on a monolayer of OP9 stromal cells (Fig 2B). The average number of 
Venus+ cells obtained from day 10 EBs (starting ESC number=3x104) was 1.5±0.3 
x104 (Suppl Table 1). After 2-3 days, round non-adherent hematopoietic cells 
appeared in the co-culture (Fig 3A) and after 4 days, 37±6.8 % of the cells expressed 
high levels of Venus (Fig 2C). Only Venus+ cells specifically co-expressed the pan-
leukocyte receptor CD45. 99±0.6 % of the Venus+CD45+ cells were positive for the cKit 
(CD117) HSC, HPC and mast cell marker (Fig2C-D) and 84±3.8 % of the Venus+CD45
+cKit+ cells were expressing the high affinity IgE immunoglobulin receptor 1α (FceRIα), a 
mast cell and basophil marker (Fig 2C-D). Whereas 5.7±3.5 % of the Venus- cells were 
expressing low levels of cKit, none of the cells had acquired FcεRIα expression (Fig 2C, 
lower left panel). These data demonstrate that the great majority of Venus+ cells have 
acquired a mast cell phenotype after 4 days of OP9 co-culture and this phenotype is 
specific only for Venus-expressing cells.
Figure 2. Gata2Venus ESC differentiation and Venus enrichment facilitates rapid and 
robust mast cell generation. (A) Hematopoietic commitment is induced during a 10 day 
embryoid body culture (blue line, day 0-10). At day 10, Venus+ (V+) erythroid-myeloid progenitors 
(EMP) are flow cytometrically sorted and plated onto OP9 stromal cells where mast cell (MC) 
commitment is induced (orange line, day 10-14). Highly proliferating phenotypic mast cells appear 
after 3-4 days of co-culture in the presence of Flt3L, IL-7 and SCF. By day 14, phenotypic mast 
cells/mast cell progenitors (MCP) can be isolated by Venus expression for analysis, or for further 
clonal expansion in methylcellulose (crimson line, day 14-18/21). (B) Representative FACS dot 
plot of day 10 mouse Gata2Venus ESC differentiation demonstrating gating strategy used for 
sorting Venus+ erythroid-myeloid progenitors (1.6%) that were seeded on OP9 cells. (C) FACS 
analysis of cells after 4 days of OP9 co-culture. 37±6.8 % of the cells expressed Venus and CD45 
(upper left panel) of which 16±3.6 % were cKit+ mast cell progenitors, and 83±4.4 % mast cells 
(upper right panel). No phenotypic mast cells were generated from Venus- cells (lower left panel). 
(D) FACS histogram plots of cKit and FceRIa expression in Venus+CD45+ cells derived after 4
days of OP9 co-culture. Values indicate mean±SEM, n=6 (upper panels). (E) FACS analysis
showing lack of B-cell (CD19), macrophage (Mac1), granulocyte/basophil (Gr1) and erythrocyte
(Ter119) lineage cells in Venus+CD45+ population after 4 days of OP9 co-culture. (F) FACS
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histogram of Venus expression in EMPs at day 10 of culture (black line) and mast cells at day 14 
of culture (MC, red line) (upper panel). Quantification of Venus mean fluorescence intensity (MFI) 
in EMP (black bar) and MC (red bar) showing significantly higher Venus protein levels in mast 
cells. Mean±SEM, ** p<0.01, n=3 (lower panel).  
To assess the purity of the Venus+CD45+ cell population, the expression of other blood 
lineage markers, such as Mac1 (macrophage), Gr1 (granulocyte/monocyte), 
CD19 (lymphocyte) and Ter119 (erythroid) was analysed (Fig 2E). None of 
these markers were found to be expressed on the Venus+CD45+ cells. 
As HSCs express Gata2 (Kaimakis et al., 2016), cKit (Sanchez et al., 1996) 
and CD45 (McKinney-Freeman et al., 2009), to examine the possibility that some 
HSC-like cells were generated in the differentiation culture, we transplanted 
Venus+CD45+Lin- cells into lethally-irradiated adult mice. Spleen analysis at 
day 8 post-transplantation showed no donor-derived colony forming unit-spleen 
activity (data not shown). Thus, the majority, if not all of Venus+CD45+ cells 
are mast cells and/or mast cell progenitors. Interestingly, a significant 
shift in the intensity of Venus expression was seen between EMPs and 
mast cells/progenitors (Fig 2F). The geometrical mean of Venus fluorescence 
intensity in mast cells/progenitors was 3.5 fold higher than in EMPs, thus 
supporting the view that the direct induction of high Gata2 expression is a 
prerequisite for the rapid commitment to the functional mast cell lineage (Sasaki et 
al., 2016).
Mature mast cells produce high levels of inflammatory mediators that are stored in the 
cytoplasmic secretory granules (Schwartz and Austen, 1980). The expression of genes 
encoding the inflammatory mediators of connective tissue mast cells (mMCP-5 chymase 
and mMCP-6 tryptase, and CPA-3 carboxypeptidase A) and of mucosal mast cells 
(mMCP-1 chymase) was examined in undifferentiated ESCs, day 10 EMPs and 
methylcellulose expanded mast cells before and after clonal re-plating (Fig 3E). High 
expression of mMCP-1; mMCP-5 and mMCP-6 was found in all mast cells samples 
before and after serial re-plating, with only low/negligible expression in some ESC or 
EMP samples. Mast cell receptors cKit and FcεR1α were similarly expressed before and 
after re-plating in all mast cell samples with some low cKit expression in ESCs. As 
expected, high levels of Gata2 were detected in EMPs and in mast cells before and after 
re-plating. The fact that the clonal expansion capacity, cellular morphology and gene 
expression profile of the mast cells were retained after serial plating (Fig 3D and 3E) 
suggests that these cultures maintain the self-renewal properties of mast cell 
progenitors. Gene expression of the chemical mediators and mast cell receptors in ESC-
derived mast cells was compared to expression in murine ear tissue which is known to 
contain mast cells. cKit, FcεR1α and FcεR1γ  were expressed 560±39, 2802±1690 and 
644±66 times more respectively than ear tissue and mediator proteases mMCP-5, 
mMCP-6 and CPA-3 were expressed at 1727±402, 570±58 and 3818±621 times higher 
than in the ear (Fig 3F). These data confirm the highly enriched production of mast cells 
from G2V ESCs and strongly suggest that these mast cells are functional. 
91
Figure 3. Gata2Venus enrichment results in the generation of functional mucosal and 
connective tissue type mast cells that express high levels of chemical mediators. (A) 
Representative image demonstrating the expansion capacity of single Venus+ mast cells derived 
from d14 of culture. Arrows indicate the centers of two macroscopic colonies that were each 
derived from single cells. Objective=4x. (B) Representative image of Toluidine blue staining of 
mast cells generated after methylcellulose expansion. Light staining indicates mucosal mast cells 
(mMC), dark staining connective tissue like mast cells (ctMC), objective=40x. (C) Representative 
image of toluidine blue stained mast cells generated after 2x clonal re-plating of methylcellulose 
colony, objective 4x. (D) Mast cell specific gene expression analysis of undifferentiated embryonic 
stem cells (ESC, n=3), erythroid-myeloid progenitors (EMP, n=3), methylcellulose expanded mast 
cells (MC, n=4) and mast cells after clonal re-plating (rpMC, n=3). No RT, no reverse transcription; 
CPA-3, carboxypeptidase; mMCP, mouse mast cell proteases. (E) Quantitative gene expression 
analysis of mast cell specific genes in methylcellulose expanded mast cells. Expression level of 
all genes was normalized to 18S expression and compared to the normalized levels in the mouse 
ear tissue that is known to contain mast cells. Mean ± SEM, n=3. (F) ELISA assay of relative 
released tryptase concentration in the medium of untreated and 5 µM c48/80 treated mast cells. 
Tryptase levels were calculated based on a tryptase standard curve. Level was set as 1 in 
untreated sample and level in c48/80 samples was calculated accordingly, *p<0.05, n=5.  
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To analyze the proliferative capacity of the Venus+ mast cells/progenitors, single 
Venus+ cells harvested after 4 days of co-culture on OP9 cells (Fig 3A) were 
plated in methylcellulose. After 3-4 days, macroscopic homogenous single cell-
derived colonies appeared, indicating a large degree of rapid expansion (Fig 3B). 
The proliferative capacity of a single day 14 derived mast cell/mast cell progenitor 
was up to 104 fold (average 2.2±1.4 x103 fold). In total, a starting culture of 3 x104 
ESC can yield up to 3.8x106 mature mast cells (average 1.6±0.5 x106) (Suppl Table 
1). This is up to 8-fold more cells generated in 21 days than previously published 
protocols in 5 or more weeks (0.5x106 cells) (Westerberg et al., 2012). Mast cell 
identity was confirmed by Toluidine blue staining (specific for intracellular granules). 
100% of these cells were toluidine blue positive and both types of mast cells - 
connective tissue (dark staining due to heparin and high histamine levels; found 
mainly in skin) and mucosal mast cells (light-staining due to no heparin and low levels 
of histamine; found in digestive tract and lung mucosa (Bischoff and Kramer, 2007; 
Welle, 1997) were present in the cultures (Fig 3C). 
Allergic responses in vivo result from the activation and degranulation of mast cells. To 
test whether G2V ESC-derived mast cells can be activated and degranulate, they were 
treated with the synthetic polyamine compound 48/80 (c48/80) (Lagunoff et al., 1983) 
which is one of the secretagogues of mast cells that include neuropeptides and 
opiates. After 60 minutes of c48/80 stimulus (5 µg/ml) a significantly 1.6-fold higher 
tryptase level was found in the cell medium as compared to the control unstimulated 
sample (Fig 3G), thus demonstrating that the G2V ESC-derived mast cells are 
functionally active and respond to common mast cell activating extracellular stimuli 
by releasing chemical mediators. 
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The known high conservation between mouse and human hematopoietic development, 
Gata2 expression and function, suggests that GATA2 could enrich human mast cells. 
To test this, we generated and characterized GATA2Venus reporter human ESCs 
(G2V-hESC) and 2 clones of iPSCs (G2V-hiPCS-1; G2V-hiPCS-2) (Suppl Fig 1). 
Phenotypic (Fig 4A) and functional (Fig 4B) hematopoietic cells were enriched in the 
Venus+ fraction upon serum-free hESC/hiPSC hematopoietic differentiation, and 
are in line with previous analyses of mouse ESCs (Kauts et al., submitted) and 
human ESC/iPSC (Huang et al., 2016). Venus+ cells sorted on days 7, 8 and 11 
following differentiation were co-cultured with OP9 cells. After 4-5 days of co-
culture, 5.5%-19% of the Venus+ cells, which constituted 3.0%-5.5% of the co-
culture cells, were of the cKit+FCeRIa+ mast cell phenotype, whereas no/few 
phenotypic mast cells were generated from Venus- fraction (Fig 4C). Toluidine 
blue staining of methylcellulose expanded colonies confirmed the mast cell 
morphology (Fig 4D). These results were consistent between G2V-hESCs and G2V-
hiPSC clones demonstrating the robustness of our approach, which, with further 
optimization, will deliver a platform for the robust generation of human mast cells. 
Our novel and innovative Gata2 reporter-based pluripotent stem cell differentiation 
approach for the rapid and efficient production of functional mast cells, represents 
a major advance that can now provide sufficient numbers of mast cells (including 
patient-specific mast cells) for high throughput drug discovery and mechanistic 
studies on mast-cell related disorders.  
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Figure 4. Gata2Venus hiPSC/ESC differentiation and generation of mast cells.  (A) 
FACS analysis of hematopoietic cell surface marker CD41 expression on Venus- and Venus+ 
populations of day 12 differentiated G2V-hESCs and G2V-hiPSCs. (B) Hematopoietic 
progenitor potential of Venus+ (V+) and Venus- (V-) cells isolated from day 12 differentiated G2V-
hES and G2V-hiPSC. Number of colony forming unit-cells (CFU-C) per 104 FACS sorted cells is 
shown. Colony types are indicated by color. CFU-granulocyte, erythrocyte, monocyte, 
macrophage (GEMM); CFU-granulocyte-macrophage (GM); CFU-macrophage (M); CFU-
granulocyte (G); burst-forming-unit erythroid (BFU-E) and CFU-primitive erythroid (EryP). 
Representative data. (C) Mast cell differentiation approach as described for murine culture in 
Figure 1A was applied to G2V-hESCs and G2V-iPSCs to generate human mast cells. Venus+ 
cells were sorted from day 11 (G2V-hES), day 7 (G2V-hiPSC-1) or day 8 (G2V-hiPSC-2) 
differentiated embryoid bodies and subjected to OP9 co-culture. After 5 (G2V-hESC; G2V-
hiPSC-2) or 4 days (G2V-hiPSC-1) of co-culture, Venus+ and Venus- cells were analyzed for 
mast cell surface markers cKit and FCeRIa by FACS. (D) Representative image of Toluidine 
blue staining of mast cell generated after 5 days of methylcellulose expansion, objective=40x. 
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Methods 
Mouse and human G2V reporter pluripotent stem cells. G2V and wild type (IB10) mouse 
ESCs were derived and cultured as undifferentiated cells as described by Kaimakis et 
al., (2016) and in Kauts et al., (submitted). hESC (line WA01 from WiCell) and iPSC 
lines (line SFCi55 from Lesley Forrester and CENSO Biotechnologies Ltd) (Yang et al., 
2016) were maintained on MEFs seeded on 0.1% gelatin-coated plates, in DMEM/F12 
supplemented with Knock-out Serum Replacement (ThermoFisher), GlutaMAX (Gibco), 
Minimum Essential Medium Non-essential Amino Acids (Lonza), 50 μM β-
mercaptoethanol (Gibco) and 10 μg/ml bFGF (PeproTech). Medium was replaced daily. 
The human GATA2Venus reporter PSCs were generated by CRISPR/Cas9 engineering. 
The GATA2-stop codon-targeting gRNA was designed and its reverse complement 
deduced. BbsI cohesive ends were added on the 5’ of each strand as appropriate. The 
insert DNA duplex was prepared by annealing, and ligated into the pSpCas9(BB)-2AGFP 
(PX458) (Addgene) vector as described by (Ran et al., 2013).  
The GATA2-T2A-H2B-Venus-pA-EF1α-Puro-pA donor vector was generated from a BAC 
(CTD-3248G10; Life Technologies). Bacterial lines were transformed with pSIM18Hygro 
(kind gift from P. Liu, Wellcome Trust Sanger Institute) to generate bacterial strains with 
heat-inducible recombinase expression. Four mini-homology arms (5’-out, 3’-out, 5’-in 
and 3’-in) were initially generated by PCR amplification of BAC DNA using the following 
PCR primers: 
GATA2 Out-5-F ttgcggccgc GCAAAATTCCCAGGACCTGCTC 
GATA2 Out-5-R ccaagctt TGCAAAACAAACAGGAGAAAGGACC 
GATA2 Out-3-F ccaagcttggatcc TCCTACCTGATGCATAGTGGC 
GATA2 Out-3-R ccctcgag GAGTTCTGGGGCCTAGAGCTATGG 
GATA2 In-5-F cggaattc CTGGCTTCCTGGGACCCTCAG 
GATA2 In-5-R gggctagcgtcgac GCCCATGGCGGTCACCATG 
GATA2 In-3-F ccctcgagggcgcgcc GGAACAGATGGACGTCGAGGACC 
GATA2 In-3-R aggcggccgc AGGACTTGGGACAGCTCAGACCAC 
5’-out arm were digested with NotI/HindIII and 3’-out arm with XhoI/HindIII. Digested 5’ 
and 3’ out-arms were ligated into XhoI/NotI digested and gel purified pBlueScript to 
generate outarm-pBlueScript. 5’-in arm were digested with EcoRI/NheI and 3’-in arm 
with XhoI/NotI. Digested 5’- and 3’-in arms were ligated with a NheI/AscI digested 
ZeoR cassette (kind gift from P.Liu) and EcoRI/NotI digested pBlueScript to generate 
5’in-arm-ZeoR-3’in-arm-pBlueScript. The entire out-arm-pBlueScript backbone 
was PCR amplified for recombineering. Competent BAC/pSIM18Hygro bacteria were 
transformed with PCR amplified out-arm-pBlueScript to generate the full homology 
region within pBlueScript. This full homology region-pBluescrip and a EcoRV/NotI 
linearised 5’in-arm-ZeoR 3’in-arm fragment were then transformed into competent SIM18 
E.coli (a strain with stable phage incorporated SIM18 recombinase; Chan et al., 2007) to
replace the GATA2 stop codon with the ZeoR cassette. The ZeoR cassette was digested
from the homology arms using SalI/AscI and homology arms ligated with a SpeI/AscI
digested T2A-Venus-pA-EF1a-PuroR-pA DNA fragment (plasmid kindly provided by W.
Wang, Wellcome Trust Sanger Institute). Sequencing was used to verify homology arm
sequences.
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8x105 hPSCs were electroporated using the Human Stem Cell Nucleofector Kit 2 (A-023 
programme) of the AMAXA Nucleofector (Lonza) according to the supplier’s protocol. 3 
μg of GATA2-T2A-H2B-Venus-pA-EF1α-Puro-pA-pBlueScript together with 2 μg of 
gRNA-pSpCas9(BB)-2A-GFP were used for transfection. Transfected cells were 
seeded on puromycin resistant MEF feeders (DR4, ATCC). 48hours post-transfection, 
1 μg/ml puromycin selection was initiated for 1 week. In total, 33 iPSC and 16 ESC 
prospective GATA2Venus clones were established and subjected to PCR based 
genotyping with primers spanning over the 3’ (4795 bp) and 5’ (5025 bp) junctions of the 
construct and the GATA2 genomic sequence (Supplementary Figure 1). Primers 
detecting GATA2 WT allele (240 bp) were used to assess the homo-/heterozygousity of 
the insertion. Clones with correct integration were subjected to karyotyping. 1 clone of 
G2V-hESC and 2 clones of G2V-hiPSC with normal karyotype were used for 
experiments. 
Multistep culture for PSC differentiation and mast cell generation. 
The three step culture procedure is summarized in Fig 2A. 
1. EMP differentiation (day 0-10). Mouse G2V ESCs were harvested by trypsinization 
and feeder depleted by incubation in the Iscove modified Dulbecco medium (IMDM) 
containing 20% fetal bovoine serum (FBC) (HyClone) and 1% penicillin/streptomycin 
(P/S) for 30 minutes at 37°C. G2V ESC differentiation was induced by forming EBs. 
Cells were allowed to aggregate by culturing them at a density of 25,000 cells/ml 
in EB differentiation medium (IMDM containing 15% FBS, 2mM GlutaMAX (Gibco), 50 
µg/ml ascorbic acid (Sigma), 4x10-4 monothioglycerol (Sigma), 300 µg/ml transferrin 
(Roche)) in bacterial petri dishes. 72 h later the medium was refreshed and 
supplemented with 5%proteome free hybridoma medium (Gibco). At day 6 of 
differentiation, the medium was supplemented with murine stem cell factor (SCF, 100 
ng/ml), IL-3 (1 ng/ml) and IL-11 (5 ng/ml) (PeproTech). Medium was refreshed every 
other day.
The differentiation of hPSC to EMPs was performed as previously described (Kennedy 
et al., 2012). Briefly, hPSCs were non-enzymatically cut using StemPro EZPassage 
Disposable Stem Cell Passaging Tool (Thermo Fisher) and aggregates were re-
suspended in Stem-Pro-34 (Invitrogen), supplemented with 10 ng/ml P/S, 2 mM L-
glutamine (Gibco), 1 mM ascorbic acid (Sigma-Aldrich), 4x10-4 M monothioglycerol 
(Sigma-Aldrich), and 150 mg/ml transferrin (Roche). Human BMP-4 (10 ng/ml), bFGF (5 
ng/ml), Activin A, 6 mM SB, VEGF (15 ng/ml), Dkk (150 ng/ml), IL-6 (10 ng/ml), IGF-1 
(25 ng/ml), IL-11 (5 ng/ml), SCF (50 ng/ml), EPO (2 U/ml), TPO (30 ng/ml), IL-3 (30 
ng/ml), and Flt-3L (10 ng/ml) (all from PeproTech) were added as indicated (Kennedy et 
al., 2012). 
2. Isolation of EMPs, mast cell commitment (day 10-14). At day 10 of differentiation, 
EBs were washed with PBS and incubated with TrypLE Express enzyme (Gibco) at 37°
C for 3-5 minutes. Enzyme was deactivated by adding PBS + 10% FCS + 1% P/S 
and homogenous single-cell suspension was obtained by re-suspending with a 
P1000 pipette.
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10,000 Venus+ cells were sorted and plated on 30,000 OP9 cells pre-seeded one day 
earlier in 24 well plate. Cells were cultured in a-MEM + 10% heat inactivated FBS + 1% 
P/S co-culture medium supplemented with murine Flt3L, IL-7 (20 ng/ml) and SCF (50 
ng/ml) (all from PeproTech). For human PSC culture, same concentration of human 
cytokines was used (PeproTech). Venus+ mast cells appeared in the culture after 2-4 
days, they could be readily isolated for experiments or further expansion by Venus+ 
expression. 
3. Expansion. After 4 days of OP9 co-culture, Venus+ cells were isolated by FACS and
plated in methylcellulose medium (Stem Cell Technologies) at concentration of 500
cells/ml. After 3-4 days of expansion, big bright dense colonies appeared. Colonies were
counted after 3-7 days of methylcellulose culture and cells were harvested by dissolving
methylcellulose in PBS. Cells were counted by trypan blue exclusion. For colony re-
plating, colonies were picked and single cells were plated into fresh methylcellulose.
Human mast cell generation was performed essentially as described for murine culture, 
but with the use of human cytokines. 
FACS analysis, cell sorting. Venus fluorochrome expression was readily detected in the 
reporter cell lines by FACS. Surface receptor expression was analyzed using the 
following antibodies purchased from eBioscience, BioLegend or BD Pharmingen: CD45-
AF700 (1:400), CD19-PE (1:200), Gr1-APC-Cy7 (1:400), CD11b-PerCP-Cy5.5 (1:500), 
Ter119-BV421 (1:400), cKit-APCeFluor780 (1:800) and FcεR1α -PE (1:200, clone MAR-
1) (for murine cells) and CD41-ef450 (1:50), FcεRIα-PE (1:50), cKit-PECy7 (1:50) (for
human cells). Dead cells were excluded with Hoechts33342 (Life Technologies). Cells
were sorted and analyzed on FACS Aria II SORP (BD Biosciences). Results analysis
was performed by FlowJo software (Tree star).
Cytospin, toluidine blue staining. 15,000 mast cells isolated after expansion in 
methylcellulose were re-suspended in 50 μl PBS and transferred into sample chamber 
containing a glass slide. Samples were centrifuged for 5 min at 200 rpm. Cells were fixed 
in methanol for 30 seconds and stained in Toluidine blue in 0.5N HCl for 1 h (mouse). 
Slides with human sample were stained with Rapid Romanowsky Stain Pack kit (TCS 
Biosciences) according to the manufacturer’s protocol. Slides were washed 2x in tap 
water and examined under Axioskop2 (Zeiss) microscope using 40x objective.  
Mast cell activation and ELISA. 1 x 106 mast cells after methylcellulose expansion were 
re-suspended in 1 ml of PBS and stimulated with 5 µg/ml of compound 48/80 (Sigma) for 
60 min at 37°C in the presence of 5% CO2. Cell suspension was centrifuged and 
supernatant was collected. Tryptase concentration in the medium was quantified using 
Mouse Mast Cell Tryptase (Rosenbaum et al.) ELISA Kit (Cusabio) according to 
manufacturer’s instructions. Tryptase standard curve was generated using a four 
parameter logistic (4-PL) curve-fit and tryptase concentrations in the sample medium 
were calculated accordingly. 
RNA extraction, cDNA synthesis, PCR and qRT-PCR. Murine and human cell total RNA 
was extracted using RNA mini or micro kit (Qiagen) according to manufacturer’s protocol. 
For murine samples, all RNA samples were standardized to 100 ng/ml, optimal RNA 
concentration needed for reverse transcription. Synthesis of cDNA was performed using 
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the Superscript VILO synthesis kit (Invitrogen) according to manufacturer’s protocol. 
Sample mixes were run at 25°C for 10 minutes, 42°C for 60 minutes (primer extension 
phase) and 85°C for 5 minutes (inactivation of reverse transcription phase) in a thermal 
cycler (MJ Research PTC 200 Thermo Cycler, BC-MJPC200). A cDNA standard curve 
for qPCR primer efficiency validation was made using a 10-fold serial dilutions of a RNA 
mix from pooled concentrated RNAs. Together with R2 value for the standard curve, 
efficiency (E, %) of all the primer sets was calculated by the formula E=(10(-1/slope)-1) x100 
10 and 2-fold dilutions. DDCt analysis was performed for primer sets with an efficiency 
range of 95-105% (all primers in this study). Taqman PCR technique was used for real 
time RNA quantification following manufacturer’s guidelines. Primer sets were 
specifically designed using “Universal ProbeLibrary Assay Design Center” 
(Supplementary Table 3).  Semi-quantitative RT-PCR was performed using BioMix Red 
(Bioline) according to manufacturer’s manual using the following primers (Supplementary 
Table 3). For human VENUS sorted samples total RNA was isolated and reverse 
transcribed using oligo-dT (Life Technologies) and SuperScript III (Life Technologies) 
according to manufacturer’s protocol. qRT-PCR was performed using Fast Sybr Green 
master mix (Life Technologies) according to manufacturer’s instructions. Primers are 
listed in Supplementary Table 3. 
Statistical Analysis. Statistical analysis was performed using an unpaired Student’s t 
test. Results were considered to be statistically significant at p value < 0.05 (*p<0.05, 
**p <0.01). Data are shown as a mean ± SEM. The number of biological replicates is 
indicated by the n value. Data analysis was done using GraphPad Prism (GraphPad 
Software). 
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Supplementary data 
Supplementary Figure 1. Generation of human GATA2Venus reporter pluripotent stem 
cells. (A) Schematic diagram of the 2A-H2B-Venus reporter and Rox site flanked puromycin 
selection cassette insertion into the 3’ untranslated region (UTR) of the human GATA2 locus. 
Primers used for detection of the WT and recombined alleles are indicated by colors (Black, WT; 
green, 5’-junction; red, 3’-junction). (B) PCR analysis of the genomic locus of GATA2 in untargeted 
(WT) and targeted ES (G2V-hESC) and iPSC clones (G2V-hiPSC). (C) Representative data of 
GATA2 gene expression in Venus+ (V+) and Venus- (V-) FACS sorted cells from day 6 
differentiated G2V-hESCs and G2V-iPSCs. Gene expression was normalized to HPRT1, set as 1 
in Venus- fraction, fold of expression in Venus+ was calculated accordingly.  
Supplementary Table 1. Mast cell generation and frequency in the G2V ESC 
multistep cultures 
exp d10 EMP  from 3x104 ESC 
d14 MC/MCP 
from 3x104 ESC 
d18-21 MC yield 
from 3x104 ESC 
1 11,504 14,923 1,242,200 
2 30,000 2,781 937,000 
3 7,541 2,623 3,834,375 
4 9,653 1,990 570,313 
5 20,087 6,421 1,156,250 
6 13,764 6,875 1,906,250 
mean 15,425 5,936 1,607,731 
±SEM 3,405 1,986 479,952 
Number of Venus+ erythroid-myeloid progenitors (EMP) at day 10 (d10), Venus+ mast cells/mast 
cell progenitors (MC/MPC) after OP9 co-culture at day 14, and total mast cell yield after 
methylcellulose expansion at day 18-21 from 3x104 input Gata2Venus mouse ES cells, n=6, 
mean±SEM. 
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Supplementary Table 2. Primer sequences 
Murine RT-PCR  forward 5’-3’ reverse 5’-3’ 
cKit	 CCATCCATCCATCCAGCACA	 CTGTTGCTGCACGTGTATGT	
FcεR1α	 ACCGTTCAAGACAGTGGAAA	 AGACGGGGCTCTCATAACTG	
mMCP-6	 TAATGACGAGCCTCTCCCAC	 CAGCCAGGTACCCTTCACTT	
mMCP-5	 TCATCTGCTGCTCCTTCTCC	 ATAGACCTTCCCGCACAGTG	
Gata2	 ATGGCAGCAGTCTCTTCCAT	 CACAGGCATTGCACAGGTAG	
MMCP-1	 CCACACTCCCGTCCTTACAT	 ACATCATGAGCTCCAAGGGT 
CPA-3	 ACACCAACAAACCATGCCTC	 TGGTGGTTAGGAGGCAGTTT	
b-actin CACCACACCTTCTTACAATGAG	 GTCTCAAACA TGATCTGGGTC	
Murine	qRT-PCR	
cKit	 GATCTGCTCTGCGTCCTGTT	 CTTGCAGATGGCTGAGACG	
FcεR1α	 CCATGGATCCTTTGACATCAG	 GATCACCTTGCGGACATTC 	
FcεR1g	 CTTACCCTACTCTACTGTCGACTCAA	 AGGCCCGTGTAGACAGCAT	
Gata2	 TGGCACCACAGTTGACACA	 TGGCACCACAGTTGACACA	
mMCP-5	 ATCTGCTGCTCCTTCTCCTG	 ACTCCGTGCCTCCAATGA	
mMCP-6	 TGCTGTGTGCTGGAAATACC	  CCCTTCACTTTGCAGACCA	
CPA-3	 GCTATTAATTCCTTATGGCTACACATT	 GTGGCAATCCTTGCAACTTT	
human	RT-PCR	
GATA2	 CAGCAAGGCTCGTTCCTGTT	 GGCTTGATGAGTGGTCGGT	
HPRT-1	 CCTGGCGTCGTGATTAGTGAT	 AGACGTTCAGTCCTGTCCATAA	
human	PCS	genotyping	
b-ACTIN AGCTGTCACATCCAGGGTCC-	 CCTCGGCCACATTGTGAACT	
5’-junction	 AGTGCTTCCAGTGTACCCCCA	 TGGTCGAGCTGGACGGCGA	
3’-junction	 GAAGGACCGCGCACCTGGT	 GATTCTGAGGTCTGGGCTCTGG	
GATA2	WT	 ACCTCCCGCCCTTCAGCC GAGGGGGTGCTGGGCCGAG 
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Key Points
• A new Gata2 reporter indicates
that all HSCs express Gata2
and corroborates findings
that Gata2 is not required for
generation of all HPCs.
• Isolatable non–Gata2-
expressing HPCs show
less potency and a distinct
genetic program, thus
having implications for
reprogramming strategies.
The Gata2 transcription factor is a pivotal regulator of hematopoietic cell development
and maintenance, highlighted by the fact that Gata2 haploinsufficiency has been
identified as the cause of some familial cases of acute myelogenous leukemia/
myelodysplastic syndrome and in MonoMac syndrome. Genetic deletion in mice has
shown that Gata2 is pivotal to the embryonic generation of hematopoietic stem cells
(HSCs) and hematopoietic progenitor cells (HPCs). It functions in the embryo during
endothelial cell to hematopoietic cell transition to affect hematopoietic cluster, HPC,
and HSC formation. Gata2 conditional deletion and overexpression studies show the
importance of Gata2 levels in hematopoiesis, during all developmental stages. Although
previous studies of cell populations phenotypically enriched in HPCs and HSCs show
expressionofGata2, therehasbeennodirectstudyofGata2expressingcellsduringnormal
hematopoiesis. In this study, we generate a Gata2Venus reporter mouse model with
unperturbed Gata2 expression to examine the hematopoietic function and transcriptome
of Gata2 expressing and nonexpressing cells. We show that all the HSCs are Gata2
expressing.However, notallHPCs in theaorta, vitellineandumbilical arteries,and fetal liver
require or express Gata2. These Gata2-independent HPCs exhibit a different functional output and genetic program, including Ras and
cyclic AMP response element-binding protein pathways and other Gata factors, compared with Gata2-dependent HPCs. Our results,
indicating that Gata2 is of major importance in programming toward HSC fate but not in all cells with HPC fate, have implications for
current reprogramming strategies. (Blood. 2016;127(11):1426-1437)
Introduction
Gata2 is one of the “heptad” transcription factors that acts on
regulatory regions of hematopoietic genes.1 It is upregulated in
vivo in Ly6aGFP1 cells undergoing endothelial-to-hematopoietic
cell transition (EHT), a process by which deﬁnitive hematopoietic
progenitors (HPCs) and hematopoietic stem cells (HSCs) are
generated in the embryo.2,3 As one of the major regulators of HPC
and HSC generation, germline deﬁciency of Gata2 results in
embryonic lethality between embryonic day (E)10 and E10.5 and
an anemic phenotype, with a decreased number of primitive and
deﬁnitive HPCs in the yolk sac (YS) and in Gata22/2 embryonic
stem (ES) cell hematopoietic differentiation cultures.4-6 Chimeric
embryo generation with Gata22/2 ES cells revealed defective
production of all hematopoietic lineages.5 The E10.5 lethality of
Gata22/2 embryos precludes the study of HSC generation in the
aorta-gonad-mesonephros (AGM) region, the ﬁrst site of de novo
HSC production. Gata21/2 embryos contain greatly reduced
number of HSCs in the AGM region.7,8 Gata2 haploinsufﬁciency
perturbs adult HSC homeostasis in mice9 and, in humans, leads
to MonoMac syndrome,10 which is associated with sporadic
myelodysplasia and myeloid leukemia. Also, rearrangement of the
remote Gata2 enhancer drives acute myeloid leukemogenesis by
activating Evi1 expression.11,12 Overexpression studies also reveal
that levels of Gata2 expression are important for its hematopoietic
function.13-15 In situ hybridization studies localize Gata2 expres-
sion to aortic endothelial cells, intra-aortic hematopoietic cluster
cells, placenta (PL), and fetal liver (FL) in the midgestation
mouse.16-18 Conditional knockout ofGata2 orGata2 regulatory
elements in vascular endothelial cells indicates that Gata2 is essential
for hematopoietic cluster formation and HSC generation.7,19,20 Gata2
plays a role in the emergence of cKit-expressing hematopoietic cells
from the endothelium.7 Later, as shown in VavCre conditional
knockout mice, Gata2 is essential for HSC maintenance,7 thus
demonstrating a role for Gata2 as previously recognized in bone
marrow LSK HSCs.21
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To date, the correlation between Gata2 and hematopoietic cell gen-
eration in the embryo has been made in the absence of prospective iso-
lation of viable Gata2-expressing cells.16 Although some hematopoietic
cells remain in the embryo in the absence of Gata2,5-8 the identity of
these cells is unknown. In this study, to further understand the require-
ment forGata2 in normal hematopoietic development,we create anduse
a mouse model in which a ﬂuorescent reporter for Gata2 (IRES-Venus
knock-in gene) does not affect the normal level or function ofGata2.We
demonstrate that all long-termrepopulatingHSCsanda largepercentage
ofHPCs in themidgestationmouse embryo areVenus1.We isolate and
characterize a Venus2 HPC population that corresponds to the HPCs
found in Gata2-null embryos. Gata2-independent hematopoietic pro-
genitors are functionally less complex and do not follow the same
genetic program as Gata2-dependent HPCs.
Materials and methods
Gata2Venus ES cells and mice
Generation of the Gata2-Venus mouse model is described in the supplemental
Methods, available on theBloodWeb site. In short, an IRES-Venus fragment and
a loxP-PGK-Puro-loxP fragment were inserted in the Gata2 39 untranslated
region (UTR). IB10 ES cells were transfected and puromycin selected, and 360
clones were polymerase chain reaction (PCR) screened for Gata2Venus (right
arm junction, 2292 bp). Correct integration was veriﬁed by Southern blot (left
arm) for 2 clones with normal karyotype. Founders were identiﬁed by
Venus PCR. First-generation G2V offspring were crossed with CAG-Cre
mice22 and backcrossed (.10 generations) with C57BL/6.
Mice and embryo production
Gata21/2 mice,5 Ly5.1 (6-8 weeks) and C57BL/6 mice were obtained/
maintained (Harlan or locally) and genotyped by PCR (supplemental Methods).
Dayof plugdiscovery is E0. Embryoswere stagedby somite pair (sp): E9.5516
to 28 sp, E105 28 to 40 sp, early E105 28 to 34 sp, E10.55 35 to 40 sp, and
E11 5 40 to 50 sp. All mouse experimentation was performed under the UK
Animals Scientiﬁc Procedures Act 1986 Project License 70/8076 andNLEthics
Committee approval and performed in compliance with Standards for Care and
Use of Laboratory Animals.
Immunostaining
Whole-mount conceptuseswere stained and imaged23; cryosections and cells for
ﬂow cytometry were stained8 using anti-CD34-biotin (1:50; BD), anti-Gata3
(1:10KT122, 111207H09;Absea), anti-Gata4 (1:50H-112, sc-9053; SantaCruz),
and anti-green ﬂuorescent protein antibodies. For ﬂow cytometry,8 cells were
stained with anti-CD31 (390; BD), anti-CD34 (RAM34; BD), anti-cKit (2B8;
BD), anti-CD41 (MWReg3; SantaCruz), anti-Sca1 (D7; Ebiosciences), and anti-
CD16/32 (2.4G2; BD) antibodies and Hoechst 33258 (BD) and analyzed
(FACSARIAIII; SORP).
Hematopoietic assays
Venus-sorted E9 to E11AGM, vitelline1umbilical arteries (VA1UA), PL, and
YS and E10 FL or Gata2-deﬁcient E9 to E10 AGM, VA1UA, and PL were
seeded in3.6mLmethylcellulose (1mLper dish;M3434;StemCell Tech) for 10
to12days.24Colonieswere counted, isolated, andwashed, andVenus expression
was examined (FACSARIAIII; Fortessa). SortedG2VE11AGM (Ly5.1/Ly5.2)
cells were transplanted24 into 9.5-Gy irradiated (C57BL/6X129) F1 recipients
(Ly5.2/Ly5.2) together with 23 105 spleen cells from the recipient strain.
Peripheral blood (PB) donor chimerism was determined by Venus PCR and/or
ﬂuorescence-activated cell sorter (FACS) at 4 months after transplantation and
scored positive if PB donor chimerism was.10%.
RNA analyses
Detailed RNA procedures are provided in supplemental Methods. The Gene
Expression Omnibus data accession number is GSE76254. Brieﬂy, RNA was
isolated fromE10.5AGMCD31 and cKit sorted cells with themirVanamiRNA
Kit (Ambion), and quality/quantity was assessed using the 2100 Bioanalyzer
(Agilent; RNA Nano/Pico chip). For RNA sequencing, samples were prepared
with theSMARTERprotocol and analyzed on an IlluminaHiSeq200 system.25-27
For quantitative reverse transcription-PCR (qRT-PCR), SuperScriptII/III
ReverseTranscriptase (LifeTechnologies) was used for ﬁrst-strand cDNA
synthesis. Primers are speciﬁed in supplemental Table 1.
Results
Generation and validation of a novel Gata2 reporter
mouse model
Previously, analysis of Gata2-expressing cells has been limited to
a reporter mouse model that results in Gata2 haploinsufﬁciency.16
Our approach allows for the expression of the reporter within the
Gata2 genomic locus without affecting the levels of Gata2 expres-
sion or protein function. This is particularly important because Gata2
haploinsufﬁciency greatly reduces the number of HS/PCs generated
during development.7,8,19,20,28 Brieﬂy, an internal ribosome entry
site sequence (IRES) followed by the Venus ﬂuorochrome gene was
recombined into the Gata2 39UTR (Figure 1A) in ES cells. The re-
sultingGata2Venus (G2V) mice bred normally and showed no overt
growth or hematopoietic defects.
To determine whether Venus reporter expression parallels that of
Gata2,G2Vbonemarrow(BM)cellswere sorted intoVenus-expressing
(Venus1) andnonexpressing (Venus2) fractions (Figure 1B). qRT-PCR
forGata2 andVenus transcripts (Gata2V/1BM) demonstrated that only
Venus1 cells express Venus and Gata2 mRNA (Figure 1C). Western
blot analysis revealed that equivalent amounts of Gata2 protein were
present in Gata21/1 and Gata2V/V adult BM cells (data not shown).
FACSanalysis showed thatGata2v/vBMLSKfrequency (388/105 cells)
are comparable to wild-type (WT) BM LSK frequency (378/105
cells). Importantly, the results of competitive limiting dilution trans-
plantation analyses of Gata2V/V and WT BM cells demonstrate that
HSCs are qualitatively and quantitatively normal in this mouse
model (Figure 1D). Thus, Venus expression correctly reports Gata2
expression without interfering with its normal expression levels or
function.
Gata2 is expressed in emerging aortic hematopoietic cluster
cells and other embryonic hematopoietic tissues
Venus expression was examined in midgestation G2V hematopoietic
tissues. Flow cytometry revealed that E9 to E11AGM,YS, PL, and FL
containedVenus1 cells (Figure 1E). At E9, 6.286 0.47%of viable YS
cells and 1.826 0.31% of AGM cells are Venus1. At E10.5 (when the
ﬁrstHSCs are generated), 3.2760.52%ofAGMcells areVenus1, and
this increases to 7.866 1.1% at E11. Table 1 shows the frequencies of
Gata2-expressing cells.29,30
Whole-mount images of E10 and E11 G2V embryos immuno-
stained with anti-CD31 antibody (marks all endothelial cells and
hematopoietic cluster cells) shows Venus1 cells along the aorta (DA).
Venus1 cells are also observed in cells of the neural tube (NT),
olfactory bulb (OB), and FL (Figure 2A-C). In the E10.5 AGM region
(4,6 diamidino-2-phenylindole [DAPI] andCD31 stained [blue and
red, respectively]), Venus expression is found in endothelial and
hematopoietic cluster cells mainly on the ventral side of the DA and in
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the urogenital (UG) region (Figure 2D-E). In the FL,Venus-expressing
cells are found in a punctate distribution pattern (Figure 2D,F). At E9,
Venus is expressed in some of the CD341 (red) endothelial cells of the
paired aorta (Figure 2G, arrowhead) and also in some of the endothelial
and hematopoietic cluster cells of theUA (Figure 2H).Venus continues
to be expressed at E11 in some aortic endothelial cells and emerging/
other hematopoietic cluster cells (Figure 2I, arrowhead). The E10.5YS
shows Venus expression in some of the CD311 (red) endothelial cells.
Overall, Venus expression is similar to what has been previously
documented for Gata2 in situ hybridization analysis.31,32 Thus, our
model allows for the prospective identiﬁcation, isolation, and character-
ization of Gata2-expressing cells during normal development.
All HSCs, but not all HPCs, express Gata2
To test for HSC activity, E11 AGM Venus1 and Venus2 cells
were transplanted into irradiated adult recipients. All long-term
repopulating HSCs were found in the Gata2Venus-expressing
fraction (Figure 3A). Nine of 19 recipients receiving Venus1 cells
were engrafted (15-71%), whereas none of the 14 Venus2 recipients
showed donor-derived hematopoietic cells. These HSCs were multi-
lineage repopulating (supplemental Figure 1) and self-renewing
(8 repopulated of 12 transplanted with 3 3 106 BM cells from
primary repopulated mice; n 5 4).
The relationship between Gata2 expression and HPC function
was also examined. E9 and E10 AGMVenus1 and Venus2 cells were
Figure 1. Gata2 Venus reporter construction and validation. (A) Schematic diagram of the IRES Venus reporter selection cassette insertion in the 39UTR of the mouse Gata2
locus and Cre-mediated removal of lox PGK-Puro lox. Primers used for detection of the targeted and recombined alleles are indicated flanking the loxP sites (yellow). (B)
Representative flow cytometric analysis and sorting plot of Venus-expressing cells in the BM of adultGata2 Venus (G2V) mice. Gated regions show percentage positive and negative
viable cells. (C) Relative levels of Gata2 and Venus mRNA in sorted Venus1 and Venus2 Gata2V/1 BM cells as determined by qRT-PCR. Gata2 transcripts in Venus1 cells 5
0.11337 6 0.00681 and Venus2 cells 5 0.00012 6 0.00003 (P 5 .000076). Venus transcripts in Venus1 cells 5 0.06722 6 0.00799 and Venus2 cells 5 0.00036 6 0.00010
(P5 .00112). Mean6 standard error of the mean (SEM), n5 3. (D) Competitive limiting dilution transplantation strategy used to test the quantity and robustness ofGata2V/V BM
HSCs compared with wild type. Percentage of donor cell chimerism in adult irradiated recipients cotransplanted with the same number of wild-type (WT) Ly5.1/5.2 and Gata2
Venus (G2V/V) Ly5.2 BM cells. Varying numbers (13 105, 33 105, 33 106) of BM cells of each genotype were injected, and peripheral blood of recipients was analyzed for donor
cell engraftment by FACS at 1 and 4 months after transplantation. n5 2 (5 mice per group). (E) Representative FACS plots demonstrating frequency of Venus expressing cells in
E11 AGM, YS, PL, and FL. Gates indicate Venus2 and Venus1 cell fractions. Percentages represent the frequency of Venus1 cells within the viable cell fraction (Table 1).
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plated in the colony forming unit–culture (CFU-C) assay. High enrich-
mentofHPCswas found in theVenus1 fractions (Table2).Surprisingly,
HPCs were found also in the Venus- fraction, although there were very
few. At E9, the Venus1 and Venus2 fractions, respectively, yielded
8.0 6 2.1 and 0.4 6 0.4 CFU-C per AGM. CFU-C numbers increased
in theVenus1 cell fraction at E10 (69.067.1) and theVenus2 fraction
increased to 8.06 2.3 CFU per AGM. However, bi- and multipotent
progenitors were found only in the Venus1 fraction (Figure 3B).
HPCactivitywasalsoexamined in theVenus1andVenus2fractionsof
other hematopoietic tissues (Table 2). E9 and E10 VA1UA (Figure 3C),
YS (Figure 3D), and PL (Figure 3E), and E10 FL (Figure 3F) contained
progenitors in both fractions. Most HPCs were Venus1. The greatest
number of CFU-C arising from Venus2 cells was found in the E9 YS
(270.06 69.8 CFU-C/YS). These data indicate that some HPCs are not
expressing Gata2. BFU-E, CFU-G, and CFU-M were the predominant
colony types in both fractions, and in contrast to the Venus1 fractions, the
Venus2 fractions of VA1UA, YS, FL, and PL yielded few or no CFU-
GEMM. Thus, all AGM HSCs express Gata2, Gata2 expression is
associated with immature HPCs, but not all HPCs are Gata2 expressing.
Some HPCs and vascular cluster cells are formed in the
absence of Gata2
Because the Venus2 fractions of midgestation G2V hematopoietic
tissues contain CFU-C, we tested whether such hematopoietic
progenitors are present in Gata2-deleted embryos. CFU-Cs were
detected in the Gata22/2 E9 AGM, E10 AGM (Figure 4A), and E10
VA1UA (Figure 4B), although signiﬁcantly fewer compared with
WT (Table 3). Gata21/2 tissues also contained fewer CFU-Cs com-
pared with WT. The E9 Gata22/2 YS contained the most CFU-C
(64.4 6 12.2; Figure 4C). In VEC-Cre:Gataf/f embryos, E10 PL
showed signiﬁcantly decreased CFU-C numbers (Figure 4D), as did
E10 AGM and YS7 compared with WT. The CFU-C remaining in
Gata22/2 embryos are predominantly CFU-G and CFU-M. Very
fewGata22/2CFU-GM and no CFU-GEMMwere observed. These
data support and validate our ﬁndings in G2V embryos that not all
HPCs are Gata2-expressing, Gata2-independent progenitors exist in
each of the early hematopoietic tissues, and theGata2-expressing cell
fraction is more enriched in multipotent progenitors.
Because hematopoietic clusters appear in the VA and UA prior to
appearance in the aorta, and are larger than in the AGM,33 we further
examined these vessels. Whole-mount microscopic analysis demon-
strates that clusters form in the absence of Gata2. The number and size
of cKit1 hematopoietic clusters in early E10 Gata21/2 and Gata22/2
VA1UA are decreased compared with WT (Figure 4E). The number
of cKit1 cells decreases 20-fold in the E10 Gata22/2 VA1UA
(Figure 4F) in correspondence to the decrease in VA1UA CFU-C
(Figure 4B), suggesting that these emerging cKit1 hematopoietic
cluster cells are part of the cohort of Gata2-independent HPCs.
Alternative genetic program is expressed in Venus2
hematopoietic cells
The molecular basis for the functional differences observed in Gata2-
dependent and -independentHPCswas examined byRNAsequencing.
As most CD311Venus2 HPCs showed cKit intermediate expres-
sion, we compared this population to CD311Venus1cKitint HPCs
(Figure 5A). Gene set enrichment analysis on genes sorted by log
ratio of Venus1 vs Venus2 FPKMs revealed that genes in the Ras
signaling pathwaywere signiﬁcantly enriched in theVenus1 compared
with the Venus2 fraction (Figure 5B). Genes upregulated by Ras were
enriched in theVenus1 fraction, and highlyupregulated genes included
Kras, Grb2 (Ras adaptor), and Sos1 and Sos2 (RasGEF activators)
(Figure 5C).Genes downregulated byRaswere enriched in theVenus2
fraction. RasGAP gene (renders Ras inactive) Rasa2 was highly
upregulated in theVenus2 fraction, whereasRasa1 andRasa3were
highly upregulated in the Venus1 fraction. Rasa4 and NF1 were ex-
pressed to similar levels. Also, Venus1 HPCs showed increased levels
ofCREB andCBP expression comparedwithVenus2HPCs and express
protein kinase A catalytic subunit genes, suggesting that Venus1
HPCs have the potential to activate CREB target genes. Gata2 has
CREB response element consensus sites (23 kb, 2300 bp upstream
transcription start site), suggesting that it is a downstream target.34,35
As Gata2 is a Notch target,18 a two- to fourfold higher expression
of Notch1 and Notch4 was found in the Venus1 fraction (Figure 5D).
Moreover, Snw1 andMaml1 (transcriptional coactivators in the Notch
pathway that interact with Notch) were upregulated (2- and 30-fold,
respectively) in Gata2-expressing HPCs.
Because Venus2HPCs are mainly restricted in their differentiation
potential to the macrophage and granulocytic lineages, we evaluated
their similarity to YS-derived erythromyeloid progenitors (EMPs) that
give rise to tissue-resident macrophages. Flow cytometric analysis for
EMPmarkers36 showed that 3.89%ofE10YSand0.72%ofE10AGM
cells were EMPs (Sca12cKit1CD411CD16/321). The majority of
EMPswereVenus2 (74% inYS, 85% inAGM;Figure 5F).AtE11, the
frequency of EMPs in the E11 YS and AGM decreased to 2.11% and
0.11%, respectively (Figure 5F), with 60% of YS and 77% of AGM
EMPs now being Venus1. Published transcriptome data on mouse YS
EMPs show the low expression of several chemokine receptors/ligands
(Cx3cr1, Cx3cl1, Ccl2, Ccr1, Ccl9, and Ccr7).37 The expression of
these genes was low or absent in Venus2 AGM cells compared with
Venus1 cells (Figure 5F).Also,Cxcr4 (highly expressed in EMPs)was
highly expressed in Venus2 AGM cells compared with Venus1 cells.
These results suggest that the Venus2 population shares similarities to
EMPs at the transcription level.
Analysis of FPKMs for heptad transcription factors previously
described as expressed inAGMHSCs andHPCs1-3 showed expression
in both theVenus1andVenus2AGMfractions (data not shown).Also,
other Gata factors were expressed in both fractions. In the mouse,
Gata1, 2, and 3 are hematopoietic transcription factors, whereas
theGata4, 5, and 6 factors are not directly related to hematopoiesis.
Table 1. Frequency of Venus1 cells in embryonic tissues of G2V
embryos
Tissue Stage
Number of experiments,
embryos analyzed % Venus1 cells/tissue
AGM E9, 16-25 sp n 5 4, 22 1.82 6 0.31
E10, 28-36 sp n 5 4, 29 3.27 6 0.52
E11, 43-49 sp n 5 4, 25 7.86 6 1.1
FL E9 nd nd
E10, 28-36 sp n 5 4, 10 13.89 6 0.7
E11, 43-49 sp n 5 4, 19 19.27 6 2.14
YS E9, 16-25 sp n 5 5, 8 6.28 6 0.47
E10, 28-36 sp n 5 6, 9 6.17 6 0.86
E11, 42-46 sp n 5 1, 3 5.25 6 0.59
PL E9, 17-23 sp n 5 3, 4 10.91 6 0.49
E10, 28-35 sp n 5 3, 6 10.8 6 1.92
E11, 42-46 sp n 5 1, 3 10.01 6 4.64
The frequency of Venus1 cells within the viable cell fraction of embryonic tissues
per embryo is presented. FACS analysis of single cell suspensions of dissected
embryonic tissues was performed to define the percentage of cells expressing Venus.
AGM contains part of the vitelline and umbilical arteries. Our data for the total number
of cells in each tissue (data not shown) correlated with published data for YS and
E9.5 AGM29 and for FL.30 The data represent mean 6 SEM of 3 to 6 independent
experiments, with the exception of E11 YS and PL data (data represent the mean 6
standard deviation of 1 experiment. E, embryonic day; n, number of independent
experiments, number of individual embryos analyzed; nd, not done; sp, somite pairs.
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qRT-PCR performed on E10.5 AGM CD311cKit1 cells (Figure 6A)
conﬁrmedGata3 expressionbyboth theVenus1andVenus2 fractions,
and Gata4 was signiﬁcantly higher in the Venus2 fraction. Gata1, 5,
and6 transcriptswere low/not detected. ImmunostainingofE10.5AGM
(WT) showed Gata3-expressing cells in the mesenchyme underlying
the ventral aspect of the aorta, aortic endothelial cells, and some cells
emerging from the aortic wall (Figure 6B) in agreement with Fitch.38
G2VE10.5AGMconﬁrmed that some aortic endothelial cells coexpress
Gata3 andGata2 (Figure 6C). Gata4 expressionwas also found in aortic
endothelial (CD341) cells, but it did not overlap with Gata2 expression
(Figure 6D). Together, these results suggest that Gata3 and/or Gata4
may provide some function in Gata2-independent hematopoietic cells.
Discussion
In this study, we prospectively enriched and characterized Gata2-
dependent and -independent HPC subsets from our novelGata2Venus
reporter mouse. Molecular analyses, together with the fact that some
Figure 2. Localization of Gata2Venus-expressing cells in embryonic hematopoietic sites. Confocal images of a whole mount immunostained E10.5 Gata2Venus
embryo showing (A) Venus (green), (B) CD31 (magenta), and (C) merged expression. Venus-expressing cells are detected in the AGM along the wall of the dorsal aorta
(dotted lines), the FL, NT, and OB. (D) Confocal image of a transverse section through the E10.5 AGM. DAPI staining (blue), CD31 (red), and Venus fluorescence (green)
revealed Gata2-expressing aortic endothelial and hematopoietic cluster cells and UG and FL cells. Enlarged images of D showing Gata2-expressing cells in (E) AGM (DA,
dorsal aorta; UG, urogenital ridges; arrowheads indicate hematopoietic cluster) and (F) FL. Venus (green) and CD34 (red) fluorescence showing endothelial and
hematopoietic cluster cells in (G) E9 paired aorta, (H) umbilical artery (UA) at E9, and (I) E11 aorta. Arrowheads indicate hematopoietic cluster. (J-M) Images of E10.5 YS
section showing DAPI merged, Venus, CD31, and merged fluorescence. Arrow denotes an endothelial cell expressing Venus and CD31.
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vascular hematopoietic cluster cells and HPCs persist in the absence
of Gata2 expression, suggest that an alternative genetic program exists
for the production of HPCs. The transcriptome differences observed
betweenVenus1andVenus2HPCsmayoffer possibilities for pathway
modiﬁcations to achieve the programming complexities necessary for
the generation/function of normal deﬁnitiveHPCs and provide insights
into the factors involved in myeloid leukemogenesis.
Gata2 expression in the developing hematopoietic system
We showed the temporal and quantitatively coordinate transcription
of Venus and Gata2 in our G2V mouse model. The strategy used39
eliminates expression level and protein alterations that affect HP/SC
development. InG2V embryos, we showed that the cells with the most
robust and complex hematopoietic potential (all HSCs andmost HPCs)
are Gata2 expressing. Imaging and FACS analyses of G2V embryos
conﬁrm that Gata2 is expressed in all hematopoietic sites during
midgestation and that the numbers of Gata2-expressing cells reﬂect the
developmental and temporal hematopoietic changes occurring in each
site. At E9, Gata2-expressing cells are found predominantly in the YS,
which at this time produces the highest numbers of the hematopoietic
progenitors (EMP) in the conceptus. Slightly later as hematopoiesis
begins in the AGMand FL, the numbers of Gata2-expressing cells also
increase.Thehighest numbersofCD311cKit1cluster cells are found in
the aorta,VA, andUAatE10.5, as quantitated bywhole-mount embryo
imaging.33Most, but not all, hematopoietic cluster cells express Gata2,
and Gata2 expression may be downregulated as HPCs differentiate.
However, we found some hematopoietic cluster cells and HPCs in
the E10 Gata22/2 vasculature, conﬁrming the existence of Gata2-
independent HPCs.5
Importantly, Gata2 is expressed in the endothelial cells of the DA.
Already at E8.5, endothelial cells lining the paired dorsal aortae express
Gata2, and it continues to be expressed in the E10.5 aorta when HSCs
are generated, thus highlighting an involvement of Gata2 in the
hemogenic program of endothelial cells. Data in VE-cadherin
conditionalGata2-deﬁcient mice and other models7,19,28,40 strongly
support the notion that Gata2 is required in hemogenic endothelium
Figure 3. Quantitation of functional HSCs and HPCs
in G2V embryonic hematopoietic tissues. HSCs in
sorted Venus1 and Venus2 cell fractions of E11 AGM
were analyzed by transplantation into irradiated adult
recipients. (A) Percentage donor cell chimerism was
determined by Venus PCR of peripheral blood DNA at
4 months after transplantation. Each dot represents
1 recipient receiving 1.7 to 6.5 embryo equivalent (ee)
of AGM cells. n 5 7. **P 5 .0089. (B-F) Hematopoietic
progenitor number per tissue in sorted Venus1 and
Venus2 cell fractions of (B) E9 and E10 AGM, (C) E9
and E10 VA1UA, (D) E9 and E10 YS, (E) E9 and E10
PL, and (F) E10 FL. CFU-C per 1 ee of tissue is shown.
Colony types designated by colored bars are CFU-
granulocyte, erythroid, monocyte, megakaryocyte (GEMM);
CFU-granulocyte, macrophage (GM); CFU-macrophage
(M); CFU-granulocyte (G), and burst forming unit-erythroid
(BFU-E). SEM of total CFU-C is shown; 2 ee of somite
pair–matched tissues were pooled for sorting and yielded
1 ee for colony analysis.
Table 2. CFU-C number in Venus1 and Venus2 cell fractions of G2V embryonic tissues
Tissue Stage Number of experiments, embryos analyzed
CFU-C/tissue/sorted cell fraction
Venus2 Venus1
AGM E9, 20-23sp n 5 2, 5 0.4 6 0.4 8.0 6 2.1
E10, 32-35sp n 5 2, 6 8.0 6 2.3 69.0 6 7.1
VA1UA E9, 20-23sp n 5 2, 5 0.8 6 0.5 2.4 6 1.0
E10, 32-35sp n 5 2, 6 7.0 6 1.5 197.7 6 36.9
YS E9, 20-23sp n 5 2, 5 270.0 6 69.8 1020 6 137.3
E10, 32-35sp n 5 2, 5 130.0 6 25.5 1252.0 6 156.0
PL E9, 20-23sp n 5 2, 5 4.0 6 1.3 22.0 6 2.5
E10, 32-35sp n 5 2, 6 14.5 6 5.3 251.7 6 32.4
FL E10, 32-35sp n 5 2, 6 20.5 6 7.6 248.7 6 75.2
Number of total CFU-C (mean 6 SEM) per tissue per G2V embryo for the sorted Venus2 and Venus1 cell fractions at E9 and E10.
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for the emergence of HSCs, as does the morpholino knockdown of
Gata2b in zebraﬁsh.41
Gata2 and the relationship with hematopoietic function
Prospective isolation and in vivo transplantation showed that all HSCs
areGata2 expressing. In contrast, someHPCs are present in theVenus2
cell fractions of G2V hematopoietic tissues and Gata22/2 hematopoi-
etic tissues. In both cases, theHPCs are restricted in their differentiation
potential to predominantly the macrophage and granulocytic lineages.
Currently, the EMP population is of high interest as a novel
hematopoietic cell subset providing tissue resident macrophages.37,42-44
Our FACS data revealed that EMPs are mainly in the Venus2 cell
population of E10YS andAGMand increased in the Venus1 population
at E11. Chemokine receptor/ligand gene sets obtained from a study
on EMP/microglia transcriptome comparisons allowed us to ﬁnd
similarities in chemokine receptor/ligand expression between EMPs
and the Venus2 HPC fraction.
Despite prevalence of EMPs in the Venus2 cell population in E10
YS and AGM, deﬁnitive progenitors are largely Venus1. The co-
existence of these HPC subsets highlights the fact that there is more
diversity in the types of progenitors generated in the embryo than was
Figure 4. CFU-C numbers and vascular hematopoietic clusters in Gata22/2 embryos. CFU-C numbers per ee found in (A) E9 and E10 AGM, (B) E9 and E10 VA1UA,
(C) E9 and E10 YS, and (D) E10 placenta. *P , .05; **P , .01. (E) Quantitation of cKit1 hematopoietic cluster cells in VA1UA of E10 Gata21/1, Gata21/2, and Gata22/2
embryos. (F) Representative whole mount images of hematopoietic cluster cells in the VA of E10 Gata21/1 (30 sp), Gata21/2 (31 sp), and Gata22/2 (30 sp) embryos stained
for cKit expression.
Table 3. CFU-C number per E9-E10 Gata2-deleted hematopoietic tissues
Tissue Stage
Genotype
WT Gata21/2 Gata22/2
AGM E9, 20-23sp 8.5 6 2.3 n 5 1, 4 2.25 6 0.9* n 5 1, 4 3.0 6 1.0 n 5 1, 2
E10, 28-34sp 62.4 6 20.8 n 5 3, 7 24.0 6 7.4* n 5 3, 13 16.7 6 6.8* n 5 3, 9
VA1UA E9, 20-23sp 7.0 6 0.6 n 5 1, 4 2.25 6 0.6* n 5 1, 4 5.0 6 2.0 n 5 1, 2
E10, 28-34sp 241.1 6 67.8 n 5 3, 7 78.7 6 12.3** n 5 3, 13 12.0 6 2.5** n 5 3, 9
YS E9, 20-23sp 772.5 6 85.3 n 5 1, 4 500.0 6 71.5* n 5 1, 4 64.4 6 12.2** n 5 1, 2
E10, 28-34sp 918.6 6 147.9 n 5 3, 7 584.6 6 89.0** n 5 3, 9 25.7 6 8.0** n 5 2, 3
Gata2f/1 or Gata2f/f VEC-Cre:Gata2f/1 VEC-Cre:Gata22/2
FL E10, 30-34sp 115.8 6 35.0 n 5 2, 5 83.0 6 20.8 n 5 2, 6 22.2 6 6.7* n 5 2, 6
PL E10, 30-34sp 406.0 6 134.0 n 5 2, 5 81.0 6 25.0* n 5 2, 6 12.0 6 4.0* n 5 2, 6
Number of total CFU-C (mean 6 SEM) per tissue shown for WT, Gata2 germline, and conditional knockout embryos at E9 and E10.
*P , .05.
**P , .01.
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Figure 5. Differential expression of signaling pathway modulators in Gata2-dependent and -independent HPCs. (A) Flow cytometric sorting gates for isolation of E10.5
AGM G2V CD311cKitintVenus2 (gray) and CD311cKitintVenus2 (green) HPCs used for RNA sequence analysis. Gene Expression Omnibus data accession number is
GSE76254. (B) Gene enrichment analysis for Ras signaling pathway genes. Bar graphs of fragments per kilobase million (FPKM) values obtained from RNA sequence
analysis of CD311cKitintVenus2 (gray bar) and CD311cKitintVenus1 (green bar) AGM cells for (C) Ras pathway and cyclic AMP response element-binding protein (CREB)
and CREB-binding protein (CBP) transcription factor genes and (D) Notch pathway genes. (E) Bar graphs of FPKM values obtained from RNA sequence analysis for a
selection of chemokine receptor/ligand genes (see Kierdorf et al37; these genes were down-/upregulated in YS EMPs compared with adult microglia [AM]). (F) Representative
FACS plots demonstrating frequency of EMPs in the Venus1 fraction, as defined as Sca12cKit1CD411CD16/321, in YS and AGM of E10 (left) and E11 (right) G2V embryos.
Numbers indicate the percentages of gated cells within the parental cell population.
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previously appreciated. In support of this are recent data from ES
cell hematopoietic differentiation cultures suggesting that there are
2 different hemogenic endothelial cell subsets45 and the fact that, in
vivo, the AGM, VA/UA, YS, PL, and head are all hemogenic
tissues.36,46-49
The highest number of Venus2HPCswas found in E9 and E10YS
(270.06 69.8 and 130.06 25.5 CFU-C, respectively) compared with
other tissues (PL, AGM, VA1UA). It is clear that Gata2 has an
important role in EHT in the hemogenic endothelial cell compartment
before or during the generation/emergence of hematopoietic cells, as
evidencedby thedecrease (but not absence) in thehematopoietic cluster
cells in Gata22/2 aorta, VA, and UA. However, it is as yet unclear at
what frequency EHT occurs in the YS, thus raising the possibility that
Gata2-independentHPCs arisedifferently thanGata2-dependentHPCs
(perhaps directly from hemangioblasts50).
We found differences in the number of CFUs from E9 YS Venus-
cells (270.0669) andGata22/2 cells (64.4612.2; Figures 3Dand4C;
Tables 2 and 3). The fourfold lower CFU number is likely related to
observations (ours and others) that colonies from Gata22/2 embryos,
YS explants, and ES cell differentiationswere smaller/less proliferative
than WT colonies, due to the complete absence of Gata2.6,7 Venus2
cells are not defective for Gata2, and the resulting colonies are normal
in size.Whereas at the timeof sorting they did not expressGata2,Gata2
expression could initiate after seeding Venus2 HPCs in methylcellu-
lose, and cells thus undergo normal proliferation/differentiation. To
test whether Venus2HPCs can convert to Venus1 cells, we analyzed
Venus expression in colonies derived from sorted YS fractions after
10 days of differentiation (Figure 7). Venus expression was found in
colonies derived from both fractions, indicating that a portion of
Venus2cells start to expressGata2 during formationof a hematopoietic
colony. Interestingly, colonies derived from Venus1 cells showed a
Gr11 and Mac11 phenotype, whereas Venus2-derived colony cells
were only Mac11. This demonstrates that Gata2 is not necessary for a
subset of HPCs and that Gata2 promotes more complex hematopoietic
function in other progenitor subsets.
Gata3/Gata4 redundancy in Gata2-independent progenitors
The expression of Gata3 and Gata4 in Venus2AGMHPCs and aortic
endothelial cells is intriguing andhighlights the potential redundancyof
Gata transcription factors in hematopoietic cell generation. Gata2 and
Gata3 can partially rescue the erythroid phenotype in Gata1-deﬁcient
mice,51,52 and although recently it was suggested that Gata3 is
redundant in HSCs,53 others clearly show that it regulates HSC cell
cycle entry54 and self-renewal.55 The fact that Gata3 and Gata4 are
expressed in Gata2-nonexpressing enriched HPCs suggests that they
may function in this early progenitor subset. Gata3-deﬁcient embryos
show decreased numbers of FL HP/SCs.56 Gata3 affects HSC de-
velopment non-cell autonomously by activating the expression of Th
(tyrosine hydroxylase) and hence, catecholamine production in the
ventro-lateral cells of the sympathetic nervous system underlying the
embryonic aorta.38 HSC production was rescuedwhen catecholamines
were administered to the pregnant dams. These investigators also found
that some aortic endothelial cells express aGata3LacZ reporter, leaving
open the possibility of a direct and overlapping role for Gata3 in some
HPCs.
Much less is known concerning Gata4 in hematopoietic develop-
ment. In zebraﬁsh, there is a close relationship between anterior
hemangioblasts and cardiac precursors.57 Together withGata5 and
Gata6, Gata4 speciﬁes these 2 anterior mesoderm derivatives. Inmice,
Gata4 is a key component of the cardiac developmental program, with
close associations between cardiac, vascular, and hematopoietic
lineages.58-60 Moreover, a subset of mouse endocardial and YS
endothelial cells express cardiacmarkers, possess hemogenic potential,
and give rise to transient deﬁnitive erythroid/myeloid progenitors.61
Our results suggest the Gata4 aortic endothelial cells and Venus2
Figure 6. Gata family gene expression in AGM
Gata2-dependent and -independent HPCs. (A) qRT-
PCR for expression of Gata1, 2, 3, 4, 5, and 6 tran-
scription factors (normalization with Gapdh) in E11
AGM CD311cKit1Venus1 and CD311cKit1Venus2 cells.
n 5 3. SEM shown with *P 5 .05 and ***P 5 .001. (B)
Transverse section of WT E10.5 AGM immunostained
for CD34 (magenta) and Gata3 (green) showing expres-
sion of Gata3 in the aortic endothelial cells and some
emerging hematopoietic cells and ventral mesenchymal
cells directly under the aorta. (C) Transverse section of
G2V E10.5 AGM immunostained for CD34 (magenta),
Gata2 (green), and Gata3 (red) showing some over-
lapping expression of Gata2 and Gata3 in aortic endo-
thelial cells (arrowheads). (D) Transverse consecutive
sections of E11 G2V AGM immunostained for CD34
(magenta) and Venus (green) in the top panels and for
CD34 (magenta) and Gata4 (red) in the bottom panels.
Gata4 expression is observed in some ventral aortic
endothelial cells and emerging hematopoietic cells
(arrow).
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Gata4-expressing HPCsmay be derivatives of mesodermal cells with a
genetic program that retains cardiac-vascular-hematopoietic potential
and can produce HPCs. Further examination of double reporter and
deﬁcient mice should reveal the overlapping and/or redundant roles
of these Gata factors.
Gata2 as a pivotal regulator of complex hematopoietic function
RNA sequence comparisons of the functionally distinct Venus1 and
Venus2 HPC subsets revealed a strong upregulation of Kras and Ras
pathwaygenes inVenus1HPCs.This pathway is particularly important
in cell differentiation, acting as amolecular switch to relay extracellular
growth signals.62 Krasmutations confer a competitive-repopulating
advantage to BM HSCs in transplantations and initiate leukemia in
mice.63 In humans, Kras mutations (together with other cooperating
gene mutations) are prevalent in patients with various forms of
myelomonocytic and myeloid leukemia.64 Interactions between on-
cogenic Ras and Gata2 have been proposed.65 The normal function
of Kras has not yet been explored fully. However, conditional de-
letion of Kras by Vav-Cre or Mx1-Cre does not affect HSCs or the
adult hematopoietic system.66However, chimericmice, produced by
Kras2/2 ES cell blastocyst injection, show no contribution ofKras2/2
cells to the hematopoietic system, suggesting that Kras may be
important during the embryonic development of the hematopoietic
system but not after its generation.
The low expression of Notch1, Notch4, and coactivators in the
Venus2 comparedwith the Venus1HPC fraction supports the fact that
early hematopoietic cells are generated independent of this signaling
pathway or implies that these are differentiated cells that have turned
off Notch signaling.67,68 Others have shown that Notch1 deletion
impairs the development of HSCs and angiogenesis,69 but not YS
primitive or deﬁnitive hematopoiesis. Moreover, Gata2 expression
in the aortic endothelium is lost when Jagged1 (ligand) is deleted.70
Our data demonstrate a direct relationship for Notch and Gata2
expression, strongly supporting a pivotal role for this pathway in
the generation of functionally complex hematopoietic cells. In the
absence of Notch signaling, less complex HPCs emerge in the AGM
or are immigrants from the YS.18,69,70 In addition, our observed
upregulated expression of some CREB genes in Venus1 HPCs
supports the involvement of these regulators in deﬁnitive hematopoi-
etic cell generation.71 Our Gata2Venus model, in combination with
recently reportedGata2distal enhancer-Evi1mousemodel, will allow
for a direct examination of the cells relevant to leukemogenesis.12
In conclusion, we enriched, localized, and characterized Gata2-
dependent and -independent subsets of hematopoietic progenitors
in Gata2Venus embryos. The combination of this reporter with
other reporter and knockout models will lead to a better understand-
ing of the role of Gata2 (and other factors) in the development and
function of multipotential HP/SCs in health, leukemogenesis, and
reprogramming.
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CHAPTER 6 
Discussion 
Discussion 
The adult hematopoietic system is established in a stepwise manner as a progressive 
generation of hematopoietic cells with increasing complexity, ultimately culminating in the 
generation of long-lived self-renewing HSCs. HSCs are on top of the hematopoietic 
hierarchy giving rise to all terminally differentiated blood cell lineages. They are capable 
of repopulating the adult organism providing life-long blood supply, thus HSC 
transplantation is a pivotal treatment strategy for curing blood disorders. As there are 
limited resources of patient compatible HSCs for transplantations, generating blood from 
other sources, such as by iPSC/ESC differentiation, has been a long term goal in blood 
research.  
Kinetic analysis has suggested that blood cells are generated from iPSC/ESC in a 
sequential order with growing complexity (Keller et al., 1993; Wiles and Keller, 1991) 
implying that with the progression of the culture, HSCs could be ultimately generated and 
isolated with the use of right markers. Although several markers, and marker combination 
has been used to characterise and isolate cells from different stages of this process, 
these approaches have not resulted in the establishment of a robust method to generate 
HSCs. This is largely due to the lack of relevant markers to enrich for cells with HSC 
identity and a defined molecular program.  
Transcriptional control is the most important regulator affecting cell fate during EHT and 
the development of HSC/HPC (reviwed in Kaimakis et al., 2013). Although the precise 
spatial and temporal onset of the HSC identity is as yet debatable, it is certain that it is 
controlled by a set of transcription factors that work in a combinatorial manner to activate 
the transcription of downstream target genes relevant to hematopiesis (Wilson et al., 
2010). In concert, these factors drive the determination of hematopoietic 
(progenitor/stem) cell fate by regulating their temporal expression pattern and the 
expression levels of their target genes. 
Gata2 has proven to be one of the key players in this set of factors, as the deletion of 
Gata2 causes severe hematopoietic defects and is lethal at the time of the first HSC 
emergence (Tsai et al., 1994). Gata2+/- embryos generate profoundly fewer HPCs and 
HSCs, and the HSCs are qualitatively challenged. However, the definitive erythroid cell 
compartment is unchanged (Rodrigues et al., 2005). On the other hand, differentiation of 
ESCs over-expressing Gata2 show that lymphoid cell potential is severely affected when 
there is more Gata2 (Nandakumar et al., 2015). Together, these data suggest that the 
levels of Gata2 are involved in the fate determination of HPCs/HSCs, as well as of several 
mature blood lineages. This evidence also implies that levels of Gata2 may play a role in 
the stepwise progression of ESC hematopoietic differentiation, and may potentially 
discriminate different (progenitor) blood cells with growing complexity that emerge in ESC 
differentiation cultures. However, as Gata2 is a transcription factor, previously it was not 
possible to isolate live Gata2 expressing cells for functional assays to characterise their 
potential in ESC cultures. Although a Gata2-GFP knockout/knockin reporter was 
generated, these results only indicated hematopoietic cells produced in a state of Gata2 
haploinsufficiency (Minegishi et al., 2003), and thus, did not reflect the physiological 
function of Gata2. 
We have generated a Gata2Venus reporter ESC line that facilitates the isolation and 
characterization of live cells expressing endogenous levels of Gata2 that emerge 
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throughout the ESC differentiation, and used these ESCs to establish a reporter mouse 
to understand the role of Gata2 in the embryonic development of HPCs/HPCs in vivo. 
This thesis research has shown the following: 
The Gata2Venus reporter discriminates stages of hematopoietic potential 
emergence that are analogous to in vivo waves of hematopoietic generation, and 
it marks all functional HPCs in ESC differentiation cultures and HSCs in the mouse 
embryo 
In the mouse embryo, the first hematopoietic cells arise from the YS blood islands 
harbouring bipotential Flk1 expressing hemangioblastic cells. They give rise to 
endothelial and primitive hematopoietic cells. Gata2 expression in the YS is detected as 
early as E7, and is involved in erythroid cell generation (Silver and Palis, 1997). Our 
Gata2Venus ESC differentiation data show that Gata2 is co-expressed with Flk1, and 
that this cell population has endothelial as well as primitive erythroid potential giving rise 
to the first hematopoietic cells in ESC cultures at day 4 of differentiation (Chapter 2). 
Thus, Gata2 function in the early stage of the Gata2Venus ESC differentiation is similar 
to that at the onset of hematopoietic cell generation in vivo. 
With the progression of the ESC differentiation culture, an increase in the phenotypic 
EMP (CD16/32+cKit+) population was observed at day 10 of differentiation within the 
Venus+ population. This may reflect another wave of hematopoietic cell generation (but 
of a more complex potential) marked by Venus expression in the ESC differentiation. In 
contrast to the earliest ESC-derived (unipotent) blood cells, Venus+ cells generated at 
this stage, shared functional similarities with the YS derived EMPs that in vivo are 
generated from E8.25 onwards (Frame et al., 2016; Frame et al., 2013) (Chapter 2). Our 
FACS and imaging data of Gata2Venus embryos demonstrated Venus expression in the 
E9 YS. Analysis of Venus+ and Venus- cells of the E9-E10 YS and AGM, revealed the 
presence of Gata2 dependent and independent EMPs. The highest numbers of Gata2 
independent EMPs were found at E9, which declined by E10 (Chapter 5). Likewise, EMP 
activity in the ESC differentiation cultures was found in the Venus+ population, with some 
phenotypic EMPs detected in the Venus- fraction. The frequency of the Venus- EMPs 
declined over time during the ESC differentiation towards more definitive hematopoietic 
cell generation (Chapter 2), thus indicating similarities between the in vivo and in vitro 
developing Venus+ cells.  
After 14 days of Gata2Venus ESC differentiation, we observed an increase in the 
frequency of cKit+CD31+ cells within the Venus+ compartment. In vivo phenotypic 
hematopoietic cluster cells are defined by co-expression of cKit and CD31, thus, 
implicating the emergence of another (perhaps more potent/aorta-like) hemogenic 
endothelium in the ESC cultures. It was not accompanied with an increased frequency of 
Venus+ cells. However, it is possible that immature hemogenic cells express Gata2 at a 
very low levels, and therefore, an increased readout is not detected by our reporter 
expression. In the embryo, hemogenic endothelium is distinguished from the rest of the 
endothelial cells by the expression of the Ly6AGFP reporter. It also marks all HSCs, but 
does not label the YS stage hematopoiesis, making it a specific marker for immature 
definitive hematopoietic cells (de Bruijn et al., 2002; Ma et al., 2002). We used Ly6AGFP 
ESCs as a reporter to distinguish the later hematopoietic potential arising in the ESC 
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cultures. RNA Sequencing of E10.5 AGM cells shows Gata2 expression in Ly6AGFP+ 
cells undergoing EHT (Solaimani Kartalaei et al., 2015), thus indicating that the 
hemogenic endothelial cells generated in the Gata2Venus ESC cultures, that express 
low levels of Gata2, might be labelled by Ly6AGFP. Moreover, our transplantation assays 
with E11 AGM derived Venus+ and Venus- sorted cells revealed that all HSCs express 
Venus (Chapter 5), thus implying that the most immature (HSC-like) potential arising in 
the ESC cultures, would be labelled by both markers. Indeed, FACS analysis revealed a 
profound increase in the CD31+cKit+ cell frequency also in the Ly6aGFP+ fraction that 
overlapped temporally with the CD31+cKit+ increased frequency in Venus+ cells. Using 
two individual reporter lines has allowed us to sub-fractionate hematopoietic cells (Figure 
1) but has not yet led to a complete understanding of the late hematopoietic potential
arising in ESC cultures.
Therefore, the next step towards more accurate delineation of the definitive 
hematopoietic cells generated in the ESC differentiation, would be the combination of 
these reporters in one ESC double reporter line. This would allow us to isolate the 
hematopoietic cells emerging in the third (and possibly even later) wave of hematopoietic 
cell generation. One probable readout for the emergence of a more complex 
hematopoietic program, is the detection of lymphoid activity (Kennedy et al., 2012). In 
the mouse embryo, after the appearance of EMPs at E8.25, cells with lymphoid potential 
are detected from E8.5 onwards (Godin et al., 1995). Therefore, B and/or T cell potential 
would indicate for the further progression of the differentiation culture, and indicate that 
the stepwise culture maturation is highly analogous to the in vivo waves of hematopoietic 
cell generation, and thus imply that ultimately cells with HSC potential may emerge (Fig 
1). Given that the Ly6aGFP and Gata2Venus reporters are well described in mouse 
embryogenesis, they facilitate a comparison between in vivo waves of hematopoiesis 
and in vitro hematopoietic cell generation. However, the use of these reporters, is only 
beginning to dissect the hematopoietic cell potential of the in vitro cultures. It is likely that 
complex reporter combinations, marking the expression of several in vivo well described 
intrinsic factors is required for the isolation of cell populations with HSC-like 
characteristics. The Gata2Venus:Ly6aGFP double reporter would facilitate this when 
combined with additional gene reporters that mark in vivo definitive 
hematopoiesis/EHT/HSCs, such as Runx1. Runx1 transcription factor has a pivotal 
function for the progression of EHT (Kissa and Herbomel, 2010) and thus, in combination 
with Ly6aGFP (marks hemogenic endothelium and HSCs) and Gata2Venus (marks all 
HSCs) would sub-fractionate the hemogenic endothelial cells that are acquiring HSC 
potential.  
The Gata2 target gene Gpr56 is required for in vitro HPC generation, and has a 
redundant expression and function with Gpr97  
The emergence of HSCs via EHT is associated with the upregulation of heptad 
transcription factors, including Gata2, and the transcriptional activation of their 
downstream targets. One such target, Gpr56, has been previously reported to positively 
regulate EHT and HSC development in the zebrafish embryos (Solaimani Kartalaei et al., 
2015). However, there have been contradictory suggestions about the function of Gpr56 
in the mouse hematopoiesis (Rao et al., 2015; Saito et al., 2013) and its role is still under 
debate.  
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The Gata2Venus reporter ESCs serve as an excellent tool to unravel the involvement of 
Gpr56 in mouse HPC/HSC development as it allows for the specific enrichment of 
functional hematopoietic cells expressing Gpr56. Our differentiation data with ESCs 
expressing Gata2Venus and WT Gpr56 suggest that Gpr56 may have a role in the ESC 
hematopoietic commitment (Chapter 3). Surprisingly, when we subjected Gata2Venus 
Gpr56 KO ESCs to hematopoietic differentiation, we detected much higher hematopoietic 
activity in the Gpr56 null Venus+ cells as compared with WT Venus+ cells. These data 
corroborate with the results of a study using Gpr56-/- adult mice (Rao et al., 2015) and 
suggest that high level of Gpr56 is dispensable for HSC development (Rao et al., 2015). 
Strikingly, we found that the expression of Gpr97 (another GPCR encoded on the same 
locus as Gpr56) and Gpr56 are redundant. Thus, the compensatory mechanisms by 
Gpr97 may account for the increased hematopoietic activity in the Gpr56 KO cells. It is 
tempting to think that possible upregulation of Gpr97 expression in the Gpr56-/- embryos 
explains the lack of hematopoietic defects in these embryos. Our differentiation data with 
Gpr56 null cells where Gpr97 was knocked down, support this view. The fact that Gpr56 
was shown to be involved in the maintenance of stem/progenitor cells in a 32D cell model 
of neutrophil differentiation (Solaimani Kartalaei et al., 2015), suggests that Gpr56 is 
required during the development of HPCs/HSCs by playing a role in their maintenance. 
To further explore the mechanism how Gpr56 regulates hematopoietic cell development, 
we will assess the dynamics of Gpr56 expression in Gpr97 KO cells. Furthermore, our 
study revealed Collagen III as a potential hematopoietic inducible factor that could 
possibly be used to stimulate the in vitro generation of HPCs/HSCs. Our ongoing 
experiments will address the specificity of Collagen signaling axis and the effect of 
concentration dependent Collagen III supply on promoting HPC/HSC development.  
Taken together, Gpr56 is a novel exciting player in hematopoietic development, however, 
recent studies exploring its function have been complicated by the function of redundant 
GPCR(s). Our further studies will take into account the redundant receptors and aim to 
address how Gpr56, and these overlapping receptors, are involved in the EHT.  
Gata2Venus reports all mast cell progenitors and mast cells generated from 
differentiated pluripotent stem cells  
Gata2 expression is downregulated during HSC/HPC differentiation into mature blood 
cell lineages, with the exception of mast cells. Both, immature and mature mast cells, 
retain high Gata2 expression. Thus, Gata2 is an important mast cell marker, and 
Gata2Venus an excellent and advantageous reporter for the isolation of these cells. Mast 
cells are the major effectors of allergic responses and mast cell dysfunction causes 
severe disorders such as anaphylaxis and mastocytosis. Despite this knowledge, and the 
fact that mast cells can be grown in culture, new mast cell disease treatment strategies 
are hampered due to the lack of a robust, rapid and high yield mast cell generation 
method. We have described a novel approach to rapidly and robustly generate large 
numbers of mast cells (Chapter 4) utilizing our novel Gata2Venus reporter ESCs, where 
Venus specifically marks highly proliferative mast cell progenitors and mast cells, that 
appear in the culture after only 14 days of mouse Gata2Venus ESC differentiation. We 
show that the method is applicable to human ESCs and iPSCs - phenotypic human mast 
cells/mast cell progenitors emerge only after 12 days of human GATA2Venus ESC/iPSC 
differentiation culture, which is at least 6 times faster than current protocols (Kovarova et 
al., 2010). We are currently further optimizing this method, so as to provide a rapid, 
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efficient and accessible source of mouse and human mast cells for drug screening and 
patient specific research applications.  
Our approach exploits co-culture of Venus+ hematopoietic progenitor cells on a layer of 
OP9 stroma resulting in a rapid induction of Gata2 expression that is marked by 
significantly increased Venus intensity. These data suggest that hematopoietic progenitor 
cells have low levels of Gata2, however, induction of Gata2 expression is a prerequisite 
for the commitment to mast cells (Chapter 4). This is in line with the previously held view 
that Gata2 functions in a dose dependent manner and Gata2+ cell identity is defined by 
its expression levels (Ling et al., 2004; Nandakumar et al., 2015; Rodrigues et al., 2005). 
Delineating direct inducers of Gata2, that are expressed by OP9 stromal cells, would 
reveal potential mast cell-specific stimulators that could be used in order to generate 
these cells from PSCs. This approach would facilitate the derivation of stroma and serum 
free protocol with defined medium components making this approach more relevant for 
clinical applications. We are currently testing some of the known Gata2 inducers, such 
as BMP4 and Notch1 for the induction of mast cell commitment (Maeno et al., 1996; 
Robert-Moreno et al., 2005). Moreover, we have shown in this thesis that OP9 cells 
express high levels of Col3a1 (Chapter 3), thus it would be interesting to explore whether 
Collagen III signaling has a role in regulating the levels of Gata2 in mast cell commitment. 
Conclusion and Future Perspectives 
In conclusion, we have established Gata2Venus reporter embryonic stem cell and 
transgenic mouse line, and characterized the involvement of Gata2 in the stepwise 
differentiation and development of hematopoietic cells (Fig 1). Our study demonstrates 
the fundamental role of Gata2 in embryonic hematopoiesis, and indicates that in 
combination with other reporters (such as the Ly6aGFP), all hematopoietic activity arising 
in the ESC differentiation cultures, can be detected. Gata2Venus and Ly6aGFP reporters 
are just beginning to dissect and provide understanding of all the different cell types and 
hematopoietic potential emerging during embryonic development. The combination of 
these reporters with others, such as the reporters for heptad transcription factors (Wilson 
et al., 2010), will allow to determination of the specific molecular signatures arising in the 
hematopoietic development and differentiation. This will greatly advance the field and will 
enable the development of future strategies in directly translating the perspectives into 
therapeutic applications.   
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Figure 1. Gata2Venus and Ly6aGFP reporter expression in hematopoietic cells. The 
Gata2Venus reporter labels the majority of hematopoietic cells, including mast cells. The 
Ly6aGFP reporter distinguishes a subset of Gata2Venus+ cells, including the hematopoietic stem 
cells (HSC). 
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Summary 
The mammalian hematopoietic system is maintained by the self-renewing, long-lived 
HSCs that provide the organism with a life-long supply of all blood lineage cells. HSCs 
are used in cell therapy applications for treating blood disorders. To overcome the 
shortage of compatible donor derived HSCs, approaches to generate HSCs de novo by 
reprogramming, or deriving them from other sources, such as pluripotent stem cells, have 
been taken. It is essential for the derivation of de novo HSCs to dissect the extrinsic and 
intrinsic signals that drive the HSC program in vivo, as well as exploring the compounds 
of the surrounding niche and microenvironment. Recent progress has pushed the field 
forward, however, we still do not know all the characteristics of HSC identity.  
Transcriptional control is the most important regulator in the process of defining cell 
identity. Gata2 is one of the key transcription factors whose precisely controlled 
expression levels have an essential role in the development of HSCs, HPCs as well as 
in several mature blood lineage cells, such as mast cells. This thesis focuses on the 
involvement of Gata2 in embryonic hematopoiesis. We characterize the involvement of 
Gata2 in in vivo HSC/HPC development and in the generation of blood (progenitor) cells 
in vitro. We exploit a novel Gata2Venus reporter, that, for the first time, allows to trace, 
characterize and isolate live cells expressing unperturbed levels of Gata2. 
The introduction in Chapter 1, provides a background to the current knowledge about 
the embryonic development of the adult hematopoietic system, focusing on endothelial-
to hematopoietic cell transition, and on some of the pivotal transcriptional regulators, 
including Gata2, and their targets involved in this process, and in the generation of HSCs. 
It introduces the scope of this study as well as specific goals of this thesis research.  
In Chapter 2, we demonstrate that Gata2Venus reporter expression in ESC 
differentiation cultures distinguishes all in vitro generated blood cells that are generated 
in a stepwise manner with growing complexity. The most immature cells arising in late 
cultures, are also marked by another hematopoietic reporter, Ly6AGFP, that in vivo 
distinguishes all HSCs, but does not mark primitive hematopoietic stages. These novel 
reporters show that ESC differentiation is highly similar to the progressive development 
of hematopoietic cells in vivo and enables the isolation of the in vitro grown hematopoietic 
cells.  
In Chapter 3, we use the Gata2Venus ESC hematopoietic differentiation to dissect the 
hematopoietic requirement of Gata2 downstream target Gpr56. We show that the 
expression and function of Gpr56 and another GPCR, Gpr97 are redundant. The deletion 
of Gpr56 and Gpr97 together blocks the definitive hematopoietic program, thus revealing 
a requirement for Gpr56 in the generation of HPCs. Moreover, our data reveal that the 
putative ligand of Gpr56, Collagen III, has a positive effect on HPC generation, and could 
possibly be used as a novel stimulator of de novo generation of HPCs/HSCs. 
In Chapter 4, we introduce a novel approach to robustly generate mast cells, the immune 
cells that play a key role in allergic reactions and inflammatory disease. Mast cell related 
research is challenged due to the long and expensive protocols in the generation of 
mature functional mast cells. Our protocol utilizes the advantageous Gata2Venus 
reporter and we show that Venus marks and enables the isolation of all functional mast 
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cells and mast cell precursors as they are produced from mouse and human PSCs with 
significantly shorter culture time than previously reported. 
In Chapter 5, we utilize the Gata2Venus ESCs to establish a Gata2Venus reporter 
mouse model. We show that all HSCs, and the majority of HPCs are Gata2 expressing, 
and reveal a Gata2 independent progenitor population with a distinct functional output 
and molecular signature. These data contribute to the knowledge needed to dissect the 
full program of HSC identity and the factors, that are essential in the reprogramming, and 
PSC differentiation approaches. 
The final chapter, Chapter 6 provides an overview of the major findings and their impact 
in the field of developmental hematopoiesis, as well as introduces the future perspectives 
of this thesis study.  
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Samenvatting 
Het hematopoietische systeem van zoogdieren wordt in stand gehouden door 
zelfvernieuwende, lang levende hematopoietische stamcellen (HSC’s) die het 
organisme voorzien van een levenslange voorraad aan alle verschillende bloedcellen. 
HSC’s worden gebruikt in celtherapie toepassingen voor de behandeling van 
bloedziekten. Om het tekort aan compatibele donor-afgeleide HSC’s te boven te komen, 
zijn benaderingen gezocht voor de de novo generatie van HSC’s door reprogrammering 
of afleiding vanuit andere bronnen, zoals pluripotente stamcellen (PSC’s). Het ontleden 
van de ex- en intrinsieke signalen die het HSC programma in vivo aansturen, en het 
verkennen van de onderdelen van de omringende nis, zijn essentieel voor de derivatie 
van de novo HSC’s. Recente vooruitgang heeft het veld verder gebracht, echter we 
weten nog steeds niet alle details van HSC indentiteit. 
Transcriptionele controle is de belangrijkste regulator van het proces van het definiëren 
van cel identiteit. Gata2 is één van de sleutel transcriptiefactoren wiens precies 
gecontroleerde expressieniveaus een essentiële rol spelen in de ontwikkeling van 
HSC’s, hematopoietische progenitor cellen (HPC’s) en meerdere soorten rijpe 
bloedcellen, zoals mastcellen. Dit proefschrift focust op de betrokkenheid van Gata2 
gedurende de embryonale hematopoiese. We karakteriseren de rol van Gata2 in 
HSC/HPC ontwikkeling in vivo en gedurende de generatie van bloed (voorloper) cellen 
in vitro. We exploiteren een nieuwe Gata2Venus reporter, die ons voor de allereerste 
keer in staat stelt om levende cellen welke onverstoorde niveaus van Gata2 tot 
expressie brengen te volgen, karakteriseren en isoleren. 
De introductie in Hoofdstuk 1, geeft een achtergrond over de huidige kennis van de 
embryonale ontwikkeling van het volwassen hematopoietische systeem, gefocust op 
de endotheliale-naar-hematopoietische celovergang, en op enkele van de hoofd 
transcriptionele regulatoren, inclusief Gata2, en hun doelwitten betrokken bij dit proces, 
en in de generatie van HSC’s. Het introduceert de strekking van deze studie en de 
specifieke doelen van dit promotieonderzoek. In Hoofdstuk 2 demonstreren we dat de 
Gata2Venus reporter expressie in embryonale stamcel (ESC) differentiatie kweken alle 
in vitro gegenereerde bloedcellen onderscheidt die gegenereerd worden op een 
stapsgewijze manier met een toenemende complexiteit. De meest onrijpe cellen die 
onstaan gedurende de late kweken, worden ook gemarkeerd door een andere 
hematopoietische reporter, Ly6AGFP, welke in vivo alle HSC’s maar niet de primitieve 
hematopoiese markeert. Deze nieuwe combinatie van reporters laat zien dat ESC 
differentiatie in grote mate overeenkomt met de progressieve ontwikkeling van 
hematopoietische cellen in vivo en maakt het mogelijk om de in vitro gegenereerde 
hematopoietische cellen te isoleren. 
In Hoofdstuk 3 gebruiken we de Gata2Venus ESC hematopoietische differentiatie om 
de hematopoietische behoefte van het Gata2 ‘downstream’ doelwit Gpr56 te ontleden. 
We laten zien dat de expressie en functie van Gpr56 en een andere GPCR, Gpr97, 
overlappend zijn. De deletie van Gpr56 en Gpr97 samen blokkeert het definitieve 
hematopoietische programma, en laat zien dat Gpr56 belangrijk is voor de generatie 
van HPC’s. Bovendien laten onze data zien dat het vermeende ligand van Gpr56, 
collageen III, een positief effect heeft op HPC generatie, en mogelijk gebruikt kan 
worden als nieuwe stimulator voor de novo generatie van HPC’s/HSC’s. 
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In Hoofdstuk 4 introduceren we een nieuwe benadering om op een robuuste manier 
mastcellen, de immuuncellen welke een hoofdrol spelen in allergische reacties en 
ontstekingsziekten, te genereren. Mastcel gerelateerd onderzoek is moeilijk door de 
lange en dure protocollen die nodig zijn voor de generatie van rijpe functionele 
mastcellen. Ons protocol gebruikt de zeer nuttige Gata2Venus reporter en we laten zien 
dat Venus alle functionele mastcellen en mastcel voorlopers markeert en hun isolatie 
mogelijk maakt  wanneer ze worden geproduceerd vanuit muis en humane pluripotente 
stamcellen met een significant kortere kweektijd dan voorheen gerapporteerd. 
In Hoofdstuk 5 maken we gebruik van de Gata2Venus ESC’s om een Gata2Venus 
muis reporter model te maken. We laten zien dat alle HSC’s, en de meerderheid aan 
HPC’s Gata2 tot expressie brengen. Dat model onthult ook een Gata2 onafhankelijke 
voorloper cel poplulatie met een aparte functie en eigen moleculair patroon. Onze 
studie, die laat zien dat Gata2 een essentiële rol heeft in het bepalen van het HSC lot, 
maar niet in de generatie van functionele HPC’s, draagt bij aan de kennis die vereist 
is voor het volledig ontleden van het programma voor het genereren van HSC identiteit 
en van de factoren die essentieel zijn in de benadering van de reprogrammering en 
differentiatie van PSC  
Het laatste hoofdstuk, Hoofdstuk 6, geeft een overzicht van alle resultaten en 
conclusies van dit proefschrift onderzoek. De belangrijkste bevindingen en hun impact 
binnen het veld van de ontwikkelingshematopoiese worden besproken en geeft een 
introductie van de toekomstperspectieven van deze proefschrift studie.  
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Kokkuvõte 
Imetajate vereloome süsteemi aluseks on vereloome tüvirakud, mis tagavad 
organismile kogu tema elu jooksul kõigi erinevate vererakkude tagavara. 
Vereloometürivakkude siirdamise tulemusena on võimalik ravida leukeemiaid ning 
mitmeid teisi verahaigusi. Edukaks siirdamiseks on vaja sobivat doonorit, kuna 
erinevate inimeste vererakud on väga erinevad. Võõra vere siirdamisel tekib 
patsiendis äge vastureaktsioon, sest organism võitleb teistsuguste rakkudega kui 
sissetungijatega. Et aga sobivaid doonoreid esineb harvadel juhtudel, tuleb leida 
meetod de novo vereloometüvirakkude tootmiseks alternatiivsetest allikatest. 
Viimasteks on näiteks pluripotentsed tüvirakud (embrüonaalsed ning 
indutseeritud pluripotentsed tüvirakud). Edukaks de novo vereloometüvirakkude 
tegemiseks on vaja õppida tundma signaaliradu ning 
transkriptsioonifaktoreid, mis reguleerivad vereloometüvirakkude arengut organismis.  
Gata2 on üks olulisemaid vereloomega seotud transkriptsioonifaktoreid. Gata2 väga 
hoolikalt kontrollitud ekspressioonitase määrab vere(tüvi)rakkude saatuse. Lisaks 
vereloometüvirakkudele on Gata2 oluline faktor ka mõnedes täiskasvanud 
funktsionaalsetes vererakutüüpides, näiteks nagu nuumrakkudes. Minu doktoritöö 
uurib Gata2 rolli vereloome arengus. Täpsemalt, iseloomustan Gata2 rolli 
vereloometüvirakkude arengul organismis ning progenitorrakkude tekkes 
pluripotentsetest rakkudest laboritingimustes (in vitro). Oma katsetes kasutan uudset 
Gata2Venus reporter raku- ja hiireliini, mis esmakordselt võimaldab jälgida ning 
eraldada elusaid rakke, mis ekspresseerivad Gata2 faktorit endogeensel tasemel. 
Sissejuhatus (esimene peatükk) annanb ülevaate vereloomearengu uurimissuuna 
hetkeseisust, keskendudes endoteelirakust vererakuks ülemineku protsessile 
(endothelial-to-hematopoietic transition) ning olulistele transkriptisioonifaktoritele 
selles protsessis, nagu näiteks Gata2 ning tema sithmärkvalgud. Sissejuhatuse 
lõpus püstitan oma lõputöö probleemi ning toon välja selle eesmärgid.  
Teises peatükis tutvustan Gata2 rolli embrüonaalsete tüvirakkude 
hematopoieetilises diferentseerumises, kasutades selleks Gata2Venus 
reporterrakuliini.  Minu tulemused näitavad, et Gata2Venus märgib kõik 
verepotentsiaaliga rakud, mis on loodud embrüonaalsetest tüvirakkudest. Nende 
tekkimine rakukultuuris toimub järk-järgult tõusva potentsiaaliga, luues esialgselt 
primitiivsed vererakud ning hiljem  komplsekssed suure potentsiaaliga 
progenitorrakud. Progenitorrakud, mis on loodud hilisemas kultuuris, on ka 
märgitud teise hematopoieetilise markeri, Ly6aGFP poolt, mis organismis märgistab 
kõik vereloometüvirakud. Selline järk-järguline vererakkude teke on väga sarnane 
organismis toimuvale vere(tüvi)rakkude arengule ning, koostöös edasiste 
uuringutega, loob suured eeldused in vitro vereloometüvirakkude genereerimiseks. 
Kolmandas peatükis kasutan Gata2Venus reporterrakuliini uurimaks Gata2 
sihtmärkvalgu, Gpr56 rolli vereloome arengus. Minu tulemused näitavad, et Gpr56 rolli 
kompenseerib selle puudumisel sama geenilookuse poolt kodeeritud Gpr97, 
mille ekspressioon tõuseb, kui Gpr56 rakkudest deleteeritakse. Gpr56 ja 
Gpr97 ko-deleteerimisel kaotavad embrüonaalsed tüvirakud aga võime 
genereerida vereprogenitorrakke, seega viidates nende geenide olulisele funktsioonile 
vereloomes. Embrüonaalsete tüvirakkude poolt vereprogenitoride tootmine aga 
suureneb, kui neid töödeldakse Kollageen III-ga, mis on Gpr56 potentsiaalne ligand. 
Seega, minu töö näitab, et Gpr56-l ning Gpr97-l on kompensatoorne, kuid vajalik 
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positiivne roll vereloomes ning Gpr56 potentisaalne ligand Kollageen III võimaldab 
indutseerida in vitro vereloomet.  
Neljands peatükis tutvustan innovatiivset mudelit nuumrakkude kiireks ning robustseks 
tootmiseks. Nuumrakud on allergiate, astma ning muude põletikuprotsesside 
initsiaatorid. Nende põhjustatud haiguste uurimine on senini olnud pärsitud, kuna 
funktsionaalsete nuumrakkude genereerimisprotokollid on äärmiselt pikaajalised ning 
kallid. Minu väljatöötatud meetod põhineb teadmisel, et nuumrakud 
ekspresseerivad kõrgel tasemel Gata2 transkriptsioonifaktorit ning kasutab ära 
Gata2Venus reportertüvirakuliini. Minu tulemused näitavad, et Venus märgib kõik 
funktsionaalsed nuumrakud ning nende eellased, mis saadakse hiire ja inimese 
pluripotentsete tüvirakkude diferentseerimisel. Seega, minu meetod võimaldab toota 
suuri koguseid funktsionaalseid nuumrakke teadustööks märkimisväärselt kiiremini 
ning odavamalt kui see oli võimalik seni, luues võimalusi nuumrakkude 
põhjustatud haiguste uurimiseks ning ravi väljatöötamiseks.  
Viiendas peatükis genereerime Gata2Venus embrüonaalsetest rakkudest 
reporterhiiremudeli, millega katsed näitavad, et kõik vereloometüvirakud, ning enamus 
progenitorrrakke organismis ekspresseerivad Gata2 faktorit. Lisaks esineb Gata2-st 
iseseisev progenitorrakkude populatsioon, millel on spetsiifiline geeniekspressiooniprofiil 
ning funtksioon. Need andmed näitavad, et Gata2 on vereloometüvirakkude 
arenguks äärmiselt vajalik ning loob suured eeldused dedasiseks 
teadustööks vereloometüvirakkude de novo genereerimise meetodi väljatöötamiseks. 
Viimases, kuuendas peatükis annan ülevaate kogu oma lõputöö tulemustest, nende 
olulisusest ning aplikatsioonidest.   
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List of acronyms  
AGM aorta-gonad-mesonephros 
AML acute myeloid leukemia 
BAC bacterial artificial chromosome  
BFU-E burst forming unit-(definitive) erythroid 
BL-CFC blast-colony forming cell 
BM bone marrow 
BMP-4 bone morphogenetic protein 4 
bp base pairs 
CB cord blood 
Cbf core binding factor 
CFU-C colony forming unit-cell 
CFU-EryP colony forming unit-(primitive) erythroid 
CFU-GEMM colony forming unit granulocyte-erythrocyte-monocyte-   
  macrophage 
CFU-GM colony forming unit granulocyte-macrophage 
cKit  proto-oncogene receptor tyrosine kinase 
CLP  common lymphoid progenitor 
CMP  common myeloid progenitor 
Col III  collagen III  
CPA-3  carboxypeptidase A3 
D day of differentiation 
DKK  dickkopf WNT signaling pathway inhibitor 
E embryonic day 
EB  embryoid body 
Ed definitive erythroid 
EGM  endothelial cell growth medium 
EHT endothelial to hematopoietic transition 
EMP erythroid-myeloid progenitor 
EPO erythropoietin 
Erg  avian erythroblastosis virus E-26 (v-ets) oncogene related 
ESC   embryonic stem cell 
EVI-1  ectopic viral integration site-1 
FcεR1α Fc receptor, IgE, high affinity I, alpha polypeptide 
FcεR1g Fc receptor, IgE, high affinity I, gamma polypeptide 
FGF  fibroblast growth factor 
FL fetal liver 
Fli1  friend leukemia integration 1 
Flk1  kinase insert domain protein receptor 
Flt3L  Fms-related tyrosine kinase 3 ligand 
FPKM  fragments per kilobase of transcript per million mapped reads 
Gata  GATA binding protein 
GFP  green fluorescent protein 
GM-CSF Granulocyte-macrophage colony-stimulating factor 
GMP  granulocyte/monocyte progenitor 
GP(C)R G-protein coupled receptor
G2V   Gata2Venus
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HEC hemogenic endothelial cell 
HPC hematopoietic progenitor cell 
HPRT hypoxanthine phosphoribosyltransferase 
HSC hematopoietic stem cell 
IAHC intra aortic hematopoietic cluster cell 
IGF-1 insulin like growth factor 
IRES internal ribosome entry site  
iPSC induced pluripotent stem cell 
KO knockout 
LG Ly6a(Sca1)GFP=Ly6Agfp 
Lmo2 LIM domain only 2 
LN lymph node 
Lyl1 lymphoblastomic leukemia 
MC mast cell 
MCP mast cell progenitor 
MEP megakaryocyte/erythroid progenitor 
mMCP-1 mast cell protease (chymase) 
mMCP-5 mast cell chymase 1 
mMCP-6 mouse tryptase beta 
MPP multipotent progenitor 
NK natural killer cell 
NT neural tube 
OB olfractory bulb 
PB human peripheral blood  
PL placenta 
PSC pluripotent stem cell 
RT reverse transcription 
Runx1 Runt-related transcription factor 1 
Sca-1 Stem cell antigen-1 
SCF stem cell factor 
Sp somite pairs 
Tal1 T cell acute lymphocytic leukemia 1 
TPO thyroid peroxidase 
UA umbilical artery 
UTR untranslated region 
VA vitelline artery 
V+ Gata2Venus expressing 
V- Gata2Venus non-expressing
VEGF vascular endothelial growth factor 
WT wild type 
YS  yolk sac 
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